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Specific phobias are among the most commonly diagnosed psychiatric disorders. 
Exposure and Response Prevention (ERP) has become the treatment of choice for 
specific phobias, and is believed to operate on the basis of fear extinction.  Animal 
studies have shown that acute administration of D-cycloserine (DCS) prior to exposure to 
a feared stimulus enhances extinction of that fear. Clinical studies in humans have 
recently demonstrated that DCS facilitates the effects of ERP therapy, presumably 
through enhancement of memory encoding and consolidation. However, the neural 
mechanisms underlying these potential benefits of DCS are not understood. The current 
study used fMRI to examine brain function in subjects with specific phobia and healthy 
control participants, with and without DCS. The primary objectives of this study were to 
examine the effects of DCS on 1) neural activity during phobic symptom provocation and 
2) neuropsychological functioning.  
Results provide evidence that DCS enhances activity in prefrontal cortex (PFC), 
anterior cingulate cortex (ACC), and insular cortex during phobic symptom provocation. 
This suggests that DCS may enhance cognitive control and interoceptive integration 
during emotional processing. Neuropsychological assessment provided evidence that 
specific phobia is associated with subtle differences in cognitive functioning, most 
notably on decision-making and strategic organization. DCS also had an effect on 
cognitive functioning, but the direction of influence depended upon clinical anxiety 
symptoms.  
The current study is the first investigation of acute DCS effects on neural 
processing during phobic symptom provocation. It is also the first study to examine acute 
DCS effects on neuropsychological functioning. Results provide direction for future 
research examining the use of acute DCS administration in enhancing fear extinction, 









Chapter 1: Introduction and Background 
Specific phobias – anxiety disorders involving persistent fear and avoidance of specified 
objects or situations (e.g., spiders) – are among the most commonly diagnosed psychiatric 
disorders, with lifetime prevalence rates of 11.3% in the United States. The cognitive 
behavioral therapy, Exposure and Response Prevention (ERP), has become the treatment of 
choice for specific phobias. ERP involves systematic and repeated exposure to a feared or 
anxiety-provoking stimulus, leading to habituation and extinction of the fear response. Animal 
models of fear extinction have shown that acute administration of D-cycloserine (DCS) prior to 
exposure to a feared stimulus enhances extinction of that fear. Clinical studies in human 
subjects with various anxiety disorders (phobia, social anxiety disorder, panic disorder, and 
obsessive-compulsive disorder) have also demonstrated that DCS facilitates the effects of ERP 
therapy. Research with animals, as well as human clinical populations, has also demonstrated 
that DCS can enhance aspects of cognitive functioning, including memory. Because of this 
research, current theories postulate that DCS facilitates fear extinction by enhancing the 
learning process and increasing consolidation of memories. However, the neural mechanisms 
underlying this process are not understood. Functional magnetic resonance imaging (fMRI) 
provides a means to measure functional changes in the brain during symptom provocation and 
memory processing. The current study used fMRI to examine patients with specific phobia and 
healthy control subjects, with and without DCS. The primary objectives of this study were to 
provide important information regarding neural mechanisms underlying symptom expression 
in specific phobia, acute DCS effects in general, and DCS treatment facilitation in particular. 
The current study also conducted cognitive assessment with these same populations, with and 
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without DCS, to further elucidate the effects of DCS on human functioning and the 
mechanisms through which it may enhance ERP therapy. This study therefore aimed to 
accomplish the following Specific Aims: 
1) Measure brain activation during exposure to phobic-related stimuli in untreated spider 
phobics and healthy control subjects. This aim was critical for defining general group 
differences in brain function during a clinically specific process (symptom provocation). 
Group differences were assessed regarding fMRI signal change during exposure to phobic-
related pictures (spiders) vs. neutral pictures (butterflies) in spider phobic patients and healthy 
control subjects that had not received DCS. It was hypothesized that the placebo spider phobic 
group would show greater activation than the placebo healthy control group in the following 
brain regions: insula, hippocampus, orbitofrontal cortex (OFC), dorsolateral prefrontal cortex 
(dlPFC), anterior cingulate cortex (ACC), and amygdala. 
2) Measure brain activation during exposure to phobic-related stimuli in spider phobics and 
healthy controls, following acute administration of DCS or placebo.  
Group differences were assessed regarding fMRI signal change during exposure to phobic-
related pictures (spiders) vs. neutral pictures (butterflies) in spider phobic patients and healthy 
control subjects who had been administered DCS or placebo. Based on previous research and 
theoretical models related to fear extinction and phobia, it was expected that the phobic DCS 
group would show increased activations in the medial PFC (mPFC; including the ACC and the 
OFC), dlPFC, and the hippocampus but decreased activations in the lateral and medial 
amygdala and insula compared to the phobic placebo group and both healthy control groups. 
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3) Measure cognitive functioning in spider phobic patients and healthy controls, following 
acute administration of DCS or placebo.  
Group differences were assessed regarding aspects of cognitive functioning shown in 
previous research to be affected by DCS administration. The aspects of cognitive functioning 
assessed included: verbal memory, nonverbal memory, executive functioning, and decision-
making. Based on previous research, it was expected that subjects administered DCS would 
perform better than those administered placebo. 
To accomplish these specific aims, the proposed study recruited individuals with and 
without spider phobia from campuses at the University of Kansas (KU), the University of 
Kansas Medical Center (KUMC), the Kansas City Center for Anxiety Treatment (KCCAT), 
and the general community. Initial assessment obtained information regarding 
exclusion/inclusion criteria, psychiatric diagnoses, and severity of spider phobia. Subjects 
meeting study criteria were scheduled to undergo medication administration, fMRI, and 
neuropsychological assessment at one time point. Subjects were pseudo-randomized to receive 
one 100 mg dose of D-cycloserine or matching placebo. Within 2-3 hours after medication 
administration, subjects underwent fMRI scanning, in which a symptom provocation paradigm 
was completed. After scanning, a battery of neuropsychological tests was completed with the 
subjects to assess cognitive functioning.  
The proposed study examined the effects of DCS administration on only one aspect of the 
fear extinction process – the initial exposure to phobic stimuli. However, this study represents 
the first step in identifying the neural mechanisms through which DCS influences fear 
extinction and ERP therapy. This work is exploratory and at an early stage of development, but 
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results are potentially of great importance to the future understanding and treatment of anxiety 
disorders.  
Specific Phobia  
Specific phobias are among the most commonly diagnosed psychiatric disorders, with 
estimated lifetime prevalence rates of 10-15% in the United States (Magee et al., 1996). 
Specific phobias are defined as “persistent fears that are excessive or unreasonable, cued by the 
presence or anticipation of specific objects or situations” (American Psychiatric Association, 
2000). Spider phobia, or arachnophobia, is a subtype of specific phobia in which the feared 
“objects” are spiders. It has been estimated that the prevalence of spider phobia in the U.S. 
population is 5.6% for females and 1.2% for males (Fredrikson, Annes, Fischer, & Wik., 
1996). Three primary aetiologies of spider phobia have been proposed: 1) direct classical 
conditioning, 2) vicarious learning through observation of another individual’s conditioning 
experience, and 3) through transmission of information or instruction related to a stimulus. 
Dramatic variations are found in the percentage of people attributing their spider phobia to 
each of these three categories and these variations may depend upon what questionnaire is used 
(the Origin’s Questionnaire [OQ] versus the Phobic Origins Questionnaire [POQ]). Anywhere 
from 6% to 48% of animal phobias have been attributed to conditioning experiences (negative 
experience related to the phobic stimulus) while 6% to 55% are due to vicarious experiences, 
and 3% to 60% developed from transmission of information (Kirby, Menzies, Daniels, & 
Smith, 1995; Ost, 1987). Differences in findings related to the two questionnaires may be due 
to underestimation by the OQ and overestimation by the POQ regarding occurrence of 
conditioning events in the aetiology of phobia (Kirby et al., 1995). Although these findings do 
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not provide much direction regarding the true percentage of cases that have developed from 
each type of aetiology, they do make the point that phobia can result from a variety of origins. 
The cognitive behavioral therapy, Exposure and Response Prevention (ERP), has become 
the treatment of choice for anxiety disorders, including specific phobia (Barlow, 2002; Davey, 
1997). ERP involves systematic and repeated exposure to the anxiety-provoking stimulus and 
focuses on decreasing avoidance of situations or objects related to that stimulus. Clinically 
significant improvement is estimated to occur in 74-95% of patients who complete one- to 
five-session exposure therapy (Chambless & Woody, 1990; Hellstrom & Ost, 1995; Ost, 
1997). Research indicates that one session treatment may be as successful as more extended 
treatment (Ost, 1996). However, ERP produces stress and discomfort and requires high 
motivation to undergo treatment. This is most likely the reason that as many as 24% of patients 
have been reported to drop out of treatment in clinical outcome trials (Marks, Kenwright, 
McDonough, Whittaker, and Mataix-Cols, 2005). Additionally, phobias will sometimes 
reappear at a later time or if the patient encounters the stimulus in different contexts 
(demonstrating lack of generalization). Exposure and Response Prevention is also used in the 
treatment of other anxiety disorders, including obsessive-compulsive disorder, panic disorder, 
post-traumatic stress disorder, and others. ERP therapy with these disorders requires more time 
and often proves difficult for patients to complete (Foa, 1996). Advances made in ERP for 
phobia would have implications for the treatment of other anxiety disorders as well. Therefore, 
further advances are needed to increase the tolerance, efficiency, and maintenance of this 
therapy. DCS has shown some initial promise in this regard. 
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Functional Neuroimaging Methods  
The specific aims and hypotheses of the current study are based upon results from previous 
research examining neurophysiological correlates of phobia and fear. Cognitive and emotional 
activation paradigms are used during functional brain imaging to investigate these correlates in 
human subjects. During activation paradigms, subjects are asked to complete a task that is 
thought to invoke a particular mental state (emotional or cognitive). The activations associated 
with this mental state can then be examined within subjects by comparing it with a similar task 
that is not thought to invoke that particular mental state. However, brain activations associated 
with the same task can also be compared between two groups of people that differ on a 
particular characteristic that is thought to affect the mental state of interest. A summary of the 
functional imaging methods most often used for cognitive and emotional activation studies will 
be provided to serve as a foundation for understanding the literature. Although there are other 
functional imaging methods available today, the current discussion will focus on positron 
emission tomography (PET) and functional magnetic resonance imaging (fMRI), which are 
most frequently used in the study of phobia and fear.  
Positron Emission Tomography. For PET, a biochemical is labeled with a radioactive 
substance and administered to the subject. When the radioactive isotopes decay within the 
body, positrons are emitted. The positrons subsequently collide with an electron, producing 
two gamma rays, or photons, moving in opposite directions (Heiss et al., 1985; Kolb & 
Wishaw, 1996). The PET scanning device detects the pairs of photons and determines the 
location of their source in the brain. Detecting the amount of gamma rays in various brain 
regions provides a measure of the labeled biochemical, which in turn allows for an indirect 
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measure of regional cerebral blood flow (rCBF; Heiss et al.). Oxygen-15 (15O) is the most 
frequently used radioactive tracer for the detection of rCBF. The vast majority of PET studies 
to be discussed utilized 15O as the radioactive isotope, though it should be noted that carbon-11 
(11C) and flouro-2-deoxy-D-glucose (18FDG) are sometimes used in other research protocols.  
 15O has a short half-life of 123 seconds and allows for multiple scans to be acquired 
during a testing session (approximately 12-15 scans). This is critical for cognitive activation 
studies in which blood flow is compared between two or more mental states. However, 
sufficient time must be provided between scans to allow for tracer washout and decay 
(approximately 10-12 minutes). The duration of data acquisition within a scan is approximately 
100 seconds, measured in time frames varying from 10 to 30 seconds in duration (Holmes, 
1995). 
 Magnetic Resonance Imaging. Magnetic Resonance Imaging (MRI) has a powerful 
magnetic field that causes protons of hydrogen nuclei to align their spins parallel with the 
magnetic field (Huettel, Song, & McCarthy, 2004; Kolb & Wishaw, 1996). Radiowaves are 
generated from an electrical coil within the MRI scanner that excites these protons, causing 
them to flip their spins away from the direction of the magnetic field. When the protons relax 
to align parallel with the magnetic field, they emit electromagnetic waves. MRI scanner 
electric coils are able to detect these electromagnetic waves. Proton density and proton 
relaxation times determine the intensity of the MRI signals (Huettel et al., 2004). Proton 
relaxation from the excited state has two components: one along the z, or longitudinal axis (T1) 
and one alone the x-y, or transverse axis (T2). With MRI, different radio wave pulse sequences 
can be used to emphasize either T1 or T2 contrast.  
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There are several different MRI techniques used to measure brain function, including 
dynamic contrast, blood oxygen level-dependent (BOLD), diffusion, and magnetic resonance 
spectroscopy. This discussion will focus on BOLD fMRI because it is the technique used in the 
majority of cognitive and emotional activation studies, including all of the fMRI studies to be 
discussed in relation to specific phobia. fMRI takes advantage of the differential magnetic 
properties of oxygenated and deoxygenated hemoglobin to indirectly measure brain function 
(Huettel et al.; Kolb & Wishaw, 1996). Deoxygenated hemoglobin has a much greater 
magnetic susceptibility, or intensity of magnetization when in a magnetic field, than 
oxygenated hemoglobin. Changes in blood flow and oxygenation level of the blood lead to an 
increase in the T2 MR signal in response to neuronal activity. Therefore, measuring T2 MR 
signal changes in response to cognitive tasks allows for an indirect measure of the associated 
neuronal activity by quantifying hemodynamic properties of brain regions.  
 During an fMRI scanning session, several runs of functional images are acquired, 
each lasting 5-10 minutes. Within each run, data are acquired as a time series of volumes, 
which are images created from a number of image slices taken throughout the brain (Huettel et 
al.2004). These slices are composed of data acquired from individual voxels. In a given fMRI 
experiment, there may be any number of runs, each consisting of approximately 100-400 
volumes. Each volume is composed of multiple slices, which in turn consists of a 64X64 or 
128X128 matrix of voxels. Voxel size is usually cubic (e.g. 3.75mm long X 3.75 mm wide X 
3.75 mm thick) though non-cubic can also be utilized (Huettel et al.).  
 There are two basic types of fMRI designs: blocked designs and event-related 
designs (Huettel et al., 2004). In a blocked design, 2 or more alternating conditions and, in 
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most cases, a baseline condition, are presented. Each stimulus block is approximately 10 to 30 
seconds in duration. In event-related designs, stimuli are presented as individual events. 
Changes in fMRI signal after the occurrence of an experimental event are measured. Blocked 
design is the method used most frequently when investigating cognitive processes that cause 
prolonged changes in emotional or cognitive states. Event-related fMRI is used to measure 
more discrete, short-term cognitive processes.  
 Both PET and fMRI data analysis can be conducted on a voxel-by-voxel basis or 
for specified regions of interest (ROIs). Voxelwise analysis involves statistical tests of each 
separate voxel, whereas ROI analysis involves statistical testing of discrete regions of voxels 
(Huettel et al., 2004). Although power may be decreased when conducting voxel-by-voxel 
analysis, it allows for inclusion of all brain regions. ROI analysis increases power but requires 
more time and effort then voxelwise analysis. Additionally, if only ROI analysis is performed, 
potentially significant activations in other regions will not be detected. The current trend is to 
include both voxelwise and ROI analyses.  
 fMRI is often preferred to PET because it does not require radioactive substance to 
be injected into the subject and has superior temporal and spatial resolution (Huettel et al., 
2004). Although fMRI is currently the preferred method for measuring brain activations 
associated with cognitive or psychological processes, PET and fMRI do have high convergent 
validity (Volkow, Rosen, & Farde, 1997). Therefore, results reported from PET and fMRI 
studies can be consolidated to develop theories of brain function. In the following section, PET 
and fMRI research examining correlates of phobia symptom provocation and fear extinction 
will be discussed. If not otherwise specified, the PET studies utilized 15O as the radioactive 
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label and the fMRI studies measured the BOLD response. Variations in imaging methodology 
will be discussed when relevant to the research findings. 
Functional Imaging Studies of Fear and Phobia 
 Neuroanatomical abbreviations frequently used within this manuscript are listed in Table 1. 
 Positron Emission Tomography. Functional imaging studies, utilizing PET or fMRI, have 
been conducted with patients suffering from specific phobia, measuring brain activity during 
exposure to fear-inducing stimuli. The majority of these studies have involved only spider 
phobia, though snake phobia, small animal phobia, and blood-injection-injury phobia have also 
been examined. The first imaging study with specific phobia was published by Mountz et al. in 
1989. These researchers utilized PET to examine brain activations of small animal-phobic and 
non-phobic subjects when exposed to feared animals (snake, spider, or rat depending upon the 
subject’s particular phobia). For symptom provocation, the feared animal was held at eye level 
in front of the subject. However, during the PET scan, subjects were instructed to close their 
eyes, though the stimuli remained in the same location. In comparison with a resting state 
baseline measure (phobic stimuli not in the room), exposure to phobic stimuli did not induce 
significant differences in brain activations. Additionally, there were no significant differences 
in activation when comparing phobic and control subjects. The lack of significant findings in 
this study could have been due to several factors. It could be the phobic stimuli were not 
provocative enough to elicit a response. However, this is unlikely considering the fact that 
subjects’ reports of anxiety level, as well as heart rate measurements, differed significantly 
between the phobic and control conditions. Another factor could be that stimulus presentation 
time was longer in duration (6 minutes) than many of the subsequent PET studies. 
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Additionally, it is not clear what duration of image acquisition was utilized. If data were 
acquired over a longer period of time, this could have had an effect on the findings due to 
washout of the radioactive tracer or habituation to the stimulus. Lastly, only ROI analyses were 
conducted by Mountz et al. whereas voxelwise analysis was included in many of the 
subsequent studies. Depending upon the size and placement of the ROIs, this method may have 
been less sensitive in detecting activation changes. Although the exact reason for insignificant 
findings in this first study is unknown, a multitude of studies conducted since have reported 
significant activation in response to phobic provocation.  
Utilizing a PET paradigm similar to that of Mountz, Rauch et al. (1995) examined 
functional activations of small animal-phobic subjects exposed to phobic stimuli. The phobic 
paradigm consisted of animals within clear cages, which the subjects touched during scanning. 
Functional activation during the phobic condition was compared to activations during a control 
condition (exposure to an empty cage) utilizing both voxelwise analysis and ROI analysis. 
Results indicated that exposure to phobic stimuli was associated with increased activations in 
the anterior cingulate cortex (ACC), left insula cortex, left somatosensory cortex, left 
orbitofrontal cortex (OFC), left thalamus, and right anterior temporal cortex. Similar results 
were reported for a combined group of simple phobia, obsessive-compulsive disorder, and 
post-traumatic stress disorder patients during provocation paradigms individualized for each 
patient (Rauch, Savage, Alpert, Fishcman, & Jenike, 1997). In this study, there were increased 
activations in the right inferior frontal cortex, right posterior medial orbitofrontal cortex, 
bilateral insula cortex, bilateral lenticulate nuclei, and bilateral brain stem. It should be noted 
that Fredrikson, Wik, Annes, Ericson, and Stone-Elander (1995) reported decreased activations 
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in many of these same regions, including the hippocampus, posterior cingulate, prefrontal, 
orbitofrontal, and temperopolar cortices during exposure to phobic versus neutral stimuli. 
(These activation changes were detected through ROI analysis; voxelwise analysis was not 
conducted.) These reports regarding decreased limbic and frontal activations contradict those 
of Rauch et al. (1995; 1997) and subsequent PET and fMRI studies, as will be discussed more 
in depth at the end of this section. 
Carlsson et al. (2004) utilized PET to examine brain activations of spider or snake phobics 
in response to phobic as well as non-phobic, fear-relevant picture stimuli. This study utilized a 
masking paradigm in which neutral stimuli were displayed directly after each phobic or non-
phobic, fear-relevant stimuli. In one condition, a very short period of time was included 
between the experimental and neutral stimuli (14 ms), whereas for the other condition, a longer 
period of time was included (308 ms). Differences in activation for the “short” and “long” 
conditions were compared, assuming that the long condition allowed for full visual processing 
while the short condition did not. During the short condition, there was left amygdala 
activation in response to fear-relevant (both phobic and non-phobic) stimuli. However, when 
exposure time allowed for complete visual processing, the amygdala activated bilaterally in 
response to phobic-relevant stimuli and showed no activation in response to non-phobic, fear-
relevant stimuli. During the long condition, subjects also showed increased activation in the 
ACC, OFC, anterior insula, and the periaquaductal gray (PAG).  
An additional PET study exposed spider phobic subjects to picture stimuli for longer 
periods of time than previous studies in order to examine habituation effects (Veltman et al., 
2004). Voxelwise analysis indicated that, compared to non-phobic subjects, spider phobic 
 12
subjects showed increased activations in the left fusiform gyrus and right parahippocampal 
gyrus when presented with phobic stimuli versus neutral stimuli (butterflies). Also reported 
were signal decreases as a function of time (unique to phobic stimuli) in the medial temporal 
lobe, including the posterior insula cortex, hypothalamus, and right amygdala.  
Functional Magnetic Resonance Imaging. The majority of studies conducted in recent 
years to examine neurophysiological responses to phobic stimuli have used fMRI as 
opposed to PET. Dilger et al. (2003) used fMRI to examine brain activations of spider 
phobic subjects and non-phobic controls to pictures of spiders, snakes, and mushrooms. 
Voxelwise analysis showed that, for spider phobic subjects but not controls, there was 
significant activation in the left amygdala and the right and left insula in response to 
spider pictures as compared to both snake and mushroom pictures. The researchers also 
examined between-group differences in brain activations, revealing spider phobic 
subjects to have stronger activations in the right and left insula, right OFC, and the 
posterior cingulate cortex in response to spider pictures, but not to snake or mushroom 
pictures. Schienle, Schafer, Walter, Stark, and Vaitl (2005) examined neural correlates of 
phobia-relevant, generally fear-inducing, disgust-inducing and affectively neutral pictures 
in both spider phobic and non-phobic individuals. The patient group showed greater 
activation to phobic-relevant stimuli in the visual association cortex, amygdala, right 
dlPFC, and right hippocampus. A neuroimaging study examining the neural correlates of 
anticipatory anxiety in spider phobia (comparing anticipation of phobic stimuli to 
anticipation of neutral stimuli) implicated the dorsal ACC, insula, thalamus, visual area, 
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and a region of the extended amygdala—the bed nucleus of the stria terminalis (BNST; 
Straube et al., 2007).  
fMRI has been used not only to examine differential activation to phobic stimuli for phobic 
and non-phobic subjects, but also to examine the effects of CBT on brain activations. Paquette 
et al. (2003) used a paradigm that included videos depicting live spiders or live butterflies. 
Spider phobic subjects had increased activations as compared to control subjects within the 
dorsolateral prefrontal and the parahippocampal gyrus, as detected through voxelwise analysis. 
By repeating the same fMRI paradigm with the spider phobic patients after completion of 
CBT, these researchers demonstrated that therapy resulted in normalization of these 
activations. However, a phobic control group (receiving no therapy) was not included in this 
study for comparison.  
Straube et al. (2006) used videos of a moving spider and of a moving, black, synthetic 
cylinder to represent phobic and neutral stimuli (respectively) during fMRI. After the initial 
scan, spider phobic subjects were randomized to a CBT or a wait-list control group, after which 
the same fMRI paradigm was repeated. Data analysis included both ROI (dorsolateral 
prefrontal cortex, inferior frontal gyrus, insula, amygdala, and posterior cingulate cortex) and 
voxelwise analysis. For the pre-treatment scan, increased activations were found in the insula 
and ACC for phobic subjects as compared to control subjects in response to phobic stimuli 
(versus neutral stimuli). These activations were reported to have normalized at the post-
treatment scanning session for subjects provided CBT, but not for the wait-listed phobic group. 
Another more recent event-related fMRI study also reported normalization of activity in the 
amygdala, as well as the ACC and insula (in response to symptom provocation), after CBT 
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treatment (Goossens et al., 2007). The most recent fMRI treatment study in spider phobia 
reported normalization (increased) of activity in the OFC from pre- to post- CBT treatment 
(Schienle et al., 2007). In this study, decreases in the amygdala and insula were positively 
correlated with decreases in phobia symptoms.  
fMRI and Fear Extinction in Healthy, Non-Phobic Subjects. In recent years, there has been 
an upsurge in human neuroimaging studies involving fear conditioning and extinction 
paradigms. This is most likely due to the progress made in animal studies of fear conditioning 
and extinction (discussed below), and the focus in psychology on translational research. In 
classical fear conditioning paradigms, subjects (animal or human) are made to fear a previously 
neutral stimulus (conditioned stimulus [CS]) through concurrent presentation with a noxious 
stimulus (unconditioned stimulus [UCS]). Fear extinction involves repeated exposure to the CS 
without concurrent presentation of the UCS. The fear extinction process is conceptualized as 
involving not an “unlearning” of the previous association, but a learning of a new, more neutral 
association. This new association therefore competes with the old CS-UCS association, making 
it appear weaker and reducing the physiological and behavioral response to the CS 
(Ledgerwood, Richardson, & Cranney, 2003). Most of what we know regarding fear 
conditioning and extinction come from animal research, which will be discussed more in depth 
in a later section. However, the following studies provide some information regarding the 
neural mechanisms underlying fear extinction in humans. 
The fear conditioning paradigm utilized by Phelps, Delgado, Nearing, and Ledoux (2004) 
consisted of pairing colored squares with a mild shock to the wrist. ROI analysis was used to 
examine activations within various regions of the amygdala and medial prefrontal cortex 
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(mPFC). Three regions of the mPFC showed differential activations in response to the 
conditioned stimulus as opposed to a neutral stimulus during fear acquisition, as well as on the 
first (Day 1) and second day (Day 2) of extinction training. During conditioning, the dorsal 
region of the bilateral anterior cingulate showed increased activation in response to the 
conditioned stimulus whereas the more ventral region of the ACC and the medial frontal gyrus 
of the mPFC showed decreased activations during presentation of the CS as compared to a 
neutral stimulus. The dorsal anterior cingulate showed increased activation during all three 
phases, though the level of activation was not correlated with the conditioned response. In the 
amygdala, there was increased activation to the CS during acquisition. However, the amygdala 
response switched during the first day of extinction, showing less activation in response to the 
CS as compared to the neutral stimulus, and then normalized during Day 2 of extinction 
training (Phelps et al., 2004). Another fMRI study examining brain activations associated with 
fear conditioning and fear extinction (Gottfried and Dolan, 2004) reported that, during 
conditioning, the rostromedial OFC, dorsomedial amygdala, and insula cortex showed 
significant activations in response to a CS as compared to a neutral stimulus. At extinction, the 
caudal OFC, right lateral amygdala, and the ventromedial PFC showed increased activations in 
response to the CS. However, activations in the medial amygdala and the rostromedial OFC 
were decreased in the extinction trial as compared to the conditioning trial (Gottfried & Dolan, 
2004). Dunsmoor, Bandettini, and Knight (2007) varied the rate at which a CS was paired with 
an UCS (from intermittent to constant) and found that activations within the ACC and 
amygdala increased as the pairing rate increased. In contrast, the dlPFC and insula were 
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activated only during intermittent pairing rates. These results would suggest that the dlPFC and 
insula are involved in the processing of uncertainty regarding fear or conditioning. 
Most recently, Milad et al. (2007) specifically examined the involvement of the dorsal 
ACC in fear conditioning. The authors reported the dorsal ACC to have greater activation 
during presentation of a stimulus that had been paired with an unconditioned stimulus (CS+) 
than one that had not (CS-). Additionally, dorsal ACC activation correlated with skin 
conductance response during CS+ presentation. Two studies (one by the same group who 
authored the last study discussed—Milad et al., 2007 and Kalisch et al., 2006) investigated the 
neural correlates of fear extinction recall. Both studies reported involvement of the 
ventromedial PFC (vmPFC) and hippocampus in extinction recall, which were correlated with 
one another, and seemed to be particularly important for recall of contextual information 
regarding extinction (Milad et al., 2007).  
Researchers have recognized that, although fear conditioning provides a good approximate 
model of phobia, it is not perfect. As discussed before, the majority of people with phobia do 
not report having personally experienced aversive conditioning to the feared object or animal. 
There may be evolutionary and genetic influences at work, in which humans with a fear of 
certain animals/objects were able to survive (along with their genetic material). This, in turn, 
caused descendants to be “programmed” with this same fear (Rakison & Derrnger, 2008). This 
would suggest that those of us without phobia simply extinguished the programmed fear 
whereas those with phobia did not experience extinction. Additionally, humans have an ability 
to learn through verbal exchange of information as well vicariously through others’ 
experiences (as discussed above). Creative neuroimaging studies have been conducted to 
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address this issue and examine distinct neural mechanisms of fear that is learned through direct 
experience, observation, or verbal information. In one such study (Phelps et al., 2001), it was 
verbally communicated to subjects that, during fMRI scanning, presentation of a certain 
colored block would be associated with a shock whereas presentation of another color would 
not involve shocks. However, no shock was ever provided. Regions of the amygdala and insula 
activated in response to the expected CS+ more than during the other conditions and amygdala 
activation correlated with skin conductance response. Additionally, amygdala response 
attenuated (or habituated) over time so that, by the end of the paradigm, amygdala activation 
for the two types of stimuli were equal. Although this paradigm could also be viewed as an 
anticipatory anxiety paradigm, it is interesting to find that expectation of aversive stimuli—
communicated through verbal information only—is associated with modulation of activity in 
the amygdala and insula. This same lab conducted another study (Olsson, Nearing, and Phelps, 
2007) in which subjects were shown videos of other individuals undergoing fear conditioning 
to certain stimuli (as a model of vicarious learning). After viewing these videos, fMRI 
scanning was conducted in which the same stimuli were presented. Increased amygdala 
activation was found for the stimuli used as CS+ in the video. Therefore, it seems that the 
amygdala is involved in the experience of fear regardless of the type of fear learning that 
occurred. 
Summary of Imaging Studies with Phobia and Fear Extinction. The report of decreased 
activations in frontal and limbic structures reported by Fredrikson et al. (1995) is contradictory 
to the results of other PET (Rauch et al. 1995; 1997) and fMRI (Dilger et al., 2003; Paquette et 
al., 2003; Straube et al., 2006) studies showing primarily increased activations in these regions. 
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The inconsistencies can partly be explained by the fact that activations within the frontal 
cortex, as measured by PET, have been reported to vary depending upon the behavioral 
reaction of the subject (Johanson et al., 1998). In the study by Johanson et al., the 133Xe 
inhalation method was used. This method allows information to be collected regarding 
superficial cortical areas only, excluding analysis of deeper brain structures. Results showed 
that subjects displaying panic reactions had decreased activations in the frontal cortex whereas 
those who did not display panic reactions had increased activations. It has been hypothesized 
that decreased activations in frontal and limbic structures may represent reduced conscious 
cognitive processing associated with a defensive response to feared stimuli whereas increased 
activations in limbic and frontal networks may be associated with the use of cognitive 
strategies for coping with exposure to feared stimuli (Paquette et al.). It has additionally been 
suggested that habituation effects during scanning could be responsible for the inconsistent 
results, as Veltman et al. (2004) demonstrated that amygdala, insula, and hypothalamus 
activations in response to phobic stimuli habituated significantly after approximately 15-25 
minutes of exposure. Although habituation may not be the only reason for inconsistent results, 
it is interesting to note that Fredrikson et al. (1995) used film clips that were four minutes in 
duration to serve as the phobic stimulus. The other PET and fMRI studies using provocation 
paradigms presented stimuli for approximately one minute and this time was often broken up 
into blocks of stimuli presentation lasting only 10-25 seconds each. By including a period of 
rest or neutral stimulation between phobic stimuli presentations, these studies could have 
decreased the effects of habituation.  
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The results of PET and fMRI studies in specific phobia have most consistently identified 
activations (signal increases during symptom provocation) in the amygdala, insula, medial 
prefrontal cortex (including the ACC and the OFC), and dorsolateral prefrontal cortex (dlPFC; 
Carlsson et al., 2004; Dilger et al. 2003; Fredrikson et al., 1995; Johanson et al., 1998; Rauch 
et al., 1995; Straube et al., 2004; Wik et al., 1996). Other areas that have been reported to 
activate in response to phobic stimuli include the temporal cortex, fusiform gyrus, 
hippocampus, parahippocampal gyrus, thalamus, putamen, periaqueductal gray, and the 
posterior cingulate (Carlsson et al., 2004; Dilger et al. 2003; Fredrikson et al., 1995; Johanson 
et al., 1998; Paquette et al., 2003; Rauch et al., 1995; Straube et al., 2004; Veltman et al., 2004; 
Wik, Fredrikson, & Fischer, 1997). A recent meta-analysis of neuroimaging studies in phobia, 
social anxiety disorder and PTSD reported the most consistent findings to be increased insula 
and amygdala activation (Etkin & Wager, 2007). Evidence has been provided that successful 
cognitive behavioral therapy normalizes activations in response to phobic stimuli in the ACC 
and insula (Straube et al., 2006; Goossens et al., 2007), and also in the DLPFC, 
parahippocampal gyrus (Paquette et al.) and OFC (Schienle et al., 2007). Fear conditioning in 
non-clinical human populations have revealed increased activations in the ACC, amygdala, 
dlPFC, insula, and OFC (Phelps et al., 2004; Dunsmoor et al., 2007; Gottfried & Dolan, 2004; 
Milad et al., 2007). Fear extinction or “habituation” processes may be associated with 
decreased activations within the amygdala, OFC, and possibly insula (Gottfried & Dolan, 
2004; Phelps et al., 2004; Veltman et al.) while the vmFC and hippocampus have been 
demonstrated to play a role in memory for fear extinction (Kalisch et al., 2006; Milad et al., 
2007). 
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Animal Studies Examining Neural Mechanisms of Fear Conditioning and Extinction 
 Animal models have contributed significantly to our understanding of anxiety disorders, 
especially regarding cued anxiety responses. There is a large animal literature utilizing 
classical fear conditioning as a model for phobia and fear extinction as a model of exposure 
therapy (McAllister & McAllister, 1971; Uys, Stein, Daniels, & Harvey, 2003). There have 
been many excellent reviews conducted recently regarding this literature and translation into 
the clinical treatment of anxiety disorders (Hofmann, 2007a, 2007b; McNally, 2007; Quirk & 
Mueller, 2008). Similar to findings reported in the neuroimaging studies described above, 
animal research has indicated that the amygdala, along with the hippocampus and prefrontal 
cortex, are important in the process of emotional learning and fear extinction (Myers & Davis, 
2002). Single-cell recording studies, as well as studies examining effects of induced brain 
lesions have provided support for these conclusions.  
 Animal research has found that the amygdala, particularly the basolateral complex of the 
amygdala (BLA), is important in emotion and the experience of fear. Lesioning of the 
amygdala leads to profound effects on emotional behavior, reducing vigilance and weariness of 
previously feared objects (Davis & Whalen, 2001; Kluver & Bucy, 1939; Weiskrantz, 1956). 
Fear conditioning seems to depend, at least partially, on NMDA receptor activation within the 
BLA (Baldwin, Holahan, Sadeghian, & Kelley, 2000; Davis & Whalen, 2001; Miserendino, 
Sananes, Melia, & Davis, 1990) and the BLA seems to be particularly important for the 
maintenance of fear once it has been acquired (Anglada-Figueroa & Quirk, 2005). 
Additionally, stimulation of the BLA can produce behavioral and autonomic changes that 
resemble a state of fear (Davis & Whalen, 2001). Although research on anxiety and fear in 
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animal studies has primarily focused on the amgydala and its connections, a related region, the 
bed nucleus of the stria terminalis (BNST) is considered part of the “extended amygdala” 
region and may be involved in the more long-term experience of fear, which could more 
closely resemble the human “anxiety” experience (Davis et al., 1997; Davis & Whalen, 2001; 
Rosen & Donley, 2006).  
 The hippocampus has also been implicated as an important structure for fear, especially 
regarding the extinction process. Fear conditioning and extinction can still occur when the 
hippocampus has been lesioned, but it cannot be maintained (Maren, Aharonov, & Fanselow, 
1997). Additionally, Corcoran, Desmond, Frey, and Maren (2005) demonstrated that 
hippocampal inactivation attenuated fear extinction (though not completely blocking it) and 
seemed to additionally diminish memory regarding contextual attributes of fear extinction. 
Therefore, the hippocampus is thought to be important for the memory of fear conditioning as 
well as fear extinction. 
 When lesions are made in the prelimbic or infralimbic regions of the medial prefrontal 
cortex, fear extinction (but not fear conditioning) is hindered in animals (Morgan, Schulkin, & 
LeDoux, 2003). Additionally, stimulation of the mPFC has also been shown to increase 
retention of extinction whereas mPFC depression caused mice to resist extinction (Herry & 
Garcia, 2002). Single cell recording studies have demonstrated that rats receiving stimulation 
of the infralimbic cortex subregion of the mPFC (which corresponds to the subcallosal anterior 
cingulate in humans) during nonreinforced CS exposure respond faster to extinction training 
and show increased retention of fear extinction (Jinks & McGregor, 1997; Milad, Vidal-
Gonzalez, & Quirk, 2004). The dorsomedial and dorsolateral prefrontal cortices have also been 
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shown to activate along with the ventral medial prefrontal cortex at post-tests of extinction 
recall (Barrett, Shumake, Jones, & Gonzalez-Lima, 2003). It is believed that these regions of 
the PFC could modulate fear extinction through the medial prefrontal cortex, or through direct 
connections with the amygdala (Milad, Rauch, Pitman, & Quirk, 2006). Single-cell recording 
studies have shown that stimulation of the mPFC causes inhibition of the amygdala’s lateral 
and central nuclei neurons (Quirk, Likhtik, Pelletier, & Pare, 2003). Additionally, single-cell 
recording studies have demonstrated that neuronal firing of neurons in the lateral nucleus of the 
amygdala (LA) are reduced during presentation of a previously CS in the absence of the UCS 
(Maren & Quirk, 2004; Repa et al., 2001). 
Animal Studies of D-cycloserine and Fear Conditioning and Extinction 
N-methyl-D-aspartate (NMDA) receptors are implicated in the fear conditioning and 
extinction process based on observations that NMDA antagonists (e.g. D,L-2-amino-5-
phosphonovaleric acid [AP5]), injected into the BLA, block the acquisition of fear in fear 
conditioning paradigms (Davis, 1992; Falls, Miserendino, & Miserendino et al., 1990; 
Richardson, Ledgerwood, & Cranney, 2004). This effect has been demonstrated using visual, 
auditory, and olfactory cues in the conditioned fear paradigm (Campeau, Miserendino, & 
Davis, 1992; Miserendino et al., 1990; Paschall, Walker, & Davis, 2001). However, studies 
also indicate that intra-amygdala infusions with NMDA antagonists do not disrupt fear-
potentiated startle (Campeau et al., 1992; Miserendino et al., 1990; Rodrigues, Schafe, & 
LeDoux, 2001). This would suggest that NMDA antagonists do not block fear acquisition by 
inactivating the amygdala nor do they prevent cognitive access and processing of the fear 
stimulus (Davis, 2002). Administration of NMDA antagonists in the BLA has been shown to 
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block fear extinction as well as fear acquisition (Falls et al., 1992). However, it does not appear 
as if the NMDA antagonists damage aspects of the amygdala associated with fear conditioning 
and extinction. This is demonstrated by the fact that rats previously included in such studies 
subsequently showed normal fear conditioning and extinction when not administered NMDA 
antagonists.  
Results from the studies described above demonstrate the role of NMDA receptors in fear 
acquisition and extinction. These findings led researchers to hypothesize that NMDA agonists 
may have the opposite effect –enhancing of the fear extinction process. Full NMDA agonists 
have been associated with neurotoxicity due to deregulation of Ca2+. However, partial NMDA 
agonists, such as D-cycloserine (DCS), are not known to produce toxicity and have few side 
effects (Davis, 2002). Walker, Ressler, Lu, and Davis (2002) demonstrated that systematic 
administration of DCS, as well as direct infusion of DCS into the basolateral nucleus of the 
amygdala, facilitated the extinction of conditioned fear in rats. In this study, a fear-potentiated 
startle paradigm was used to examine the effects of 3.25, 15, and 30 mg/kg doses of DCS as 
compared to saline injections. The fear extinction response was dose-dependent. All DCS 
groups experienced enhanced fear extinction compared to the saline group and the 15 and 30 
mg/kg DCS groups showed greater fear extinction than the 3.25 mg/kg DCS group. The fear 
extinction enhancement properties of DCS have been replicated by other researchers using a 
variety of fear-conditioning paradigms (Ho et al., 2005; Ledgerwood, Richardson, & Cranney, 
2003, 2004; Yang & Lu, 2005). In these studies, DCS had an effect on fear extinction only 
when it was paired with extinction training, not when it was administered alone. Ledgerwood, 
et al. (2003) also demonstrated that DCS can enhance extinction if administered after 
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extinction training, though the effects decreased as the time between extinction training and 
DCS administration increased. These results were interpreted to indicate that DSC produces 
effects through enhancing memory consolidation regarding the fear extinction process.  
Another concept of fear conditioning in animal paradigms is reinstatement. Animals that 
undergo fear extinction will subsequently have their fears “reinstated” in response to UCS 
exposure. Ledgerwood et al. (2004) demonstrated that rats that had undergone fear extinction 
supplemented with DCS (as compared to saline) did not experience reinstatement. This would 
indicate that not only does DCS administration enhance the effects of fear extinction, it helps 
to maintain extinction. Additionally, if two separate conditioned stimuli have been paired with 
an UCS, rats that undergo DCS-supplemented fear extinction with only one CS will also show 
extinction of fear associated with the other CS (Ledgerwood, Richardson, & Cranney, 2005). 
This generalization across the conditioned stimuli does not occur in rats provided only saline 
prior to fear extinction. Furthermore, rats that have undergone DCS-supplemented fear 
extinction are not impaired in their ability to acquire fear in the future, even when that fear 
involves the previous CS or UCS (Ledgerwood et al., 2005). Therefore, not only does DCS 
enhance fear extinction, it appears to enhance the maintenance and generalization of fear 
extinction as well. Additionally, it appears that these effects are produced without causing 
permanent disability regarding fear acquisition and learning. 
Human Studies of D-cycloserine and Exposure and Response Prevention 
The first study to examine the effects of DCS on ERP therapy did so with height phobia 
(Ressler et al., 2004). Subjects were randomly assigned to one of three treatment groups: 
placebo with virtual reality exposure (VRE) therapy (n=10), 50 mg DCS with VRE therapy 
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(n=8), and 500 mg DCS with VRE therapy (n=9). Each subject underwent two 35-45 minute 
VRE sessions within a 1-2 week period. Subjects took medication 2-4 hours prior to the 
therapy sessions. One week following the second VRE session, the groups that received DCS 
showed significantly less fear of heights, as measured by the subjective units of distress scale 
(SUDS) at successive elevator floors (as experienced through virtual reality). This difference 
was observed for both the 50 mg and the 500 mg DCS groups. Twenty-one of the subjects 
returned for follow-up assessment 3 months later. Again, those treated with DCS-supplemented 
therapy experienced significantly less fear of heights (as measured by SUDS) than those 
treated with placebo-supplemented therapy. A similar study was conducted with social anxiety 
disorder (Hofmann, Pollack, and Otto, 2006a), using 50 mg DCS, administered one hour prior 
to each of 4 sessions of ERP therapy. The DCS group had greater decreases in social anxiety 
symptoms (as measured by the Social Phobia and Anxiety Inventory) at post-treatment and one 
month follow-up. The effect size for the difference at follow-up (Cohen d=1.43) was even 
greater than that at post-treatment (Cohen d=.98). 
Two studies have been published reporting null results for the effects of DCS (Guastella 
et al., 2007a and 2007b). Both of these studies used non-clinical samples, however. The first 
(Guastella et al., 2007a) recruited college undergraduates who had a fear of spiders (but not 
diagnosable as spider phobia) and provided one session of ERP, augmented with either 50mg 
DCS, 500mg DCS, or placebo. The second study (Guastella et al., 2007b) conducted a 
differential shock conditioning paradigm with non-anxious control subjects and administered 
either 50 mg DCS, 500 mg DCS, or placebo prior to fear extinction trials. For both of these 
studies, there were no significant findings regarding skin conductance or self-report measures 
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of anxiety. In response to these null findings, many researchers postulated that DCS effects 
would only be detectable if the population was diagnosable with a clinical anxiety disorder. 
Otherwise, even just one session of ERP could produce a floor effect across groups in which 
effects would not be detected. In response to these criticisms, the same lab that reported null 
findings conducted a study examining the effects of DCS in social anxiety disorder (Guastellla 
et al., 2008). With four sessions of ERP, those receiving 50 mg of DCS augmentation (1 hour 
prior to session) had a greater reduction in anxiety symptoms than those provided placebo. This 
effect was apparent at post- treatment and follow-up, though the effect seizes were lower than 
that reported by Hofmann et al. (2006a). For the DCS group only, anxiety reduction was 
related to subjects’ appraisals about their speech performances. The authors postulated that 
adaptive learning and self-appraisal may be potential mechanisms for the effects of DCS. 
Three studies have been published thus far examining the effect of DCS-augmented ERP 
for OCD. The first of these (Storch et al., 2007) conducted 10 weekly sessions of ERP, 
augmented with 250 mg of DCS, administered 4 hours prior to each session. For a variety of 
outcome measures (including the Y-BOCS) assessed at pre-treatment, post-treatment, and 2-
months follow-up, there were no differences between treatment groups (though both groups 
benefited significantly from treatment). Kushner et al., (2007) examined the effects of 125 mg 
DCS versus placebo, administered two hours prior to 10 ERP sessions (conducted twice 
weekly). Although comparing groups on Y-BOCS scores at mid- and post- treatment revealed 
no differences, the DCS group did have a faster response to treatment as measured through 
estimated SUDS ratings of hierarchy items. This effect was only significant at Session 4, 
however. The groups did not differ at the end of treatment. Interestingly, the DCS group had a 
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significantly lower dropout rate (approximately 7%) than placebo (approximately 35%). The 
most recent DCS study in OCD administered 100 mg DCS or placebo one hour prior to each of 
10 sessions ERP, conducted twice weekly (Wilhelm et al., 2008). The DCS group had greater 
decreases in symptoms (as assessed by the Y-BOCS) at mid-treatment and post-treatment, 
though the effect only reached significance at mid-treatment. In addition, depression scores (as 
assessed by the BDI) decreased significantly more in the DCS group as measured at post-
treatment. Although it was recognized that the effect seen for depressive symptoms may have 
been secondary to accelerated progress in regards to the OCD symptoms, the authors also 
suggested that alteration of dysfunctional beliefs may provide a common mechanisms for the 
enhancing effects of DCS for both depressive and OCD symptoms.  
In summary, results from clinical studies with DCS-augmented ERP have been 
promising. There is some indication that it may not only influence behavior, but also 
cognitions and appraisals. Therefore, the mechanisms of DCS in clinical treatment may be 
more complex than what can be measured in animal studies. It will be important for future 
research to identify the specific cognitive, behavioral, and neural mechanisms for DCS in 
human populations in order to supplement the knowledge gained from animal studies. 
Functional Imaging Studies of D-Cycloserine 
 To the author’s knowledge, there has been only one neuroimaging study investigating the 
effects of acute D-cycloserine administration. Britton et al. (2007) administered 500 mg DCS 
or placebo to healthy subjects (with no clinical diagnosis) 1.5 hours prior to fMRI scanning. 
During scanning, subjects viewed either fearful or happy faces during 80-second blocks 
(surrounded by 20-second fixation blocks). This paradigm has previously been shown to be 
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associated with initial amygdala activation and subsequent habituation throughout the 
paradigm. The paradigm was chosen in order to examine the effects of DCS on amygdala 
activation and habituation. Therefore, fMRI analysis was restricted to the bilateral amygdala. 
There were no differences found between groups regarding subjective anxiety state. Amygdala 
activation was decreased in the early period of the paradigm for the DCS group and therefore 
also showed less habituation in this region than the placebo group. This finding was opposite 
from what was predicted by the investigators. The authors interpreted this as evidence that 
DCS may alter the overall level of amygdala activation instead of influencing the speed of 
amygdala activation. However, it was noted that the paradigm did not allow for high enough 
temporal resolution to examine the very early amygdala response and therefore the possibility 
still remains that DCS is associated with exaggerated initial amygdala response that then 
habituates very quickly. It was also noted that whole-brain analyses were not performed and 
therefore conclusions cannot be made regarding whether the amygdala is being affected 
directly or through other brain regions modulating amygdala activity. Further research is 
needed to examine these possibilities as well as to examine neural effects of DCS in clinical 
populations.  
Network Models of Fear Processing and Extinction 
 Despite apparent differences in the experience of anxiety and mechanisms for the 
alleviation of anxiety between humans and animals, the primary neural networks that have 
been implicated are relatively similar. Neurophysiological models of emotional and, more 
specifically fear processing, have been proposed by other researchers and most often implicate 
the amygdala, prefrontal cortex, insula, and ACC (Phan, Wager, Taylor, and Liberzon, 2004). 
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Brain imaging studies in humans with specific phobia also indicate that these regions become 
activated during exposure to phobic stimuli. As mentioned before, extinction is currently 
thought to involve the learning of a new association that competes with an older association. 
However, the neurophysiological basis of this process is less understood than for fear 
processing in general. The brain regions hypothesized to play important roles in the extinction 
process are generally the same regions implicated in fear processing (Phan et al.). The brain 
regions implicated in fear processing and fear extinction are part of limbic and paralimbic brain 
networks, thought to comprise affect regulation systems that assign reward and punishment 
value to stimuli in the environment (Scheinle et al., 2005). The animal and human research 
relevant to each region will be summarized below to provide a basis for the hypotheses and 
results presented in the current study. 
 Amygdala. The amygdala is thought to lie at the center of the brain’s emotional processing 
system (Lang, Davis, & Ohman, 2000). As discussed previously, it has been shown to be 
involved in both fear acquisition and fear extinction in animals and is correlated with response 
to feared stimuli in both phobic and non-phobic human populations (Flynn, Benson, & Ardila, 
1999). Purportedly, over 60% of studies that have examined fear-processing in non-phobic, 
healthy control subjects report amygdala activation (Phan et al., 2004). It is believed that after 
sensory input is relayed through the thalamus, it diverges into two pathways, a direct and an 
indirect (Flynn et al.). The direct pathway continues directly to the amygdala, allowing 
immediate processing of potentially dangerous stimuli (Flynn et al.). The existence of such a 
pathway is illustrated in studies that have reported amygdala activation in response to short, 
masked stimuli that are not consciously processed by the subject (e.g. Carlsson et al., 2004). 
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The more indirect pathway is thought to involve the hippocampus, parahippocampal gyrus, and 
the sensory, association and prefrontal cortices (Flynn et al.). Through this indirect pathway, 
the significance of stimuli can be more accurately estimated, by allowing the consideration of 
previous experience and contextual cues.  
 Neurons in the lateral nucleus of the amygdala are thought to modulate the activity of the 
neurons in the central nucleus (Davis, 2006). The lateral nucleus connects to the basal 
amygdala (including basolateral, basomedial, and accessory basal nuclei), which in turn, 
connects to the central nucleus (Anglada-Figueroa & Quirk, 2005). The basal amygdala is the 
primary source for projections between the amygdala and prefrontal cortex. Animal research 
has provided evidence that, although the basal amygdala may not be necessary for the 
acquisition of fear, it is important in the maintenance of fear (Anglada-Figueroa & Quirk). 
Although regions of the amygdala have been shown to activate in response to exposure with 
feared stimuli, it has been demonstrated that the amygdala activations decrease in humans 
during fear extinction (Gottfried and Dolan, 2004; Phelps et al., 2004).  
 As noted earlier, DCS has been shown to influence fear extinction in animals when injected 
directly into the basolateral amygdala (i.e. Walker et al., 2002). Additionally, a neuroimaging 
study provided evidence that 500 mg DCS decreases activity in the amygdala for non-anxious 
control subjects during the processing of emotional faces (Britton et al., 2007). 
 Prefrontal Cortex. It is thought that sensory information enters conscious awareness only 
after being processed by the prefrontal cortex (Flynn et al., 1999). The prefrontal cortex is 
believed to be involved in using relevant information supplied through connections with the 
amygdala, sensory cortices, hippocampus, and other regions to regulate behavioral and visceral 
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responses to environmental stimuli (Flynn et al.). The medial prefrontal cortex, including the 
orbitofrontal cortex and the anterior cingulate cortex (ACC), is thought to play a role in 
emotion-related decision-making and emotional self-regulation (Phan et al., 2004). It was 
found to be activated in 50% of studies examining emotional processing in humans (Phan et 
al.). Therefore, this may be a common region to all different emotions, including fear (Phan et 
al.). It has been hypothesized that the mPFC is involved in the cognitive aspects of emotional 
experience, including attention, appraisal and awareness of the emotion (Phan et al.). The 
dorsolateral PFC is thought to engage working memory processes to prepare and select 
responses to the threatening stimuli (Flynn et al.). The ACC is thought to be involved in 
regulating attention to environmental stimuli for the purpose of cognitive and emotional 
processing (Phan et al.). The prefrontal cortex in general may serve as a “top-down” modulator 
of the emotional responses generated by the amygdala.  
 The ventral medial, dorsomedial and dorsolateral prefrontal cortices have all been shown to 
activate during extinction training of a conditioned stimulus (Milad et al., 2006). Thickness of 
the medial OFC region has also been shown to correlate with level of extinction retention in 
humans (Rauch et al., 2005). Research demonstrating diminished fear extinction with 
prelimbic or infralimbic medial, as well as dorsomedial, prefrontal cortex lesions, support the 
theory that the prefrontal cortex plays an important role in the fear extinction process (Morgan 
& LeDoux, 1995). The vmPFC (along with the hippocampus) is also thought to play a major 
role in memory for fear extinction (Milad et al., 2007)  
 It has been demonstrated in anxiety disorders other than specific phobia (e.g. social phobia 
and post-traumatic stress disorder) that prefrontal cortex activity has an inverse relationship 
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with amygdala activity (Milad et al., 2006). Additionally, when tasks require increased 
cognitive effort (e.g. appraising stimulus for personal relatedness), amygdala activations 
decrease as PFC and ACC activations increase (Phan et al., 2004). These findings, along with 
results from single-cell recording studies in animals (discussed previously), can be viewed as 
evidence for the regulatory role of the PFC in the emotional processing network (Quirk et al., 
2003; Rosenkranz, Moore, & Grace, 2003). 
 Although animal research on DCS and fear extinction has focused primarily on DCS 
effects through the amygdala and hippocampus, recent research has provided evidence that 
DCS also influences neural events and behavior through the mPFC (Fujihira et al., 2007; Murai 
et al., 2007).  
  Insula. The insula is closely connected to both the amygdala and the ACC and is thought to 
relay information regarding interoceptive and internal somatic sensations (Flynn et al., 1999). 
It may be involved in integrating this information with cues provided about the external 
environment. The insula is also known to be involved in the modulation of autonomic 
functions, such as cardiovascular and pulmonary activity and has been theorized to play a role 
in fear conditioning (Flynn et al). This region has not received as much attention as the 
amygdala and other areas of the PFC and therefore its exact role in emotional processing is not 
understood. However, current theories postulate that the insula is involved in the prediction or 
anticipation of body states (i.e. in response to feared stimuli) as well as the integration of 
somatic information and bodily states (Paulus & Stein, 2006). 
 Hippocampus. The hippocampus, which has been conceived as the central region 
associated with learning and memory, has been implicated in fear conditioning and extinction 
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as well. Because fear extinction is most often viewed as the learning of a new association to 
compete with an old association, it would be expected that the hippocampus would be involved 
in the process. Animal research has added much to the understanding of the hippocampi role in 
fear extinction and learning by demonstrating that it is necessary for recall of contextual cues 
related to conditioning/extinction, as well as for the normal acquisition of fear extinction 
(Corcoran et al., 2005; Xavier, Stein, & Bueno, 1990). It is thought to modulate the response of 
the amygdala to phobic or feared stimuli through neural connections with both the amygdala 
and the prefrontal cortex.  
 Animal studies have shown that DCS can enhance synaptic plasticity in the hippocampus 
(Billard & Rouaud, 2007; Yaka et al., 2007). Additionally, direct infusion of DCS into the 
hippocampus has been shown to influence learning and behavior (Ohno & Watanabe, 1998; 
Rouaud & Billard, 2003; Yamamoto et al., in press).   
 Neural Network Model of Fear Extinction. A neural circuitry responsible for fear extinction 
has been proposed by several researchers (Cannistraro & Rauch, 2001; Maren & Quirk, 2004; 
Milad et al., 2006; Myers & Davis, 2002). This theorized network primarily involves regions 
of the prefrontal cortex and amygdala, but also includes the insula, hippocampus, and sensory 
cortices. Pictoral representation of this network is displayed in Figure 1. It is hypothesized that 
fear extinction involves an inhibitory or regulatory power of the mPFC and the ACC over the 
amygdala (Maren & Quirk, 2004; Myers & Davis, 2002). This could be viewed as a 
mechanism through which cognitive processes are used to inhibit a conditioned response to the 
old association in order to allow for the establishment of a new association. Through 
connections between these structures and the hippocampus, new learning takes place and 
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contextual cues are attached to the newly learned association (Cannistraro & Rauch). The 
insula has not frequently been included in these theoretical models of fear extinction because 
its role has been supported primarily through human imaging studies and not through animal 
research. However, because it is thought to play an important role in the integration of 
information and modulation of autonomic functions, it is included in the model presented. 
Neverthless, because so much is unknown about this region, the direct relationship between 
this region and the others is not specified.  
Phobia and Cognition 
Neurocognitive function has become an important focus of anxiety-related research 
within the past decade. However, this research has concentrated primarily on obsessive-
compulsive disorder (Airaksinen, Larsson, & Forsell, 2005; Dirson, Bouvard, Cottraux, & 
Martin, 1995; Purcell, Maruff, Kyrios, & Pantelis, 1998; Savage et al., 1996, 1999, 2000), with 
only a few studies published regarding panic disorder and/or social phobia (Asmundson, Stein, 
Larsen, & Walker, 1995; Cohen et al., 1996; Lucas, Telch, & Bigler, 1991; Purcell et al., 
1998). There has been very little research examining cognitive functioning of patients with 
specific phobias (Castaneda et a., 2008). When this clinical group is included, it is usually to 
serve as a control group for the investigation of cognitive function in other anxiety disorders 
(Leplow, Murphy, & Nutzinger, 2002). When cognitive functioning of specific phobia patients 
has been compared to normal controls, no deficits have been found (Airaksinen et al., 2005). 
This includes measures of general intellectual functioning, verbal memory, non-verbal 
memory, verbal fluency, and executive functioning (Airaksinen et al.; Leplow et al.). However, 
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it should be recognized that thorough characterization of neuropsychological functioning in 
phobic individuals has not been conducted. 
There is some evidence that when phobic stimuli are involved within cognitive tasks, the 
performance of phobic patients is negatively affected. For example, when spider-related words 
are included in a Stroop color naming task, spider phobic patients are slower in color naming 
than non-phobic controls (Thorpe & Salkovskis, 1997). It has also been reported that spider 
phobic patients are impaired in the recall of anxiety-related words as compared to words 
relating to stimulus features of spiders (Watts & Coyle, 1993). However, there have been other 
studies reporting no differences between phobic patients and non-phobic controls regarding 
stimulus recall or Stroop performance involving phobic-related stimuli (Kindt, Bierman, & 
Brosschot, 1997; Kulas, Conger, & Smolin, 2003; Sawchuk, Meunier, Lohr, & Westendorf, 
2002; Thorpe & Salkovskis, 2000).  
D-cycloserine and Cognition 
Animal research has repeatedly demonstrated that DCS can enhance processes of 
learning and memory in rats and various other animals (monkeys, rabbits, etc.). These effects 
have been demonstrated in both normal, healthy animals (Anderson, Lindberg, & Myhrer, 
2002; Land & Riccio, 1999; Lelong, Dauphin, & Boulouard, 2001; Matsuoka & Aigner, 1996; 
Monahan et al., 1989; Thompson & Disterhoft, 1997), as well those with chemically-induced 
(Kishi, Ohno, & Watanabe, 1998; Meyer, Knox, Purwin, Spangler, & Ingram, 1998; Schneider, 
Tinker, Van Velson, & Giardiniere, 2000) or lesion-induced (Reikkinen, Ikonen, & Riekkinen, 
1998a and 1998b) cognitive deficits. Acute DCS administration appears to increase 
consolidation and maintenance of spatial memory (e.g. water maze task; Meyer et al., 1998; 
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Riekkinen et al., 1998b), non-spatial memory (e.g. simultaneous brightness discrimination test, 
eye-blink conditioning task; Anderson et al., 2002; StrØmme Johannssen & Nyhrer, 2002; 
Thompson & Disterhoft, 1997), and visual recognition memory (Matsuoka & Aigner, 1996). 
This cognitive enhancement is thought to be mediated primarily through actions within the 
hippocampus. This theory is supported by findings that DCS fails to alleviate induced 
cognitive deficits in rats when the hippocampus is inactivated (Riekkinen, Ikonen, & 
Riekkinen, 1999). Additionally, Rouaud & Billard (2003) found DCS to facilitate long term 
potentiation and synaptic plasticity within the hippocampus of rats, providing a possible 
mechanism for memory consolidation and maintenance. Although animal research would 
suggest that DCS can enhance cognitive functioning across various tasks and domains, one 
cannot assume that this will necessarily hold true in human populations. Cognitive functioning 
in humans has evolved to a much higher, abstract level than is found in most animals and often 
involves verbal information. Cognitive tasks used in animals, by necessity, all involve some 
type of reward aspect (i.e. food) in order to motivate the animal to complete tasks. In human 
studies, we are able to verbally explain the rules of a task and we often rely on subject’s 
intrinsic motivation or their feelings of obligation (i.e. to research or the investigator) to 
convince them to complete the task to the best of their ability. Therefore, studies concerning 
the effects of acute DCS on human cognitive functioning (with and without the aspect of 
reward) are needed to elucidate the findings from animal research. 
In human research, there have been some clinical studies reporting prolonged, daily DCS 
administration to enhance cognitive performance of Alzheimer’s disease patients (Schwartz, 
Hashtroudi, Herting, Schwartz, & Deutsch, 1996; Tsai, Falk, Gunther, & Coyle, 1999). 
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Increased cognitive functioning of Alzheimer’s patients, as assessed by the Alzheimer’s 
Disease Assessment Scale (ADAS), which includes measures of language ability, memory, and 
orientation to time and place, has been reported in response to 50 mg/day and 100 mg/day 
doses, but not with 15 mg/day doses (Tsai, Falk, & Gunther, 1998; Tsai et al., 1999). Randolph 
et al. (1994) found no significant clinical benefit for one week DCS administration (25, 50, 
100, 175, 300, and 500 mg) on cognitive functioning as assessed by the ADAS and the 
Repeatable Battery for the Assessment of Dementia (RBAD). A more recent study found no 
clinical benefit of daily DCS administration (2, 10, 30, 100, and 200 mg/day) on cognitive 
functioning as assessed by the Clinical Global Impression (CGI) scale, for which the clinician 
provides ratings on severity of illness, global improvement, and efficacy (Laake & 
Oeksengaard, 2002). Therefore, it appears that while DCS may produce increased cognitive 
functioning with Alzheimer’s patients, results are inconsistent. 
There have also been reports that repeated DCS administration (50 mg/day) can have a 
beneficial effect on the cognitive functioning of schizophrenia patients, as measured by 
Sternberg’s Item Recognition paradigm, a continuous-performance, choice-reaction-time task 
(Goff, Tsai, Monoach, & Coyle, 1995). However, attempts to replicate this finding have failed, 
despite additional (though inconsistent) reports of decreased negative symptoms in 
schizophrenic patients with DCS administration (Duncan et al., 2004; Goff et al., 1996; Goff et 
al., 2005; Goff, Henderson, Evins, & Amico, 1999).  
There has been one study investigating the effects of DCS administration on the cognitive 
functioning of anxiety patients. Heresco-Levy et al. (2002) examined the effects of repeated 
DCS administration on emotional and cognitive symptoms experienced by patients with post-
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traumatic stress disorder (PTSD). These subjects were given either 25 mg DCS or placebo 
twice daily for a period of 4 weeks. After this period, subjects underwent a 2-week “washout” 
period followed by a 4-week crossover treatment period. A battery of psychological and 
neuropsychological tests was administered bi-weekly throughout the study. Although DCS 
treatment was not associated with any clinically significant improvement in the 
emotional/psychological symptoms of PTSD, it was associated with improvements on the 
Wisconsin Card Sorting Test, a measure of executive function (Heresco-Levy et al., 2002).  
Discrepancies in study results regarding cognitive enhancement of DCS could be due to a 
number of factors. It is possible that differences in outcome measures could have different 
levels of sensitivity to the effects of DCS. For example, the Clinical Global Impression Scale 
that is produced from clinician reports (Laake & Oeksengaard, 2002) may not have been as 
sensitive as an implicit verbal memory task (Schwartz et al., 1996). Additionally, to the 
author’s knowledge, systematic investigation of optimal dosage for cognitive enhancement has 
not been conducted. Therefore, the amount and frequency of dosage may have affected the 
results. However, this is unlikely considering that consistent results were not even reported for 
studies including similar dosing schedules (Randolph et al., 1994; Tsai et al., 1998; Tsai et al., 
1999). Results from animal studies with DCS may provide some insight regarding the 
inconsistency of results in these human studies. Every animal study reporting beneficial 
cognitive effects of DCS has done so using acute administration. That is, they have all 
measured some aspect of functioning or behavior within 30 minutes of DCS administration—
not after prolonged, daily administration, as was used in the human studies.  
 39
It is possible that prolonged exposure to DCS may eliminate the enhancement properties 
of the drug. In fact, there have been animal studies suggesting this to be so. It has been shown 
that if mice are pre-exposed to 3mg/kg DCS twice a day for 15 days prior to maze training, 
there is no enhancement of the learning process (Quartermain, Mower, Rafferty, Herting, & 
Lanthorn, 1994). Even when researchers increased the dose of the DCS administered on the 
day of training, the beneficial effects were not reinstated. Another study demonstrated the same 
type of effect in relation to fear extinction. Rats were injected with 0, 1, or 5 dosages of DCS 
within a 10-day period (administered every other day). After this 10-day period, rats were lead 
through a fear conditioning paradigm. The day following fear conditioning, rats underwent a 
fear extinction paradigm augmented with DCS. The performance of rats given 5 previous 
injections of DCS was equal to rats provided saline prior to extinction. The rats with less pre-
exposure to DCS exhibited the expected enhancement of fear extinction (Ledgerwood et al., 
2003). Further analysis within this same study demonstrated that DCS was still able to enhance 
fear extinction if a 4-week interval was placed between DCS pre-exposures and the extinction 
paradigm. This research would suggest that prolonged administration of DCS does not have the 
cognitive or fear extinction enhancement properties that acute administration appears to have. 
If this is true for humans as well as for animals, it would eliminate any rationale for the 
prolonged, daily administration of DCS to treat cognitive impairment.  
There has been only one study, to the author’s knowledge, that has examined the 
cognitive effects of acute DCS administration. This study (Bailey et al., 2007) compared 
subjects treated with 50 mg DCS or placebo (90 minutes prior to testing) during either a high-
anxiety (induced by Co2 inhalation) or low-anxiety (air inhalation) state on the Manikin task. 
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The Manikin task is a visuospatial manipulation task. For the low-anxiety groups, those treated 
with DCS performed better on this task (as measured by number of correct responses) and 
reported the task to be easier (on a self-report measure) than did the placebo-treated group. The 
authors interpreted this to show that DCS enhances the process of learning during low-anxiety 
states. However, the use of the Manikin task as a measure of learning has not been validated. 
Additionally, increased performance at several points during the task does not represent 
enhanced learning. This would be better tested through a time X group interaction analysis to 
examine whether the DCS group increased their performance throughout the task more than the 
other group. (For the study discussed, this was not the case.) Therefore, although this study 
suggests that DCS may modulate cognitive functioning, the results are not conclusive. Further 
research examining the effects of acute DCS administration on cognitive functioning is needed 
to elucidate findings from animal research and to provide guidance for the future clinical 
applications of DCS.  
Pharmacokinetics of D-cycloserine 
DCS readily penetrates the blood-brain barrier and acts on the strychnine insensitive 
glycine-recognition sites of the NMDA subtype of glutamate receptors (Richardson, 
Ledgerwood, & Cranney, 2004). The intrinsic activity of DCS is 40 – 86% depending on the 
experimental paradigm used in the study. DCS is considered a partial agonist for the 
NR1/NR2A and NR1/NR2B heteromers. It is considered a partial agonist because it acts as an 
agonist in the presence of low glycine concentrations and as an antagonist in the presence of 
high glycine concentrations (Danysz & Parsons, 1998).  
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DCS not only has varying agonist/anatagonist properties depending on endogenous 
glycine levels, but also has varying properties depending upon the dose of DCS itself. DCS 
seems to act as an agonist at smaller doses and an antagonist at higher doses. This effect is 
most likely due to agonistic actions at NR1/NR2C receptors at lower doses and inhibition of 
NR1/NR2A and NR1/NR2B receptors at high doses (Danysz & Parsons, 1998).  
The endogenous agent, D-serine has been found to have high concentrations in the 
cerebral cortex, hippocampus, striatum, and limbic system and low concentrations within the 
diencephalons, cerebellum, and pons-medulla in mammals. This work has been conducted 
primarily with mice, but similar results have been found in human and other primates. These 
results also correlate with the distribution of glutamate and glycine NMDA receptor sites 
(Nishikawa, 2005).  
With a single oral dose of 250 mg DCS, peak CSF concentrations (12.8 mg/ml) are 
reached two hours after administration and have a plasma half-life of approximately nine hours 
(Nair, Epstein, Baron, & Mulinos, 1956; Peloquin, 1991). DCS has been used for more than 30 
years as an antibiotic for tuberculosis, for which it has been prescribed at daily doses ranging 
from 500-2000 mg. Being a partial NMDA agonist, DCS does not appear to lead to 
excitotoxicity like full NMDA agonists (Heresco-Levy et al., 2002). In studies reporting 
administration of 50-500 mg DCS acutely or with treatment duration of less than one week, no 
clear drug-related side effects have been reported (Hofmann et al., 2006a; Kim et al., 2000; 
Kushner et al., 2007; Randolph et al., 1994; Ressler et al., 2004; Storch et al., 2007; van 
Berckel et al., 1998; Wilhelm et al., 2008). However, the following side effects of daily, 
prolonged administration of DCS (primarily with doses greater than 500 mg) have been 
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reported: tremor, hallucinations, delusions, catatonic reactions, clinical depression, exaggerated 
reflexes, speech difficulties (dysarthria), and slight paralysis (Cascella, Macciardi, Cavallini, & 
Smeraldi, 1994; Mandell & Sande, 1990; Storey & McLean, 1957). Additionally, there is some 
indication that epilepsy patients may be at higher risk of developing side effects from repeated 
administration with DCS, particularly if consumed concurrently with ethanol (Wlaz, Baron, & 
Losher, 1994). The occurrence of the symptoms listed has been rare, and none have occurred in 
response to a single dose of DCS, as used in the current study.  
It is important to note that the effect of DCS administration on overall hemodynamic 
response has not been directly examined in human subjects (and is not measured in the current 
study). However, a recent study with primates provides evidence that DCS does not significant 
influence overall cardiovascular activity (i.e. body temperature, systolic and diastolic blood 












Chapter 2: Method 
Subjects 
Pre-study Affective Ratings for Stimulus Validation 
Prior to initiation of the proposed project, 10 spider phobic patients were recruited to 
provide affective ratings/validation of visual stimuli to be used during the fMRI symptom 
provocation paradigm. Eighty pictures of spiders and 20 pictures of butterflies, obtained from 
validated databases, such as the International Affective Picture System (IAPS) (Lang, Bradley, 
& Cuthbert, 1999), as well as from internet and other published sources, were included. 
Subjects were asked to rate each picture according to “arousal” using the Self-Assessment 
Manikin (SAM). The SAM was utilized for collection of normative data regarding the IAPS 
(Lang et al., 1999) and is a nonverbal method to quantify subjective feelings states. The 
version of the SAM that was used in the current study consisted of five icons defining a 9-point 
scale for arousal (1=extremely aroused, 9=extremely calm).  
Subjects recruited for this validation study were not included in the entire study protocol. 
They were recruited in the same manner as the rest of the study subjects (described below) and 
screened using the Spider Phobia Questionnaire (SPQ) and eligibility survey. This screening 
process required approximately 15-20 minutes for completion. Those who met criteria were 
scheduled for an appointment at either the Kansas City Center for Anxiety Treatment 
(KCCAT) or Hoglund Brain Imaging Center (HBIC). At this appointment, they were asked to 
provide written consent. After providing affective ratings for the potential stimuli, these 
subjects’ involvement in the study was complete. Completion of pre-study affective ratings 
required approximately 30 minutes of each subject’s time.  
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There were 3 male and 7 female raters included in this validation study. The mean age 
was 26.50 (SD=4.50) and the mean years of education was 16.60 (SD=1.90). The average SPQ 
raw score for this group was 19.20 (SD=4.69). The average rating for all 80 spider pictures 
included was 3.90 (SD=1.74). The mean rating for the 15 butterfly pictures was 7.65 (SD=.45). 
The 60 spider pictures rated as most arousing by these subjects were included for use in the 
fMRI symptom provocation paradigm. The average arousal rating for these 60 pictures was 
2.91 (SD=.45). The difference between ratings for the spider and butterfly pictures was 
significant (t(73) = 36.65, p<.001).  
Recruitment 
Throughout the one year of the present study, 54 subjects (27 phobic, 27 non-phobic 
healthy controls) were recruited from 1) advertisements on the KUMC and KU campuses, 2) 
advertisements in online community newspapers and publications (pitch.com and 
craigslist.com), and 3) the University of Kansas (KU) undergraduate Introductory Psychology 
research subject pool. To aid in recruitment, subjects were provided $50 compensation for the 
fMRI scanning session. Additionally, subjects were provided the opportunity to receive a black 
and white, printed picture of their brain, obtained through MRI. 
Potential subjects within the KU-Lawrence undergraduate research pool were provided 
the opportunity to complete several questions from the SPQ as part of the web-based, mass 
pre-screening process directed by the Department of Psychology. Subjects who were identified 
as having symptoms indicative of spider phobia were contacted by email or phone to complete 
the screening questionnaire. Those identified as possible control subjects were contacted in the 
same manner. Potential subjects originating from sources other than the undergraduate research 
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pool were instructed to call or email research personnel at Hoglund Brain Imaging Center 
(HBIC). When a potential subject was contacted, pre-screening was conducted utilizing an 
eligibility survey and the SPQ. Those identified as potential subjects were scheduled for 
clinical assessment at KCCAT.  
Consent 
At the initial session (the clinical assessment session), written informed consent was 
obtained from each subject prior to beginning assessment. Subjects were informed that they 
could withdraw from the study at any time by contacting research personnel. If consent was 
withdrawn, participation in the study was terminated and no additional data was collected or 
used for analysis. However, subjects were unable to collect the $50 compensation if they failed 
to complete the fMRI session. 
Inclusion/Exclusion Criteria 
All subjects were right-handed adults between 18 and 55 years of age. Subjects in the 
phobic group scored at least 16 on the SPQ (which is 3.5 standard deviations above the mean 
for non-phobic populations) and met diagnostic criteria for spider phobia, as defined by the 
Diagnostic and Statistical Manual of Mental Disorders (DSM-IV) (American Psychiatric 
Association, 2000). Subjects included in the control group scored a 2 or below on the SPQ 
(which is.5 standard deviations below the mean reported for non-phobic populations). All 
female subjects had pregnancy ruled out via urine pregnancy (beta-HCG) test administered 
immediately prior to medication administration. This pregnancy test was administered by 
nursing staff at the General Clinical Research Center (GCRC) at KUMC. Additionally, 
subjects with medical conditions unsuitable for MR scanning were not included. This required 
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exclusion of individuals who had a pacemaker, vascular clips, or other internal metal. Because 
of contraindications with DCS treatment, subjects with a history of epilepsy or seizures of any 
etiology were also excluded. Because of increased risk of allergic reaction to the tarantula in 
the behavioral avoidance test, individuals reporting diagnosis of asthma or an allergy to bee 
stings or spider bites were excluded. Additionally, subjects reporting present or past diagnosis 
of a developmental disorder, neurological disorder, or head injury (with positive loss of 
consciousness and hospitalization) were not included. Those reporting past substance 
dependence, including all types of alcohol, elicit drugs, or medications, but excluding caffeine 
(as measured through ADIS interview) were also excluded. Spider phobic subjects reporting 
psychotic symptoms, major depression, dysthymia, substance abuse or dependence (excluding 
caffeine), claustrophobia, or any other Axis I psychopathology as defined by the DSM-IV and 
measured by the ADIS (other than phobia) were excluded from the study. Subjects recruited 
for the non-phobic control group were also excluded if they had any Axis I psychopathology as 
defined by the DSM-IV (American Psychiatric Association). Subjects in both groups were off 
all psychotropic medications for at least 6 months and had no history of treatment for anxiety 
or depressive disorders.  
Privacy and Confidentiality 
 The intial assessment and all behavioral and cognitive assessments were completed in 
a private room with only the examiner present. If there was a reason for additional 
research staff to be present or to observe such assessments (e.g. for research personnel 
training), the subject was asked for their verbal consent. The MRI control room and 
scanner are located in a private area. The door to the control room was locked during 
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scanning to prevent individuals not involved in the study from entering. Only research 
personnel and MRI technicians were allowed within the control and scanning room when 
the subject was being scanned. Data and safety monitoring was conducted by research 
personnel at HBIC. Identification numbers were assigned to each subject at the time of 
the initial assessment. Data used for analysis were de-identified and accessible to 
research personnel only. The staff of the GCRC had access to information regarding 
demographic information, identification number, and group assignment of each subject, 
as well as data collected by the GCRC nurses (i.e. blood pressure, pulse, heigh, weight, 
and demographic information).  
Procedure 
Initial Assessment 
Following written informed consent, clinical information was collected by a trained 
clinician (Robin Aupperle, M.A.) under the supervision of Lisa Hale, Ph.D. at KCCAT. 
Assessment included the Anxiety Disorders Interview Schedule (ADIS) for DSM-IV (Brown, 
DiNardo, & Barlow, 1994), the Weschsler Abbreviate Scale of Intelligence (WASI), a 
behavioral approach/avoidance task (BAT), and the Beck Depression Inventory, all described 
below. The initial assessment required approximately 1.5 to 2 hours for completion. 
Anxiety Disorders Interview Schedule (ADIS) for DSM-IV. In addition to anxiety 
disorders, the ADIS provides modules for a wide range of psychiatric symptoms, including 
depression (MDD and dysthymia), psychosis, mania/hypomania, and substance abuse (Brown 
et al., 1994). The ADIS was used to diagnose spider phobia as well as to screen for comorbid 
diagnoses. Within the non-phobic control group, it was used to screen for symptoms of Axis I 
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psychopathology. Test-retest reliability of the ADIS was reported average to high for the 
following disorders when used to diagnose individuals according to the DSM-III-R: simple 
phobia, social phobia, obsessive-compulsive disorder, and panic disorder (Di Nardo, Moras, 
Barlow, Rapee, & Brown, 1993). Inter-rater reliability of the ADIS has been reported as high 
for both anxiety disorders and affective disorders when used to diagnose according to both the 
DSM-III and the DSM IV (Brown, DiNardo, Lehman, & Campbell, 2001; Di Nardo, O’Brien, 
Barlow, Waddell, & Blanchard, 1983). Administration time of the ADIS for an experienced 
examiner has been estimated at approximately 90 minutes. However, because the populations 
included in the current study were relatively free of psychiatric symptoms, this time was 
shortened significantly to approximately 45 minutes.  
Spider Questionnaire (SPQ). The Spider Questionnaire was an additional tool used to 
diagnose (in the phobic group) and screen for (in the non-phobic group) spider phobia 
(Klorman, Hastings, Weerts, Melamed, & Lang, 1974). Norms for non-phobic and phobic 
college populations was provided by Fredrikson (1983). The mean and standard deviation for 
non-phobic subjects was 3.8 (3.42), while that reported for phobic subjects was 23.76 (3.8). 
For the current study, SPQ scores of subjects in the control group were all .5 standard 
deviations below the non-phobic mean (≤ 2). All scores for subjects in the phobic group were 
3.5 standard deviations above the non-phobic mean (≥ 16). This instrument has been shown to 
have the ability to discriminate between phobic and non-phobic individuals and has been 
reported to have high internal consistency and test-retest correlations (Fredrikson, 1983; 
Johnsen & Hugdahl, 1990; Muris & Merckelbach, 1996). Additionally, it appears to be 
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sensitive to the effects of behavioral therapy (Muris & Merckelbach). Administration time 
ranged between 5-10 minutes. 
Beck Depression Inventory II (BDI-II). The BDI-II is a 21-item, self-report measure and 
one of the most widely used instruments to assess severity of depressive symptoms (Beck, 
Steer, &Brown, 1996b). Subjects choose one of four statements relating to each item that best 
describes how they have felt over the previous two weeks. As an example, the first item is 
“Sadness” and the options are: 0=”I do not feel sad”, 1=”I feel sad much of the time”, 2=”I am 
sad all of the time”; and 3=”I am so sad or unhappy that I can’t stand it”. A total score is 
obtained by summing the responses to the 21 items and therefore, the range of possible scores 
is 0 – 63. Scores below 4 are considered below normal for healthy, non-depressed controls, 5 – 
9 is considered normal (subclinical), 10 – 18 is considered mild to moderate depression, 19 – 
29 is considered moderate to severe depression, 30 – 63 is considered severe depression. All 
subjects in the current study scored in the ‘normal’ or ‘below normal’ range. The BDI-II has 
been reported to have adequate internal consistency (=.91) and test-retest reliability (r=.93), 
as well as construct validity as compared with the Hamilton Depression Rating Scale (r=.71; 
Beck, Steer, Ball, & Ranieri, 1996a; Beck et al., 1996b). This measure required 5 – 10 minutes 
to complete.  
Behavioral Avoidance Task (BAT). Behavioral approach/avoidance tasks are used to 
measure levels of pathological avoidance in anxiety disorders, and are commonly implemented 
in the assessment of specific phobias, including spider phobia (Hersen & Bellack, 1988; 
McLean & Woody, 2001; Ost, 1989). For the BAT, subjects were seated in a comfortable chair 
at a long conference table in a room alone with the examiner. A movable box of plexiglass, 
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containing a live spider was placed at the far end of the table. The spider was a Chilean rose 
hair tarantula, chosen for its docile nature. Risks associated with handling this type of tarantula 
and the safety precautions taken to minimize this risk are included in Appendix C. Subjects 
were asked to hold a string connected to the box. They were asked to pull on the string and 
bring the box to the point in which they began to feel uncomfortable. It was emphasized that 
the subjects were not to force themselves or make themselves feel excessively uncomfortable. 
Performance on this test was measured by a 13-point scale: 0 = distance between subject and 
spider more than 8 feet, 1 = distance between 7 and 8 feet; 2 = distance between 6 and 7 feet, 3 
= distance between 5 and 6 feet, 4 = distance between 4 and 5 feet, 5 = distance between 3 and 
4 feet, 6 = distance between 2 and 3 feet, 7 = distance between 1 and 2 feet, 8 = distance less 
than 1 foot, 9 = subject’s hand on box, lid is not open, 10 = lid open, 11 = lid open, hand 
reaching into box, 12 = holding spider in hand. Subjects were also asked to estimate their 
anxiety level on a SUDS scale (subjective units of distress; scale of 0 - 8) at the point in which 
they terminated the task. The method and scoring procedure for this task is based upon that 
described by Merckelbach, Jong, & Arntz (1991). The BAT took approximately 2 - 3 minutes 
to administer. 
Wechsler Adult Intelligence Scale (WAIS) Vocabulary and Matrix Reasoning Subtests. 
The WAIS is “an individually administered clinical instrument for assessing the intellectual 
ability of adults aged 16 through 89” (Wechsler, 1997). It consists of several subtests that 
measure different aspects of the construct intelligence. When the complete battery of tests is 
used, three IQ scores (Verbal, Performance, and Full Scale) and four Index scores (Verbal 
Comprehension, Perceptual Organization, Working Memory, and Processing Speed) can be 
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obtained. However, for the purposes of this study, only the Vocabulary and Matrix Reasoning 
subtests were administered. These tests were used as a quick measure of both verbal and 
performance intelligence, to ensure that the various groups included in the study did not differ 
on intellectual functioning. The vocabulary test is meant to measure expressive and receptive 
vocabulary. It consists of 33 orally and visually presented words that the subject defines orally. 
Each item is scored on a three point scale (0=obviously wrong, 1=correct, but shows poverty of 
content, 2=shows good understanding of the word). The individual item scores are summed to 
obtain a total raw score, which can then be converted to a scaled score using normative data 
(based on age) provided in the manual (Wechsler, 1997). The matrix reasoning test is meant to 
measure visual information processing and abstract reasoning skills. It consists of 26 items, 
each of which is an incomplete gridded pattern that the subject completes by selecting one of 
five possible choices. The number of correct responses is summed for a total raw score. This 
score can be converted to a scaled score using normative data (based on age) provided in the 
manual (Wechsler, 1997). Administration of these two subtests in the current study was 
approximately 20 - 30 minutes.  
fMRI Scanning and Neuropsychological Measures 
Those who still met inclusion criteria after the initial assessment were scheduled for a 
study session that included DCS/placebo administration, fMRI scanning, and 
neuropsychological testing. During fMRI, a block-design, symptom provocation paradigm was 
utilized. The following assessment tools were utilized in the neuropsychological testing 
battery: 1) Rey-Osterrieth Complex Figure Test (RCFT), 2) Wisconsin Card Sorting Test 
(WCST), 3) Iowa Gambling Test, and 4) Wechsler Memory Scale III (WMS-III)). Completion 
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of all procedures involved at this one time point required approximately 5 to 6 hours. A more 
detailed description of the risks and benefits of the current study, as well as the data and safety 
monitoring plan, were prepared for the institutional review board (IRB) human subjects 
committee (HSC) application, and are included in Appendix A.  
Medication. The study conducted by Ressler and colleagues (2004) demonstrated that 
both 50 mg and 500 mg doses of DCS were effective in increasing response to ERP treatment. 
There was some indication that the 500 mg dose was associated with less beneficial results. 
Clinical studies currently being conducted and published using DCS-supplemented exposure 
therapy are using 50-100 mg doses (Guastella et al., 2008; Kushner et al., 2007; Wilhelm et al., 
2008; and information provided through consultation with Michael Davis, Ph.D.; Sabine 
Wilhelm, Ph.D,, and Stefan Hoffman, Ph.D.). However, D’Souza et al. (2000) was able to 
detect only trace levels of DCS in cerebrospinal fluid (CSF) after acute oral administration of a 
50 mg dose. Research has shown that with a single oral dose of 250 mg DCS, CSF levels reach 
peak concentrations (12.8 mg/ml) 2 hours after administration and have a plasma half-life of 
approximately 9 hours (Nair et al., 1991). Subjects in the present study were administered 100 
mg of DCS. This dose was chosen in order to 1) remain consistent with the current clinical 
investigations being conducted with DCS, 2) minimize the potential for side effects and 3) 
optimize the effects of the medication and the availability of the medication to the central 
nervous system. The DCS and placebo pills were prepared by the KUMC investigational 
pharmacy.  
An investigational new drug application (IND) was submitted to the Food and Drug 
Administration on March 21, 2006. The FDA concluded that the proposed study met all of the 
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requirements for exemption from the IND regulations and, therefore, an IND was not required 
to conduct this investigation. The official letter from the FDA stating they would not accept the 
IND application was received on March 31, 2006. 
DCS and placebo pills were obtained from and prepared by the KUMC investigational 
pharmacy and administered by nursing staff at the KUMC General Clinical Research Center 
(GCRC). Randomization of subjects to receive either DCS or placebo was conducted by 
Sandra Hall, Ph.D. (who, at the time, held the position of Research Assistant Professor, 
Department of Preventive Medicine and Public Health, KUMC), who communicated the 
results of randomization (subject numbers and group assignment of each) to staff at the KUMC 
investigational pharmacy. Dr. Hall conducted separate, block randomizations (with 12 subjects 
per block) for the phobic and non-phobic groups, so that half of each group was randomized to 
receive DCS while the other half was randomized to receive placebo. Each subject therefore 
had a 50% chance of receiving DCS. All investigators, test administrators, and subjects were 
blind to group assignment until after all data for a particular “block” had been collected and 
scored (or preprocessed in the case of fMRI data). Additional subjects added to the study 
(beyond the 24 per diagnostic group) were either randomized along with the second block of 
subjects or assigned to a treatment group based upon the assignment of the subject they were 
replacing. Regardless, the investigators remained blind to all subjects’ treatment group 
assignment until after all data had been collected and scored. Nursing staff at the GCRC 
monitored subjects 2-3 hours after drug administration for potential side effects. An adverse 
symptom checklist (ASC) was administered after the fMRI session to assess for potential side 
effects.  
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Rey-Osterrieth Complex Figure Test (RCFT). The RCFT is used to assess visuospatial 
construction, learning strategy, and visual memory (Spreen & Strauss, 1998). Subjects are first 
asked to copy a complex figure and then to reproduce that figure by memory after a 20-minute 
delay. The copy and memory trial are scored on accuracy (including attributed of both 
“accuracy” and placement), and organization of the reproduction (Deckersbach et al., 2000; 
Savage et al., 1999; Taylor, 1959, as cited in Spreen and Strauss, 1998). Standardized scores 
are calculated based on normative data provided by Meyers and Meyers (1995). High inter-
rater reliability has been reported for total accuracy scores of the RCFT, though the reliability 
of each individual item score is more variable (Fastenau, 1996). Scores on the copy trial of the 
RCFT have been reported to correlate with orbitofrontal cortex volume in obsessive-
compulsive disorder, and the organizational strategies required in this test are thought to be 
related to frontal-striatal networks (Choi et al., 2004; Savage et al., 2000). Administration time 
was approximately 10-15 minutes, excluding the delay (Spreen & Strauss).  
Wisconsin Card Sorting Test (WCST). The WCST is thought to measure executive 
functioning and working memory (Spreen & Strauss, 1998). The task requires strategic 
planning, use of environmental feedback, and inhibition of impulsive responses. During this 
test, four “key” cards are set in front of the subject: the first card has one red triangle, the 
second has two green stars, the third has three yellow crosses, and the fourth has four blue 
circles. The subject is asked to take one card at a time from two, 64-card decks (with various 
combinations of color, form, and number) and place each card below the key card they think it 
best matches. They are not told how to match the cards but are told each time whether they are 
right or wrong. The rule for matching the cards varies by color, form, and number, though the 
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subject is not informed of when the rule changes. Standardized scores are calculated by the 
WCST-computer scoring program and based on normative data provided in the WCST-revised 
manual (Heaton, 2003; Heaton, Chelune, Talley, Kay, & Curtis, 1993). The scores that were 
analyzed for the proposed study include total items correct, total errors made, categories 
completed, failures to maintain set, and perseverative responses. Standardized scores can be 
calculated based on normative samples separated by age and education level. The WCST has 
been shown to be sensitive to damage to the frontal lobe and subcortical structures (Heaton et 
al., 1993). Activations within the frontal (specifically the dorsolateral prefrontal cortex) and 
temporal regions have also been shown to relate to WCST task performance (Fallgatter & 
Strik, 1995; Konishi et al., 1999; Ragland et al., 1998; Volz et al., 1997).  
Iowa Gambling Test. The Gambling Test was developed by Bechara, Damasio, Damasio, 
and Anderson (1994) and is thought to measure aspects of emotion-based learning, decision-
making, goal-directed behavior, and inhibitory processes. The computer version of the 
Gambling Test was administered for the current study. During this test, four decks of cards (A, 
B, C, D) are shown on a computer screen. The subject is “given” $2,000 of virtual money to 
start the game (which is indicated on the computer screen).  For each trial, subjects are asked to 
choose one card from the 4 decks presented. They are told that each time they choose a card 
they will win money. Every so often, however, their choice is associated with a loss of money 
as well. The goal of the game is to win as much money as possible. Some decks are considered 
"bad decks" because they are higher-risk and will lead to losses over the long run. Other decks 
are considered "good decks" because they are lower-risk and lead to gains over the long run. 
The decks differ from each other in the number of trials over which the losses are distributed. 
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The score for this test is based on number of cards taken from each deck (“good” decks versus 
“bad” decks) (Bechara, Tranel, & Damasio, 2000). Scores can be calculated in this manner for 
each of 5 “blocks” (trials 1-20, 21-40, 41-60, 61-80, and 81-100), as well as for the entire task. 
Analyses for the current study focused on total score, but scores for each individual block were 
also calculated. Damage to the ventro-medial prefrontal cortex is associated with deficits on 
the Iowa Gambling Task and activity in this area has been reported to relate to individuals’ 
reactions to the reward and punishment aspects of the task (Oya et al., 2005). Activity in the 
medial frontal gyrus, as measured by fMRI, has been reported to relate to risk anticipation 
aspects of the task (Fukui, Murai, Fukuyama, Hayashi, & Hanakawa, 2005).  
Wechsler Memory Scale, 3rd edition (WMS-III) Logical Memory and Faces Subtests. The 
Logical Memory subtest of the WMS-III is a test of auditory/verbal memory. Two stories are 
read aloud to the subject, who is then asked to recall as many details from the story as they can 
remember. After a 25-35 minute delay, subjects are asked to again recall as many details from 
each story as they can. Scoring is based upon the number of details correctly recalled for both 
immediate (Logical Memory I [LM-I]) and delayed (Logical Memory II [LM-II) conditions. 
Additionally, the percent retention score is calculated to indicate the information retained from 
immediate to delayed recall and is based on the following formula: (LM-II total score / LM-I 
story total score) *100. The Faces subtest of the WMS-III is a test of visual/nonverbal memory. 
Pictures of faces are displayed one at a time to the subject. After this initial presentation, 
subjects are shown more faces, some of which were displayed before and some of which were 
not. The subjects are asked to indicate whether they had viewed the faces previously (‘old” 
faces) or if they had not (“new” faces). After a 25-35 minute delay, subjects are shown another 
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set of faces and asked again to indicate which ones they were asked to remember and which 
ones are new. Scoring is based on the number of faces correctly recalled. A percent retention 
score is calculated in the same way as described for the Logical Memory test. Standardized 
scores can be obtained for both of these tests using normative data (on age and education) 
provided in the WMS-III manual (Wechsler, 2002). Administration time in the present study 
was approximately 20-30 minutes. 
Adverse Symptom Checklist (ASC): The adverse symptom checklist was adapted from a 
version used by Dr. Eric Storch of the University of Florida in a previous investigation 
examining the effects of DCS on ERP for obsessive-compulsive disorder. Dr. Storch provided 
the checklist for use in this study. The checklist required subjects to rate how “bothersome” 
they found each of 27 symptoms to be at the time of assessment, using a scale of 0 (not at all) 
to 3 (severe).  The items related to neurological, gastrointestinal, cardiovascular, 
musculoskeletal, and other symptoms. As part of the ASC, subjects were also asked to indicate 
if they believed they were given the medication (DCS) or the placebo pill.  
fMRI. MRI Scanning was performed at HBIC using a 3 Tesla (3T) head-only Siemens 
Allegra scanner (Siemens, Erlangen, Germany) fitted with a quadrature head coil. Following 
automated scout image acquisition (a low-resolution image that serves as a localizer for the 
remaining scans) and shimming procedures performed to improve the magnetic field 
homogeneity, T1-weighted anatomic images were acquired with a 3D spoiled gradient echo 
(SPGR) sequence (repetition time/echo time [TR/TE] = 23/4 ms, flip angle = 8, field of view 
[FOV] = 256 mm, matrix = 256 x 192, slice thickness = 1 mm). This scan was used for slice 
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localization for the functional scans, transformation into Talairach space, and coregistration 
with fMRI data.  
Following structural scanning, two gradient echo blood oxygen level dependent (BOLD) 
scans were acquired. These runs included 43 contiguous coronal slices, perpendicular to the 
anterior commissure (AC) – posterior commissure (PC) line (TR/TE = 3000/40 ms, flip angle 
= 90, FOV = 192 mm, matrix = 64 x 64, slice thickness = 3 mm, 0.5 skip, in-plane resolution 
= 3 x 3 mm, 130 data points). Slice acquisition was set for whole-brain coverage (though often, 
the very anterior part of the occipital lobe was not obtained). Visual stimuli were projected 
through 3D limited view goggles (Resonance Technology, Inc., Northridge, California) 
connected to the stimuli-generating computer program (NeuroSTIM, Neuroscan, El Paso, TX). 
The proposed symptom provocation fMRI paradigm was based on paradigms used for previous 
functional imaging research with spider phobic patients (e.g., Straube et al., 2004).  
There were three condition types included in the symptom provocation paradigm: 
1. Phobic Stimulus: Subjects were exposed to pictures of spiders. The pictures used as 
stimuli in this paradigm were those identified through the stimulus validation procedure 
described earlier.  
2. Non-Phobic/Neutral Stimulus: Subjects were exposed to neutral stimuli, consisting of 
pictures of butterflies. It was possible that patients with spider phobia would experience phobic 
symptoms related to other small animals including snakes, rats, and even dogs. Butterflies 
were, therefore, chosen as the neutral stimulus because of their similarity to spiders and 
because of the unlikelihood that they would invoke phobic fear in spider-phobic subjects. 
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Butterfly stimuli were also used in the baseline condition of Paquette et al. (2003). The pictures 
were of similar brightness, resolution, and size to the spider pictures.  
3. Low Level Baseline Comparison: Subjects were asked to focus on blurred images of 
similar brightness, resolution, and size to the spider and butterfly pictures. These blurred 
images were created by applying a Gaussian kernel to the animal pictures (so the objects were 
not identifiable). This method has been used to generate low-level baseline stimuli in previous 
studies conducted at HBIC (e.g., Holsen et al., 2005). 
For the symptom provocation paradigm, subjects underwent two fMRI functional 
scanning runs. Each run alternated between blocks of pictures from the phobic, non-phobic, 
and baseline conditions. Before the first provocation run and after each of the two runs, 
subjects were asked to report their subjective units of distress (SUDS) on a scale of 0 - 8 to 
measure the intensity of induced anxiety. The order of the blocks within a run was 
counterbalanced within- and across-subjects in order to prevent order effects. There were 10 
novel pictures presented within each block (pseudo-randomized for every scanning run). 
Pictures were presented on a screen for 2.5 seconds each, with an interstimulus interval (ISI) of 
0.5 seconds. Subjects were asked to remember the pictures displayed during scanning and were 
then given a memory task immediately following fMRI. For the memory task, 30 pictures (15 
spider and 15 butterfly) shown during scanning were chosen for recall and were interspersed 
with 20 novel distracter images (10 spider and 10 butterfly). Outside of the scanner, subjects 
were shown these images on a computer screen and instructed to press one key if they believed 
they had been shown the image in the scanner and another key if they believe they had not 
been shown the image. Recognition discriminability indices were calculated for this 
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recognition memory test using the following formula: 100*[1-((#false positives + # false 
negatives)/total # pictures)]. These indices were calculated for the spider pictures, the butterfly 
pictures, and the total (all pictures combined).  
Data analysis 
fMRI data were analyzed using the BrainVoyager QX statistical package (Goebel & 
Jansma, 2004; Brain Innovation, Maastricht, Netherlands). Several “pre-processing” steps were 
taken to prepare raw BOLD data for analysis. These steps include motion correction, spatial 
and temporal smoothing, and anatomic transformation. First, trilinear 3D motion correction 
used the first image of each volume as a reference to which all other images within that volume 
were aligned through translation and rotation, correcting for head motion along the three axes 
(x,y, and z). These six motion correction parameters were also detrended (linear trend 
removed), z-transformed, and entered as variables of no interest in the multi-study general 
linear model to further correct for subject motion. Motion in any run of more than 4 mm along 
any axis (x, y, or z) resulted in the discard of that run. Additionally, motion that was consistent 
with the paradigm itself and caused visible artifact in the single-study general linear model for 
that run also resulted in the discard of that run. Sinc-interpolated slice scan time correction was 
used to shift each voxel’s time series to allow all scans within a volume to be analyzed as if 
they were acquired at the exact same time (in reality the slices are collected over the length of 
the TR, in this case 3 seconds). 3D spatial smoothing with a 4-mm Gaussian filter was also 
conducted. Spatial smoothing reduces the resolution of an image by averaging together 
adjacent voxels, which increases the signal-to-noise ratio. High pass filter temporal smoothing 
was similarly used to smooth pixels temporally throughout a time-series, reducing the 
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“jitteriness” of the data. Functional images were then realigned to the anatomic images 
obtained within each session and normalized to the BrainVoyager template image, which 
conforms to the space defined by the Talairach and Tournoux’s (1988) stereotaxic atlas.  
Brain Voyager QX software was used to conduct statistical tests of the preprocessed data 
to produce statistical parametric maps (SPMs; Friston et al., 1995). Multiple regression 
analysis with a general linear model (GLM), allowing for multiple predictors, was used to 
examine differences in BOLD response between the experimental conditions (e.g. spider 
versus butterfly conditions). Regressors representing the experimental predictors of interest, as 
well as the motion correction regressors representing variables of no interest, were entered into 
the GLM. The regressors of interest were modeled with a hemodynamic response filter, which 
corrects for temporal delays in the BOLD response to a scan condition. All regressors were 
entered into the multiple-regression analysis using a random-effects model. Contrasts between 
conditions of interest were assessed with t statistics for each voxel. The resulting statistics for 
each voxel were then displayed pictorially on statistical parametric maps (different colors 
corresponding to varying levels of significance) and overlaid on three-dimensional renderings 
of an averaged-group brain. Voxel values were considered significant if they exceeded a 
threshold of p<.001 and had a minimum cluster size of 3 contiguous voxels. While the whole 
brain was inspected for areas of significant activation, a priori regions of interest (ROIs) were 
specified based on results of previous work and were the focus of analyses and discussion.  
Analytical Procedures by Hypotheses 
Prior to testing the specific study hypotheses, demographic, clinical, and adverse 
symptom data were examined for differences between groups. For continuous variables, 
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two-way ANOVAs were used to identify main effects and interactions for diagnosis and 
treatment. Because of the small sample size, Fisher’s exact tests (instead of chi-square) 
were used to identify differences in categorical variables between diagnostic and 
treatment groups, as well as individual groups. Additional statistical analyses conducted 
(including repeated measures ANOVA, paired-samples t-tests, and Pearson correlations) 
will be explained in the results section when relevant. Behavioral data related to the fMRI 
paradigms were analyzed in the same manner. Contrasts were considered significant if 
they met p < .05.  
Specific Aims 1 and 2 were tested using data collected during the fMRI symptom 
provocation paradigm. Data from neuropsychological testing were used to test Specific 
Aim 3. Hypotheses specified a priori are included below in italics, allowing for direct 
connections to be made between study hypotheses and analytical procedures.  
Aim 1: There will be a significant diagnosis x condition interaction in that the spider 
phobic group will show greater activation than the healthy control group during 
presentation of spider (phobic) pictures as compared to butterfly (nonphobic) pictures, in 
the following brain regions (bilaterally): lateral and medial amygdala, insula, medial 
prefrontal cortex (including the ACC and the orbitofrontal cortex[OFC]), dorsolateral 
prefrontal cortex (dlPFC), and the hippocampus. 
Analyses for this Specific aim 1 were restricted to the untreated (placebo) phobic 
and healthy control subjects. This hypothesis was directly tested using a diagnosis 
(phobia vs. control) x condition (spiders vs. butterflies) design. Additionally, condition 
main effects were conducted to investigate the neural response of each group separately.  
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Aim 2: There will be a significant treatment x condition interaction in which the DCS 
phobic group will show increased activations in the medial PFC (including ACC and the 
OFC), dorsolateral prefrontal cortex, and the hippocampus but decreased activations in 
the lateral and medial amygdala and insula compared to the placebo phobic group 
during presentation of spider (phobic) pictures (as compared to butterfly pictures).It is 
hypothesized that the DCS control group will not show differences in activation compared 
to the placebo control group. 
Specific Aim 2 hypothesis includes subjects from all four groups (phobic placebo, 
phobic DCS, healthy control placebo, healthy control DCS) and relates to the effects of 
DCS on neural activation during phobic symptom provocation. To examine DCS effects 
during the provocation paradigm, the direct interactions of treatment (DCS > placebo) x 
condition (spiders > butterflies) were conducted for 1) the control groups and 2) the 
phobic groups. Main effects were then conducted within each group (DCS phobic and 
DCS control) to investigate the neural response of each group separately. As described 
previously, there were numerous studies reporting the blood flow correlates of symptom 
provocation in specific phobia. Research has also provided evidence of regional 
activations that normalize after successful ERP therapy. However, because the paradigm 
used does not mimic an entire treatment, it was not hypothesized that DCS administration 
would simply cause normalization of phobic activations. The provocation paradigm more 
similarly mimics that of animal and human studies examining the initial steps of the fear 
extinction process, in which a CS is presented after the subjects have undergone CS-UCS 
fear conditioning. It was therefore hypothesized that DCS would enhance the effects 
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associated with the initial steps of fear extinction. The hypotheses regarding the influence 
of DCS on brain activations during phobic provocation were based primarily upon the 
fear extinction research and the neural circuitry model of fear extinction outlined above.  
Aim 3.1: It is hypothesized that subjects in the DCS groups (phobic DCS and healthy 
control DCS) will obtain better scores on all cognitive measures. It is not expected that 
there will be differences between Diagnostic groups on cognitive performance.  
Specific Aim 3 hypothesis relates to the effect of DCS on cognitive functioning. 
Aim 3 was tested through statistical analysis of individual test scores using the Statistical 
Package for the Social Sciences (SPSS). Neuropsychological tests were scored according 
to their respective manuals and/or previous literature, as described in the measures 
section. Raw scores were the focus of analyses for this study. There were two separate 
scores (accuracy and organization) for each of the Rey Complex Figure Test stages (copy, 
immediate recall, and delayed recall); five for the Wisconsin Card Sort (categories 
completed, total items correct, total number of errors, failures to maintain set, and 
preservative responses); one for the Iowa Gambling Task (good choices – bad choices); 
and six for the Wechsler Memory Scale III (Logical Memory I total, Logical Memory II 
total, Logical Memory retention score, Faces I total, Faces II total, and Faces retention 
score). Two-way ANOVAs were used to examine the diagnosis (phobic versus placebo) x 
treatment (DCS v placebo) interaction, as well as the main effects for both diagnosis and 
treatment. These same methods were used to examine differences among groups in 
anxiety (SUDS) level during the symptom provocation paradigm. Contrasts were 
considered significant if they met p < .05. However, the fact that multiple comparisons 
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were made is taken into account during discussion and interpretation. Hypotheses for Aim 
3 postulated in the proposed study are based upon the animal and human research 





















Chapter 3: Results 
Demographics 
A total of 54 subjects were enrolled in the study. Five subjects were excluded 
from all analyses. One withdrew from the study because of claustrophobia symptoms in 
the scanner; four were excluded because of scanner artifact that made all fMRI data 
unusable. Therefore, a total of 49 subjects (23 control, 26 phobic) were included in 
analyses of demographic, clinical, and neuropsychological data. However, additional 
subjects had to be excluded from fMRI analyses because of excessive motion or motion 
that was consistent with the paradigm (i.e. movement only when seeing spider pictures). 
As discussed in the sections below, only the subjects included in fMRI analyses were 
included in the analysis of behavioral data related to the fMRI paradigm.  
As described in the procedures section, two-way, multi-factor analyses of 
variance (ANOVA) were conducted to identify main effects and interactions of diagnosis 
and treatment. Repeated measures ANOVA were used when relevant. Fisher’s exact tests 
were used to compare differences between groups regarding categorical variables. The 
same basic statistical steps were used for demographic, clinical, adverse symptom, 
behavioral, and neuropsychological data. Unless otherwise mentioned, raw scores 
(instead of standardized scores) were used in the analyses. 
 The demographic data for all subjects (N = 49) are included in Table 2. Regarding 
age, there were no significant main effects for diagnosis or treatment (Fs<1), nor was 
there a significant interaction (F(1,45) = 1.71, p=.197). There were also no differences in 
years of education by diagnosis, treatment, or the diagnostic x treatment interaction (all 
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Fs<or=1). In total, there were 14 males and 35 females who participated. As determined 
by Fisher’s exact test (two-tailed), there were no differences in gender makeup between 
treatment (p=1.00) or diagnostic (p=.149) groups, nor were there significant differences 
between any of the individual groups. However, it should be noted that there was a trend 
for the placebo phobic group to have a lower ratio of males to females than the DCS 
phobic group (p=.073). This was due to randomization and not under control of the 
investigator.  
The WAIS vocabulary raw scores correspond to an average scaled score of 13.82 
(SD=2.56) for placebo controls, 13.58 (SD=1.93) for DCS controls, 14.25 (SD=2.09) for 
placebo phobics, 12.77 (SD=1.88) for DCS phobics, and 13.58 (SD=2.12) for the group 
as a whole. The matrix reasoning raw scores corresponded to average scaled scores of 
13.45 (SD=2.46) for the placebo controls, 13.92 (SD=2.27) for the DCS controls, 14.42 
(SD=2.23) for the placebo phobics, 13.92 (SD=2.06) for the DCS phobics, and 13.94 
(SD=2.21) for the group as a whole. These scores are all in the superior range. There 
were no significant main effects or interactions involving diagnosis or treatment for 
WAIS vocabulary or matrix reasoning raw scores (all Fs<1).  
Overall, the demographic measures indicate that the current study population was 
a young, primarily female, highly educated, highly intelligent group of individuals. No 
group differences in demographics were identified. Therefore, these variables are not 





Clinical data for all study groups are also displayed in Table 2. It should be noted 
that, although data were available for the SPQ and BAT for every subject (49 subjects 
total), the BDI was added to the study after a few of the subjects had already been tested. 
Therefore, the BDI data shown in Table 2 are for 45 subjects total (19 control [9 placebo, 
10 DCS]; 23 phobic [13 placebo, 13 DCS). The average BDI score for all groups was less 
than 3.0, which is in the subclinical or “normal” range. There was no main effect for 
diagnosis (F(1,41)=2.30, p=.1375), or for treatment (F(1,41)=1.88, p=.178), and no 
significant diagnosis x treatment interaction (F<1) on BDI score. The mean SPQ scores 
for the phobic groups were similar to that reported previously for phobic populations and 
the scores for the control groups were even lower than that previously reported for non-
phobic populations (Fredrikson, 1983; Kindt, Brosschot, & Boiten, 1999). The average 
BAT score for placebo controls and DCS controls indicate that most of these individuals 
were able to touch or hold the live tarantula. The SUDS level (on a scale of 0-8) also 
stayed low for the control groups during the BAT. The average BAT scores for the 
placebo phobics and DCS phobics indicate that most of these individuals stopped the test 
when the spider was over 4 feet away. They also reported a moderate level of SUDS 
during this test. The main effect of diagnosis was significant for the SPQ 
(F(1,45)=825.95, p<.001), BAT score (F(1,45)=887.13, p<.001), and the SUDS level 
reported during the BAT (F(1,45)=167.70, p<.001). As apparent in Table 2, these effects 
were caused by the phobic groups scoring higher on the SPQ and lower on the BAT, and 
reporting higher SUDS on the BAT. There was no significant effect for treatment (SPQ, 
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F(1,45)=2.31, p=.135; BAT score, F(1,45)=1.20, p=.279; SUDS, F(1,45)=.20, p=.659), 
nor was there a significant diagnosis x treatment interaction (SPQ, F(1,45)=2.72, p=.106; 
BAT score, F(1,45)=.011, p=.918; SUDS, F(1,45)=1.27, p=.266) for any of these 
variables.  
The clinical measures indicate that depression was not a significant problem for 
any of the groups (or individuals) in the study. The phobia measures (SPQ and BAT) 
significantly differentiated the control and phobic groups. From these results (and report 
on the ADIS), it can be concluded that individuals in the phobic group met criteria for 
spider phobia while those in the control group reported and exhibited minimal fear of 
spiders.  
Adverse Symptom Checklist (ASC) 
Data for the ASC are shown in Table 3. The ASC was added after several subjects 
had already completed the study and was available for a total of 36 subjects (16 control [8 
placebo, 8 DCS]; 20 phobic [10 placebo, 10 DCS]). On the ASC, there were a number of 
subjects who reported mild symptoms such as headache, drowsiness, dry mouth, and 
difficulty concentrating. However, there were no serious adverse events that occurred as a 
result of this study and no symptoms were reported that required medical attention. 
Subjects were also asked to indicate which pill (DCS v placebo) they thought they had 
been administered. These data were available for 48 of the subjects (23 control [11 
placebo, 12 DCS]; 25 phobic [12 placebo, 13 DCS). Fisher’s exact tests were used to 
compare groups on their opinion as well as the accuracy of their opinion. For ASC score, 
neither the main effect for treatment (F(1,32)=.30, p=.586), nor the diagnosis x treatment 
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interaction (F(1,32)=1.42, p=.243) was significant. However, there was a significant main 
effect for diagnosis (F(1,32)=7.56, p=.010), with the phobic groups reporting 
significantly more side effects on the ASC than the control groups. Fischer’s exact tests 
(two-sided) revealed that the phobic groups were also more likely than the control groups 
to believe they had been delivered DCS (p=.009). However, it should be noted that the 
phobic group was not significantly more accurate in their guess than controls (p=.401). 
When comparing treatment groups, only one variable, accuracy was significantly 
different. The placebo groups were more accurate in their opinion than the DCS groups 
(p=.003). This was caused by the fact that a much greater number of subjects believed 
they were given placebo (N=35) than DCS (N=13).  
From results of the ASC, it can be concluded that the subjects were not able to 
predict whether or not they were given the active medication. It can also be concluded 
that administration of 100 mg DCS was not associated with significant, detectable side 
effects.  
Neuropsychological Measures 
Rey-Osterrieth Complex Figure Test (RCFT)  
Average raw scores on the RCFT are shown in Table 4. There were no main 
effects or diagnosis x treatment interactions for RCFT immediate or delayed recall 
accuracy (all Fs<1). There were no treatment effects on RCFT copy organizational score 
(F(1,44)=.15, p=.697), but there was a main effect for diagnosis (F(1,44)=5.48, p=.024), 
indicating that controls had higher organization scores than phobics. The diagnosis by 
treatment interaction was not significant for RCFT organizational score (F<1).  
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Iowa Gambling Test (IGT) 
One subject did not complete the IGT because he reported being told the “rules” 
to the test in a class he had taken previously. Therefore, 48 subjects (23 control [11 
placebo, 12 DCS]; 25 phobic [12 placebo, 13 DCS]) were available for analyses related 
to the IGT. As shown in Table 5, there was a main effect for diagnosis on the IGT total 
score (F(1,44)=7.37, p=.009) in which the control groups performed better than the 
phobic groups. Post-hoc analyses using independent student t-tests revealed this effect 
was due primarily to differences in blocks 3 (t(46)=2.28, p=.027), 4 (t(46)=2.54, p=.014), 
and 5 (t(46)=2.92, p=.005). (However, it should be noted that if a Bonferroni correction 
were used, only the difference in block 5 would remain significant.) There was a trend for 
treatment to have an effect on IGT total score (F(1,44)=3.67, p=.062). The diagnosis x 
treatment interaction was not significant (F(1,44)=.85, p=.361). Repeated measures 
ANOVA was conducted to examine if there were any main effects or interactions 
involving diagnosis and treatment for the change in score across IGT blocks. Across all 
groups, there was a linear increase in IGT block score (F(1,44)=55.01, p<.001) and this 
trend was affected significantly by diagnostic group (F(1,44)=5.28, p=.026), indicating 
that phobics had less of a linear increase in score across blocks. There were no other 
differences for the change in score across blocks (all Fs<1). The performance of phobic 
and control groups across the five IGT blocks is displayed in Figure 2. 
Wisconsin Card Sorting Test (WCST) 
One subject did not complete the WCST because he reported previously being 
shown how to score the WCST. Therefore, a total of 48 subjects (23 control [11 placebo, 
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12 DCS]; 24 phobic [13 placebo, 12 DCS]) were available for analyses related to the 
WCST. As shown in Table 6, all subjects performed very well on the WCST. Almost 
every subject completed all 6 sets (M=5.85, SD=.74). There were no significant 
differences in WCST performance by diagnosis or treatment, nor was there a diagnosis x 
treatment interaction (all Fs<1). 
Wechsler Memory Scale (WMS-III) 
The raw scores for the Wechsler Memory Scale (WMS-III) Logical Memory and 
Faces subtests are shown in Table 7. Repeated measures ANOVAs were used to 
investigate main effects and interactions involving diagnosis and treatment for the WMS-
II immediate and delayed recall scores (separate analyses were conducted for the Logical 
Memory and Faces subtests). As indicated in Table 7, there were no significant main 
effects for diagnosis (LM, F(1,45)=1.16, p=.287; Faces, F(1,45)<1), treatment (LM, 
F(1,45)<1; Faces, F(1,45)=1.09, p=.302), or for the diagnosis x treatment interaction 
(Fs<1). 
 In summary, neuropsychological results suggest that the control group performed 
better than phobics on measures of emotional decision making (IGT) and organization of 
visuospatial information (RCFT). DCS did not seem to have a profound effect on 
neuropsychological functioning, though there was trend for DCS to negatively impact 
performance of controls during the emotional decision making task (IGT).  
Provocation Paradigm 
Three subjects were excluded from analyses for the fMRI provocation paradigm, 
as they exhibited motion that was consistent with the paradigm (movement only during 
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the spider condition). When motion is consistent with the paradigm, the motion 
correction steps described earlier are unable to completely correct for it (because the 
signal strength changes caused by motion cannot be disentangled from those caused by 
the paradigm itself), and artifact is visible in the GLM results (Friston et al., 1995; 
Hajnal, Myers, & Oatridge, 1994; Morgan et al., 2007). Therefore, there were 46 subjects 
included in analyses for this paradigm (23 phobic [12 placebo, 11 DCS], 23 control [11 
placebo, 12 DCS]). 
Behavioral Analyses 
Subjective units of distress levels (SUDS; 0 – 8) were reported prior to the first 
provocation run (Pre SUDS) and after each of the two provocation runs (SUDS 1 and 
SUDS 2). Additionally, recognition discriminability indices were calculated for subjects’ 
recognition memory performance after fMRI scanning (for spider pictures, butterfly 
pictures, and total recognition). These variables were compared between groups in the 
same manner as the demographic, clinical, and neuropsychological data (described 
above) and the results are displayed in Table 8. As shown, both phobic groups reported 
average anticipation SUDS (Pre SUDS) at approximately 3.0 whereas SUDS for the 
actual pictures was approximately 5.0 to 6.0 and stayed at that level for spider pictures 
during the second scan. Average SUDS for the control groups stayed close to 0 at all time 
points. Univariate ANOVA revealed there to be a significant main effect for diagnosis on 
anticipatory SUDS level (F(1,42)=70.42, p<.001). There was no effect for treatment and 
no diagnosis x treatment interaction on anticipatory SUDS (Fs<1). Repeated measures 
ANOVA revealed a significant main effect for diagnosis on SUDS levels for scan 1 and 2 
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(F(1,42)=671.70, p<.001). There were no significant differences in SUDS levels for 
treatment (F(1,42)=2.03, p=.162) or for the diagnostic x treatment interaction 
(F(1,42)=1.83, p=.183). Results also indicated that there was no significant difference in 
SUDS between scan 1 and 2 (F(1,42)<1). This remained true when constricting analyses 
to the phobic group only (F(1,21)<1). This indicates that there was no habituation of 
SUDS during the scanning session.  
As shown in Table 8, there was a main effect for diagnosis on recognition 
discriminability for spider stimuli (Spider D’; F(1,42)=6.582, p=.014), as well as on total 
recognition discriminability (Total D’; F(1,42)=6.02, p=.018). These differences came 
about because phobics performed better than controls. However, there was no effect of 
diagnosis on recognition of butterfly pictures (Butterfly D’; F(1,42)=.05, p=.825). Neither 
the treatment main effect nor the diagnosis x treatment interaction were significant for 
any of these recognition variables (all Fs<1). 
As intended, the provocation paradigm seemed to elicit anxiety in the phobic but 
not in the control group (indicated by SUDS levels). The phobic group also exhibited 
better memory for spider stimuli than the control group. DCS did not seem to have an 
effect on subjective anxiety or memory for emotional stimuli.  
fMRI analyses 
For the fMRI analyses, only the specified regions of interest (and regions adjacent 
to those of interest) will be discussed and presented in the tables referenced. However, 
the full results for each contrast mentioned are included in Appendix B. The basic steps 
for analyses included 1) examining the direct interaction of group x condition (results 
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displayed in Table 9 and 10) and 2) examining main effects for spider versus butterfly 
within each group separately (results displayed in Table 11).  
Specific aim 1. This aim related to differences between diagnostic groups in 
neural response to phobic symptom provocation. To test this aim, the diagnosis (phobic > 
control) x condition (spider > butterfly) interaction effect was examined within the 
placebo-treated groups. As shown in Table 9, this interaction revealed significant 
differences between the placebo phobic and control groups (for spiders > butterflies) in 
regions of interest including the right bed nucleus of the stria terminalis (BNST, extended 
amygdala; t(21)=4.42, x,y,z=9,-1,-2), right insula (t(21)=-4.70; x,y,z=33,-16,13), right 
parahippocampal gyrus (PHG; t(21)=-4.80; x,y,z=24,-25,-20), left dorsolateral prefrontal 
cortex (dlPFC; t(21)=-4.54; x,y,z=-48,23,31), and left putamen (t(21)=4.56; x,y,z=-24,-
7,1) . It should be noted that the findings within the insula and PHG were in the opposite 
direction from expected—with the control subjects showing greater differences for 
spiders versus butterflies. To further investigate the reason for this unexpected finding, 
we examined the group interaction regarding spiders versus low-level baseline, as well as 
butterflies versus low-level baseline. These results are also displayed in Table 9. For the 
spider condition, phobics showed greater activations than controls in the dorsal anterior 
cingulate (ACC; BA24; t(21)=4.24; x,y,z=0,5,40), bilateral insula (t(21)=6.03; x,y,z=39,-
10,-8), bilateral caudate (t(21)=4.48, x,y,z=-15,5,1), left putamen (t(21)=4.13; x,y,z=-24,-
4,1), right BNST (t(11)=4.88, x,y,z=9,-1,-2), and bilateral frontal operculum (t(21)=5.26; 
x,y,z=45,14,-2). For the butterfly condition, the phobics also showed greater activations 
than controls in the left ACC (t(21)=4.67; x,y,z=-6,29,10), bilateral posterior cingulate 
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(t(21)=5.24; x,y,z=12,-16,37), bilateral insula (t(21)=5.32; x,y,z=-36,25,10), left caudate 
(t(21)=4.35; x,y,z=-24,8,7), right putamen (t(21)=4.75; x,y,z=15,14,1), and bilateral 
frontal operculum (t(21)=4.58; x,y,z=42,-4,4). These results suggest that, within the 
phobic group, many regions of interest were activating in response to both spider and 
butterfly conditions. This could have contributed to the limited (and somewhat 
inconsistent) findings from the diagnostic group interaction for spiders versus butterflies. 
The main effect of condition was also examined within each of the placebo 
groups separately and these results are listed in Table 11. Comparing spider and butterfly 
conditions, the placebo phobic group showed activations that were greater for spiders 
versus butterflies in several of the predicted regions, including left lateral amygdala 
(cluster spreading into central and basomedial amygdala; t(11)=9.06; x,y,z=-24,-4, -14), 
right central (t(11)=4.72, x,y,z=24,-4,-11) and basomedial amygdala (t(11)=5.97; 
x,y,z=18,-1,-11), right BNST (t(11)=4.93; x,y,z=12,-1,-5), right insula (t(11)=5.41; 
x,y,z=36,2,1), right dlPFC (BA9; t(11)=7.35; x,y,z=42,5,37), and bilateral hippocampus 
(t(11)=6.37; x,y,z=27,-10,-14), as well as other related regions, including the right 
ventrolateral PFC (vlPFC; BA45/46; t(11)=8.22; x,y,z=45,32,10) , right insular claustrum 
(t(11)=5.71; x,y,z=30,11,1), left limitans claustrum (t(11)=6.88; x,y,z=-33,-13,-5), right 
ventral pallidum (t(11)=4.93; x,y,z=12,-1,-5), and left ventral putamen (t(11)=5.33; 
x,y,z=-30,-22,-5). Several of these activations are displayed in Figure 5. The placebo 
control group showed greater responses to spiders than butterflies in similar areas, 
including the left lateral amygdala (t(10)=5.29; x,y,z=-27,-4,-20), right preamygdalar 
claustrum (t(10)=5.32; x,y,z=27,-1,-11), right insula (t(10)=5.12; x,y,z=36,2,1), left OFC 
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(BA47; t(10)=5.37; x,y,z=-30,32,-5), left superior frontopolar area (BA10; t(10)=-5.40; 
x,y,z=-18,59,1), and right inferior frontal gyrus (BA45; t(10)=5.59; x,y,z=45, -1,31). 
Several of these activations are displayed in Figure 6. The contrast between spider and 
butterfly conditions resulted in increased activation for the phobic group in regions of 
interest that were not found for the control group. These regions included the basomedial 
and central amygdala, CA1 and CA3 fields of the hippocampus, and the dlPFC.  
Results related to specific aim 1.1 suggest that the following brain regions 
activated in response to phobic stimuli in a way that was unique to the phobic group: 
amygdala, insula, cingulate, hippocampus, and dlPFC. Figure 3 shows average BOLD 
activation (% signal change) for selected regions that were significant for the spider > 
butterfly contrast within the placebo phobic but not the placebo control group. As shown, 
there is a trend for the phobic group to have greater activations than controls in the right 
basomedial amygdala and left hippocampus during the phobic condition, though this 
difference did not reach the specified level of significance.  However, also shown are 
BOLD activations within the BNST, in which phobics exhibited increased activation to 
phobic stimuli, while controls showed the opposite response. This caused the diagnosis x 
condition interaction to be significant for this region.  
 Specific aim 2. This aim related to the effects of DCS on neural activations 
during symptom provocation. Results from the direct treatment group (DCS > placebo) x 
condition (spider > butterfly) interaction are displayed in Table 10 and Figures 5 and 6. 
The DCS phobic group had greater differential activations (spiders > butterflies) than the 
placebo phobic group in the following regions of interest: left dlPFC (BA9 & 46; 
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t(21)=4.41; x,y,z=-36,29,31), bilateral inferior frontal gyrus (t(21)=4.66; x,y,z=48,8,28), 
right dorsal ACC (t(21)=3.98; x,y,z=12,14,34), and bilateral insula (t(21)=6.19; x,y,z=-
39,-7,10). Many of these activations are displayed in Figure 5. We knew from analyses 
comparing placebo phobic and placebo control groups that many regions of interest 
exhibited increased activation to butterfly as well as spider stimuli for the phobic group. 
Therefore, we also examined the effect of DCS on activations for the spider and butterfly 
conditions separately (as compared to the low-level baseline). The DCS phobics had 
greater differential activations than placebo phobics when comparing spider and low-
level baseline conditions in the following regions of interest: left inferior frontal gyrus 
(t(21)=4.88; x,y,z=-48,23,22), and right dlPFC (t(21)=4.14; x,y,z=27,41,31). The left 
presubiculum showed greater differential activation for the placebo group than the DCS 
group (t(21)=-4.66; x,y,z=-18,-22,-14). It is important to note that, when looking at Table 
10 and the table in Appendix D, almost all of the activation differences found for this 
contrast were greater for the DCS-treated subjects. There were significant differential 
activations between the DCS and placebo phobic groups for the butterfly versus low-level 
baseline condition in the left inferior frontal gyrus (t(21)=-4.75;x,y,z=-33,1,31), left 
dlPFC (t(21)=-3.94; x,y,z=-18,35,31), left ACC (t(21)=-5.61; x,y,z=-3,-31,34), left 
caudate (t(21)=-4.64; x,y,z=-24,8,7), right subiculum (t(21)=-4.34; x,y,z=24, -37,-5), left 
parasubiculum (t(21)=-4.00; x,y,z=-18,-13,-20), and right claustrum (t(21)=-4.21; 
x,y,z=30,-22,4). Almost all of the activations differences found for this contrast were 
greater for the placebo-treated subjects. 
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 The direct Group X Condition interaction revealed significant differences 
between the DCS and the placebo control groups (for spiders > butterflies) in only the 
following two areas related to a priori regions of interest: left ventral ACC (BA 24; 6 
voxels; t(21)= 3.916084, x,y,z = -6,26,4) and left caudate (t(21)=4.61; x,y,z=-9,14,10). 
When comparing these groups with regard to the contrast of spiders versus low-level 
baseline, no regions of interest showed significant differential activations, though a small 
cluster in the frontal operculum was significantly greater for DCS controls (t(21)=3.92; 
x,y,z==42,11,7). When comparing the groups with regard to the contrast of butterfly 
stimuli versus low-level baseline, the left insula (t(21)=3.99; x,y,z=-33,13,10), left 
putamen (t(21)=4.446; x,y,z=-24,2,16), left frontal operculum (t(21)=4.58; x,y,z=-
36,14,16), and left caudate (t(21)=4.12; x,y,z=-18,-1,22) activated significantly more in 
the DCS group than the placebo control group. Because there are so few significant 
findings with respect to the comparison between DCS and placebo control groups, these 
results are only shown in Appendix B. Many of the significant differential activations for 
this interaction are displayed in Figure 6. 
 The main effects for spider versus butterfly conditions were also examined 
separately for each of the DCS groups (phobic and control). This allows for comparisons 
to be made with the results reported earlier for each of the placebo groups. The DCS 
phobic group showed greater activations for spiders versus butterflies in many different 
regions of interest, including bilateral insula (t(10)=8.03; x,y,z=-30,20,10), bilateral 
inferior frontal gyrus (t(10)==5.79; x,y,z=54,5,25), bilateral dlPFC (t(10)==8.00; x,y,z=-
24,44,28), right OFC (t(10)=5.00;x,y,z=-33,35,-11), bilateral dorsal ACC 
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(t(10)=6.78;x,y,z=-3,17,31 and t(10)=8.79; x,y,z=6,2,46). These results are listed in Table 
11 and many of the activations are displayed in Figure 5. In contrast to the placebo 
phobic group, the DCS phobic group did not have significant activations within the 
amygdala or hippocampus, though there was a cluster within the left basolateral 
amygdala that did not meet the cluster threshold. It is also important to note that the 
placebo phobic subjects did not have significant activations in the inferior frontal gyrus, 
OFC, or cingulate. The DCS control group showed greater activations for the spider 
versus butterfly condition in the following regions of interest, all left lateralized: superior 
rostral gyrus (t(11)=6.39; x,y,z=-6,56,4), dlPFC (t(11)=5.23; x,y,z=-42,5,43), lateral PFC 
(t(11)=5.60; x,y,z=-48,26,7), left lateral OFC (t(11)=5.12;x,y,z=-36, 29,-11), anterior 
(t(11)=6.90; x,y,z=-15,44,10) and posterior cingulate (t(11)=4.80; x,y,z=-3,-22,34). These 
results are listed in Table 11 and many of the activations are displayed in Figure 6. Again, 
it should be noted that the DCS control group did not show significant activations within 
the amygdala whereas the placebo control group did. The placebo control group, on the 
other hand, did not show significant activations within the dlPFC, vlPFC, superior rostral 
gyrus, or cingulate.  
 To illustrate the DCS findings, the BOLD % signal change in selected regions 
of interest found to be significantly different between the placebo and DCS phobic 
groups (spider > butterfly) are presented in Figure 4. As shown, DCS was associated with 
enhanced signal change within the insula and dorsal ACC (as well as areas of the PFC, 
not shown). Signal change for the left lateral amygdala, which was significant within the 
placebo- but not the DCS- phobic group, is also shown in Figure 4. As shown, the 
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placebo- and DCS- phobic groups exhibited similar patterns of activation in the left 
lateral amgydala. Based on this observation, as well as the fact that the treatment x 
condition interaction was not significant within the amgydala, it can be concluded that 
DCS did not significantly modulate activity in this region. The differences between 
groups are apparent pictorially in Figure 5.  
 In summary, results suggest that DCS may exert an influence on neural response 
patterns to phobic stimuli by enhancing PFC, ACC, and insula activations for both phobic 
and non-phobic subjects. However, this effect may be more robust when the individuals 
are experiencing a phobic (or emotional) response to the stimuli.  
 Correlational analyses. Correlational analyses were conducted within the 
phobic groups to examine the relationship between 1) regions of interest and both clinical 
and behavioral data and 2) between amygdala and prefrontal regions of interest (because 
of theorized inhibitory relationships). Regions of interest for each phobic group (DCS or 
Placebo) were those found significant for the spider > butterfly contrast within that group. 
Correlations were conducted using bivariate Pearson correlations. These correlational 
analyses were conducted for the two phobic groups (DCS and placebo) separately. 
Correlations were considered significant if they met p<.05.  
 Amygdala regions for the placebo phobic group included the left lateral 
amygdala (x,y,z=-24,-4,-14), right central amygdala (x,y,z=24,-4,-11), right basomedial 
amygdala (x,y,z=18,-1,-11), and right BNST (x,y,z=12,-1,-5). Prefrontal cortex regions 
for this group included the right vlPFC (45, 32, 10) and dlPFC (42, 5, 37). Also included 
in correlational analyses for the placebo phobic group was the right insula (x,y,z=36,2,1).    
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 For the DCS phobic group, the maximum voxel of the left basolateral amygdala 
(BLA; x,y,z=-18,-1,-18) was used for correlational analyses. This region was significant 
for the spider > butterfly contrast within the DCS group, though did not meet the 
specified cluster threshold. Prefrontal cortex regions included the left (BA9; x,y,z=-
24,44,28) and right dlPFC (BA 46, x,y,z=45,35,13), left (x,y,z=-45, 20, 22) and right 
inferior frontal gyrus (IFG; x,y,z=-45, 20, 22), and left (x,y,z=-33,35,-11) and right OFC 
(x,y,z=45,17,-5), Additional regions of interest included in correlational analyses for the 
DCS phobic group included two regions of the dorsal ACC (BA 24, x,y,z=6,2,46; BA 32, 
x,y,z=-3,17,31) and the left (x,y,z=-30,20,10) and right insula (x,y,z=36,2,4).  
 Within each group separately, the amygdala, insula, and prefrontal regions were 
examined for significant correlations with measures of phobia symptoms (SUDS during 
fMRI, BAT, SPQ). For the placebo phobic group, there were significant correlations 
between the SPQ and 1) right basomedial amygdala (r=.70, p=.011), and 2) left vlPFC 
(r=.60, p=.038). There was also a significant correlation between fMRI SUDS level and 
the left lateral amygdala (r=.65, p=.023). There were no correlations within the placebo 
phobic group for the BAT. In the DCS phobic group, there were significant correlations 
between SUDS level and activation in the right OFC (r=.63, p=.039) and between BAT 
score and the right IFG (r=.72, p=.012). There were no other correlations for these 
variables in the DCS phobic group. 
 Correlations were also examined between the amygdala and areas of the PFC. 
Coordinates for both the amygdala and PFC regions for each group are described above. 
In the placebo phobic group, there were positive correlations between the right 
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basomedial amygdala and both the vlPFC (r=.76, p=.004) and dlPFC (r=.59, p=.045). For 
the DCS phobic group, there was a significant negative correlation between the left BLA 
and the left OFC (r=-.75, p=.008).  
 Results from correlational analyses indicate that the right basomedial amygdala 
and vlPFC correlated with severity of phobia, while left lateral amygdala correlated with 
SUDS level, in the placebo phobic group. In the DCS phobic group, only prefrontal 
regions (IFG and OFC) correlated with phobia measures (BAT and SPQ). Additionally, 
in the DCS group, there was a negative correlation between the OFC and BLA, while in 
the placebo group, prefrontal and amygdala activations were positively correlated. 
Therefore, DCS potentially serves to strengthen the inhibitory connections between the 













Chapter 4: Discussion 
 This study examined the effects of DCS on brain activations for both spider phobic 
and healthy control subjects during phobic symptom provocation. Results from this study 
replicate findings from previous fMRI symptom provocation studies and demonstrate that 
un-treated phobic subjects have unique activations to phobic stimuli (compared to non-
phobic controls) in the bilateral central and basomedial amygdala, right bed nucleus of 
the stria terminalis (BNST; extended amygdala), bilateral hippocampus, and right lateral 
prefrontal cortex (PFC; dorsolateral [dlPFC] and ventrolateral [vlPFC]). Study results 
provide evidence that, in phobic subjects, DCS enhanced bilateral PFC (dlPFC and 
inferior frontal gyrus), dorsal anterior cingulate (ACC), and bilateral insula activations, 
and led to unique activations in the OFC, during phobic symptom provocation. For 
controls, DCS administration enhanced activations to spider stimuli in the ventral ACC 
and left caudate, and led to unique activations (compared to placebo controls) in the left 
lateral PFC (dlPFC and vlPFC). Results of neuropsychological testing provide evidence 
that specific phobia may be associated with subtle differences in cognitive functioning, 
including decreased performance during emotional decision-making and qualitative 
differences in strategic processing. There was a trend for DCS to negatively affect 
performance of non-phobic controls during emotional decision-making tasks. More in-
depth discussion of findings from each aspect of the current study is presented below.  
Clinical Measures and Adverse Symptoms 
The mean SPQ scores for the phobic groups were similar to those reported 
previously for phobic populations (Fredrikson, 1983; Kindt, Brosschot, & Boiten, 1999). 
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Based on the BAT and SPQ, as well as the ADIS, it can be concluded that the subjects in 
the phobic group met criteria for spider phobia and that those in the control group had 
little, if any, fear of spiders. Although findings from the adverse symptom checklist 
suggest phobic individuals may be hypervigilant toward medication effects, there was no 
indication of side effects related to D-cycloserine (DCS). This is consistent with reports 
from clinical studies using similar doses of DCS (Guastella et al., 2008; Hofmann et al., 
2006a; Kushner et al., 2007; Ressler et al., 2004; Storch et al., 2007; Wilhelm et al., 
2008). It can be assumed that subjects were unable to determine whether they had been 
administered DCS or placebo. Therefore, results are most likely not due to altered 
expectations of functioning by those administered DCS. 
Neuropsychological Measures: Diagnostic effects 
Compared to the control group, the phobic group exhibited performance 
differences on various neuropsychological measures. These differences consisted of 1) 
decreased organizational strategy on the Rey Complex Figure Test (RCFT) and 2) 
decreased performance on the Iowa Gambling Test (IGT). Neuropsychological deficits in 
the specific phobics in the current study are surprising given the fact that no such 
differences have previously been identified. Only one other study (Airaksinen et al., 
2005) has examined the neuropsychological performance of phobic subjects on neutral 
tasks that are unrelated to their phobia. In this study, no differences between phobic and 
non-phobic subjects were found. However, this study did not examine the qualitative way 
in which information was processed, nor did it include measures involving emotional 
decision-making.  
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The current neuropsychological results suggest that individuals with specific 
phobia may use qualitatively different strategies during nonverbal memory encoding 
tasks. The phobic subjects were less organized when copying the RCFT figure, but 
showed normal recall. This suggests that they were either using other, uncommon but 
equally effective, strategies to encode the information or were using compensatory 
mechanisms (i.e. enhanced memory for details) to maintain their performance. Decreased 
use of the common structural organization scheme on the RCFT has been reported for 
other anxiety disorder populations, primarily OCD (Savage et al., 1999; Savage et al., 
2000) and OCD-related disorders (Deckersbach et al., 2000; Sherman et al., 2006). 
However, for these populations, the decrease in organization is usually associated with 
subsequent decreased recall performance. In contrast, studies examining encoding 
strategy in anxiety disorders other than OCD, such as PTSD (Jenkins et al., 1998; Moritz 
et al., 2005), have not found significant differences on RCFT organization and recall 
compared to non-anxious control groups.  
 Researchers have suggested that individuals use emotional signals during the Iowa 
Gambling Task to guide decision-making even when they are not explicitly aware of the 
reasons for those decisions (Bechara et al., 1997; Miu et al., 2008). In light of these 
suggestions, it is surprising that performance of phobic individuals on the IGT or other 
emotional decision-making tasks has not been reported previously. Decreased IGT 
performance has been reported in OCD, though results have been inconsistent (Cavallaro 
et al., 2003; Kuelz, Hohagen, & Voderholzer, 2004; Nielen et al., 2002). Panic disorder 
patients have been shown to perform similar to controls on the IGT (Cavedini et al., 
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2002). However, decreased performance on the IGT has been reported for individuals 
with high trait anxiety (Miu et al., 2008). It has been suggested that in anxiety disorders 
(especially OCD), increased baseline levels of emotional activation decrease the “signal-
to-noise” ratio and prevent adequate detection of subtle emotional changes (Savage, 
2002). Inability to detect these emotional “hints” could contribute to impaired decision-
making on tasks such as the Iowa Gambling Test. Future research should aim to test such 
hypotheses by examining emotional decision-making in a variety of anxiety-disordered 
populations.  
Because the current study employed a small sample size and findings are in 
opposition to those of previous studies involving non-OCD subjects, these 
neuropsychological results should be considered preliminary. However, the results 
provide initial support for subtle neuropsychological differences associated with specific 
phobia that warrant further investigation.  
 Phobics also exhibited enhanced memory for spider pictures during the fMRI 
symptom provocation paradigm. This is consistent with a previous report of increased 
memory for phobic-related script information (Kindt et al., 1999). It is also in line with 
the generally held understanding that memory is greater for events that elicit emotional 
arousal (McGaugh, 2006). However, it should be noted that some studies have found no 
differences between phobic and non-phobic subjects’ recall of phobic-related stimuli 
(Kulas et al., 2003; Thorpe & Salkovskis, 2000). The inconsistencies may stem from 
variations in the type of stimuli used as well variable task difficulty. In the current study, 
the encoding task (the symptom provocation paradigm) was of a long duration (12 
 88
consecutive minutes) and the recognition task was relatively difficult. Emotional arousal 
to the spider pictures may have enabled phobics to sustain attention throughout this 
extended time period, thereby increasing memory recall.  
Neuropsychological Measures: Treatment effects 
D-cycloserine was not associated with profound differences in 
neuropsychological functioning in the current study. However, there was a trend for DCS 
to negatively affect IGT performance. Larger studies are needed to examine the effects of 
DCS on emotional decision-making. 
The fact that DCS failed to have an effect on memory for phobic-related stimuli 
was surprising considering theories postulating that DCS enhances memory consolidation 
related to fear extinction (Davis et al., 2006; Hofmann et al., 2006b). As previously 
mentioned, the sample size in the current study was relatively small for examining 
differences in behavioral measures. Additionally, we only measured one aspect of 
memory for the phobic stimuli, namely explicit recognition. DCS may influence different 
aspects of memory, such as consolidation of stimulus-response associations, or enhanced 
memory of contextual and abstract information. These alternatives will be discussed 
further in relation to the neuroimaging results. Further examination of the specific 
cognitive effects of DCS could be useful for understanding its potential in terms of 
enhancing ERP therapy.  
Provocation paradigm: Diagnostic effects 
Levels of fear (SUDS ratings) reported for spider pictures during the fMRI 
symptom provocation paradigm were significantly higher for the phobic than control 
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groups, supporting the use of this paradigm in provoking phobic symptoms. Additionally, 
these SUDS levels were similar to fear and arousal levels reported in other neuroimaging 
studies of spider phobia (Paquette et al., 2003; Schienle et al., 2005, 2007; Straube et al., 
2006), supporting the generalizability of results. The lack of behavioral habituation to the 
spider pictures was evident by the fact that there was no change in SUDS level from scan 
1 to 2. Therefore, it can be concluded that both scans were successful at provoking 
phobic symptoms.  
Symptom provocation (as indicated through the contrast of spiders > butterflies) 
within the placebo phobic group was associated with activation in areas of the amygdala 
(including the BNST), hippocampus, and PFC. These results are consistent with previous 
research and a priori hypotheses. Results for the direct interaction of diagnosis (placebo 
phobic > placebo control) X condition (spider > butterfly) indicate that the BNST and a 
region within the striatum (left putamen) exhibited greater differential activation for the 
placebo phobic group while the right insula, right parahippocampal gyrus (PHG), and left 
dlPFC were greater for controls.  
Although the results for the diagnosis X condition interaction only partly support 
a priori hypotheses, they are not surprising. Meta-analyses and reviews of neuroimaging 
in specific phobia do report consistent findings of greater activation in phobics than 
controls in the amygdala, insula, and PFC (Etkin & Wagner, 2007; Gottfried & Dolan, 
2004; Miller et al., 2005; Stein, 2006). However, results from diagnostic group X 
condition interaction analyses are inconsistent across individual studies. For example, 
Paquette et al. (2003) reported phobics to have greater activations in only the inferior 
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frontal gyrus and PHG; Schienle et al. (2007) reported phobics to have greater activations 
in the amygdala and fusiform gyrus while controls had greater activations in the ACC, 
orbitofrontal cortex (OFC), and dlPFC; and Straube et al. (2006) reported the phobic 
group to have greater activation in the insula and ACC while controls showed increased 
activation in the amygdala and PHG. The fact that these studies utilized varying types of 
stimuli as “control” conditions (i.e. snakes, mushrooms, butterflies, household items) 
may have contributed to the inconsistencies.  
When contrasting each of the “active” conditions (spider and butterfly) with the 
low-level baseline condition in the current study, it was found that the phobic group had 
greater responses than controls to both spider and butterfly stimuli (though more so to the 
spider stimuli). Results from the diagnosis X condition (spider > butterfly) interaction 
were, therefore, not reflective of regions specific to phobic symptom provocation, but 
those in which the phobic group activated more to the butterfly condition. The idea that 
specific phobia is associated with abnormal activation patterns to stimuli unrelated to the 
phobia (and that do not increase anxiety or distress) is an interesting topic of research. 
However, it was not the focus of this study. Instead, we were interested in neural 
activation patterns unique to the processing of phobic stimuli for individuals with specific 
phobia. Therefore, the unique activations of phobic subjects (compared to control 
subjects) for the spider > butterfly contrast will be the focus of the following discussion 
regarding neural correlates of phobic fear. 
The regions which were activated uniquely for the placebo phobic group during 
symptom provocation (spider > butterfly), included right dlPFC and vlPFC, bilateral 
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central and basomedial amygdala (lateral amygdala was activated in both phobics and 
controls), right BNST (also significant for direct group interaction), bilateral 
hippocampus, and left putamen (also significant for direct group interaction). Left lateral 
and right basomedial amygdala activations were also found to significantly correlate with 
measures of phobia severity (as assessed by fMRI SUDS levels and the SPQ, 
respectively). Activation within the vlPFC also correlated significantly with SPQ score. 
Interestingly, there were positive correlations between the right basomedial amygdala and 
both the vlPFC and dlPFC. 
Much of the focus in animal and human research of fear processing has been on 
the medial PFC. Lesions in this area strongly influence emotional behavior and activation 
of this area seems to enhance fear extinction (Herry & Garcia, 2002; Jinks & McGregor, 
1997; Milad & Quirk, 2002; Quirk et al., 2003). However, lesions to the lateral PFC have 
been shown to influence emotional behavior in animals as well—increasing responses to 
conditioned fear (Lacroix et al., 2000). It is important to recognize that the lateral PFC 
seems to be especially developed in humans and may therefore have unique functions 
that are not completely homologous in animals. Several human imaging studies have 
reported lateral PFC activation during either symptom provocation in anxiety disorders or 
during fear processing in non-anxious controls (Dunsmoor et al., 2007; Milad et al., 
2006; Paquette et al., 2003; Schienle et al., 2005).  In support of these findings, the 
current study found right dlPFC and vlPFC activations that were unique to the phobic 
group (compared to the placebo control group) during exposure to phobic stimuli. 
Regions of the lateral PFC have been implicated in both reappraisal and distraction 
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methods of cognitive modulation during anticipatory anxiety (in healthy, non-anxious 
controls; Kalisch et al., 2005, 2006). The dlPFC in particular is believed to be involved in 
working memory and the selection of responses to emotional stimuli (Miller et al., 2005). 
Dorsolateral PFC activation has also been shown to activate for phobics that successfully 
control their behavioral response to symptom provocation, but not for those who 
experience panic symptoms (Johanson et al., 1998). The existence of lateral PFC 
activations in the current study may reflect attempts to control responses to phobic 
stimuli, thus allowing subjects to maintain focus on the task at hand and complete the 
fMRI scan. However, the fact that anxiety remained relatively high and PFC activation 
correlated positively with amygdala activation suggests that these attempts were at least 
partially unsuccessful.  
The amygdala is thought to lie at the center of the brain’s emotional processing 
system and is involved in rapid fear responses (Lang, Davis, & Ohman, 2000; Walker et 
al., 2003). As discussed previously, it has been shown to be involved in both fear 
acquisition and extinction in animals and is correlated with response to feared stimuli in 
both phobic and non-phobic human populations (Flynn et al., 1999).  The central 
amygdala is thought to be more involved in coordination of the actual fear response (i.e. 
autonomic and behavioral responses) whereas the basolateral complex (BLA) is more 
involved in plasticity related to fear learning (Anglada-Figueroa & Quirk, 2005; Davis, 
2006). The BNST is considered part of the “extended amygdala” and is thought to 
potentially be involved in the long-term experience of fear (Davis & Shi, 1999; Davis, 
Walker, & Lee, 1997; Davis & Whalen, 2001; Rosen & Donley, 2006; Walker et al., 
 93
2003). The BNST receives input from the medial prefrontal cortex and the central 
nucleus of the amygdala (Kalin et al., 2005; Straube et al., 2007; Walker et al., 2003). In 
animal studies, anxiety or fear responses are associated with activation of the BNST 
(Kalin et al., 2005), while lesioning of the BNST seems to attenuate behavioral signs of 
anxiety (e.g. Fendt et al., 2003; Waddell, Morris, & Bouton, 2006). Amygdala activation 
has been reported for phobic symptom provocation in several previous studies (Carlsson 
et al., 2004; Dilger et al., 2003; Goosens et al., 2007; Schienle et al., 2005). However, 
there has been only one published study reporting BNST activation associated with 
specific phobia (Straube et al., 2007).  
The current study found amygdala activation when comparing spider to butterfly 
stimuli, in both placebo phobic and placebo control groups. This is consistent with 
suggestions that amygdala activation is not specific to anxiety disorders or even fear-
processing (Stein et al., 2007; Wendt, Lotze, Weike, Hosten, & Hamm, 2007). However, 
it is important to recognize that in the current study, amygdala activation for the phobic 
group extended into regions that were not activated in controls. This suggests that the 
neural response within the amygdala differed between the groups in some way. However, 
this is most likely not simply a matter of the amygdala being either “on” or “off”, but of 
differences in signaling within subregions of the amygdala. The resolution of fMRI 
makes it difficult to draw firm conclusions regarding the role of amygdala subregions. 
However, previous human neuroimaging studies provide evidence that ventral regions of 
the amygdala are more involved in processing saliency while dorsal regions are more 
involved in processing fear (Kim, Somerville, Johnstone, Alexander, & Whalen, 2003; 
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Whalen, Shin, McInerney, Fischer, Wright, & Rauch, 2001). Current results support this 
theory, revealing the control group to have primarily left ventral amygdala activation, 
while the phobic group exhibited maximum activation in the left dorsal amygdala (see 
Figures 5 and 6). This study is also one of only two studies reporting BNST activation in 
response to phobic symptom provocation (Straube et al., 2007). This is important in that 
it corroborates animal research showing the BNST to be important in fear processing. 
Research in human brain imaging related to anxiety disorders may need to adjust its focus 
to include not only subregions of the amygdala proper, but also regions within the 
“extended amygdala”, such as the BNST.  
The hippocampus is perceived as a central region associated with learning and 
memory (Neves, Cooke, & Bliss, 2008). It has been shown to be important in both fear 
conditioning and extinction—especially regarding recall of contextual cues (Corcoran et 
al., 2005; Maren et al., 1997; Quirk & Mueller, 2008). The hippocampus is thought to 
modulate amygdala activity through neural connections with both the amygdala and the 
prefrontal cortex (Corcoran et al., 2005; Maren et al., 1997). Findings from the current 
study implicate the involvement of the hippocampus in the processing of phobic stimuli 
and are consistent with findings reported by previous studies (Milad et al., 2007; Paquette 
et al., 2003; Schienle et al., 2005). It should be noted that many studies have failed to find 
hippocampal activation (Dilger et al., 2003; Etkin & Wagner, 2007; Straube et al., 2006). 
However, both human and animal studies support the importance of the hippocampus in 
fear processing. The current findings of hippocampal activation would suggest that the 
phobic subjects are engaging memory networks. However, this engagement could either 
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be related to 1) memories of phobic-related cues that were previously learned (and are 
activated by exposure to new phobic stimuli) or 2) the encoding of new memories 
regarding the presented phobic stimuli and related contextual cues.   
Although the importance of the ventral striatum, including the putamen, in 
reinforcement learning is widely recognized (i.e. Balleine, Delgado, and Hikosaka, 2007; 
Delgado, 2007; Wickens, Budd, Hyland, & Arbuthnott, 2007), this region has not been a 
primary focus of research on fear processing (Ollson & Phelps, 2007). There have been 
consistent findings of putamen, or ventral striatum, activation during symptom 
provocation in OCD (Kwon et al., 2003; Mataix-Cols et al., 2004; Perani et al, 1995). 
However, only a few studies have reported putamen activation associated with specific 
phobia (Schienle et al., 2005). Results reported by recent fear conditioning studies in 
healthy, non-clinical human populations (using neuroimaging techniques; Jensen et al. 
2003; Seymour et al. 2004) and animals (Iordanova et al., 2006) provide reason to believe 
that the ventral striatum may play a role in predictive fear learning and the allocation of 
attention towards predictors of danger (McNally & Westbrook, 2006). In particular, the 
putamen may play a role in the coding of stimulus-action (especially motor) associations 
(Balleine, Delgado, and Hikosaka, 2007). Therefore, putamen activation found during 
phobic symptom provocation in the current study may relate to 1) the allocation of 
attention to the spider stimuli as potential predictors of danger or 2) encoding of the 
association between phobic stimuli and the subjects own responses.  
In summary, symptom provocation in spider phobia was associated with unique 
activations in regions thought to be involved in the direct experience of fear and anxiety 
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(amygdala and BNST), the prediction of danger (putamen), the cognitive control of 
emotional responses (PFC), as well as emotional learning and memory (hippocampus, as 
well as all of the above). These results support the hypotheses stated in specific aim 1.1 
and are consistent with findings from previous studies. Therefore, this paradigm should 
be considered valid for use in examining the effects of DCS on neural activation 
responses to phobic symptom provocation. 
Provocation paradigm: Treatment effects 
The primary aim of this study was to investigate the effects of DCS on neural 
activations during exposure to phobic stimuli. This information is directly relevant to 
clinical findings that acute DCS administration enhances the effects of exposure (ERP) 
therapy for anxiety disorders. Results from this study suggest DCS exerts an influence on 
neural response patterns to phobic stimuli by enhancing prefrontal (PFC) activations for 
both phobic and non-phobic subjects. This effect seemed more robust when individuals 
were experiencing a phobic (or emotional) response to the stimuli. DCS did not have an 
effect on SUDS levels reported during the symptom provocation paradigm. As DCS has 
not been shown to influence the startle response or initial anxiety/distress to a feared 
stimulus, this is not surprising (Davis et al., 2006; Ressler et al., 2004; Walker et al., 
2002). A recent animal study found that DCS could increase reconsolidation of fear 
memory when exposure to the conditioned stimulus (CS+) was not of long enough 
duration to achieve extinction (Lee, Milton, & Everitt, 2006). Therefore, it is important 
that while DCS was not associated with a decrease in SUDS through the exposure, it also 
did not seem to increase SUDS levels—and presumably did not further sensitize the 
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subjects to spiders. DCS was also not associated with any changes in recognition memory 
for stimuli presented during the symptom provocation paradigm. The null results from 
behavioral measures suggest that neuroimaging findings are not simply due to changes in 
behavior or level of anxiety experienced. Therefore, the effects observed are most likely 
due to the drug itself.   
In both phobic and control groups, DCS was associated with increased or unique 
activations to spiders versus butterflies in the dlPFC and ACC (primarily dorsal in the 
phobic group; ventral in the control group). In the phobic group, DCS was additionally 
associated with greater activation in the bilateral inferior frontal gyrus and insula, as well 
as unique activations in the right OFC. In the control group, there were additional effects 
of DCS within the left caudate and rostromedial PFC. It should also be noted that, in the 
DCS-phobic group, right OFC and inferior frontal gyrus activations correlated 
significantly with severity of phobia (as measured by fMRI SUDS level and BAT, 
respectively). This is in contrast to the placebo-phobic group, in which primarily 
amygdala (as well as vlPFC) activations were correlated with symptom severity. 
Additionally, there was a negative correlation between the left OFC and BLA in the DCS 
phobic group, whereas a positive correlation between PFC and amygdala activation was 
found for the placebo phobic group.  
As apparent in Figures 5 and 6, the activations for the condition (spider > 
butterfly) contrast were much more pronounced within both phobic groups than control 
groups and the treatment interaction effect within the phobic group was also more 
pronounced than that of the control group. As the primary focus of this study was to 
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investigate possible mechanisms for DCS-augmented exposure therapy in anxiety 
disorders, the primary focus of discussion will be on findings from the phobic group. 
However, it is interesting to note that DCS enhanced primarily dorsal aspects of the ACC 
in phobics, but enhanced primarily ventral ACC in controls. The dorsal aspects of the 
ACC are considered to be involved in more “cognitive” tasks whereas the ventral ACC is 
involved in tasks that are more emotional in nature (Bush, Luu, and Posner, 2000). It is 
possible that the regional influence of DCS within the ACC depends upon the emotional 
arousal of subjects. If the task produces high emotional arousal, DCS may serve to 
enhance cognitive processing of stimuli through enhanced dorsal ACC activation. If the 
task is salient, but not necessarily emotional arousing, DCS may serve to enhance 
emotional processing of the stimuli through enhanced ventral ACC activation. The 
differential effects of DCS on behavioral, cognitive, and biological functioning in various 
clinical and non-clinical populations, and during tasks of varying emotional intensity 
should be examined by future research. 
The effects of DCS within the phobic group were driven both by increased 
activations to spider stimuli and decreased activations to butterfly stimuli (compared to 
the placebo-treated phobics). DCS, therefore, seems to differentially influence the 
processing of both feared and non-feared stimuli, presented within the same session. This 
may relate to an increase in selective attention for salient and fear-provoking stimuli—
decreasing distractions from the fear extinction process. Alternatively, this could relate to 
a decrease in anticipatory anxiety between exposure blocks. Either way, it suggests that 
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DCS does not serve to simply enhance brain activation to all stimuli during the time in 
which the drug is active within the central nervous system (CNS).  
Current findings suggesting DCS can enhance PFC activation is consistent with 
recent animal research suggesting DCS mediates NMDA-receptor activity within the 
medial PFC (mPFC; Fujihira et al., 2007; Millecamps et al., 2007; Murai et al., 2007). 
However, in animal research examining DCS effects on fear extinction, the prefrontal 
cortex has taken a back seat to the amygdala and hippocampus. The only other human 
neuroimaging study to investigate the effects of acute DCS did not examine changes in 
regions of the PFC—only the amygdala (Britton et al., 2007). Therefore, the current 
study provides initial, preliminary evidence that activity in regions within the PFC are 
enhanced by DCS administration during fear processing. Future animal and human 
research of DCS-augmented fear extinction should further evaluate effects within various 
regions of the PFC.  
Animal research on fear learning in general (not involving DCS) suggests the PFC 
is required for fear extinction and memory for extinction (Anglada-Figueroa & Quirk, 
2005; Morgan, Schulkin, & LeDoux, 2003). As mentioned previously, most previous 
research has focused on the inhibitory influences of the medial PFC in fear processing, 
though there have been studies suggesting the lateral PFC plays a similar role (Dunsmoor 
et al., 2007; Lacroix et al., 2000; Milad et al, 2006; Milad & Quirk, 2002; Schienle et al., 
2005; Paquette et al., 2003). The current study found DCS to be associated with enhanced 
activations in primarily lateral regions of the PFC and OFC, as well as areas of the dorsal 
ACC. Increased lateral PFC activation has been associated with reappraisal, distraction, 
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and other cognitive strategies to regulate emotional response (Kalisch et al., 2005, 2006). 
It is possible that DCS is increasing the use of such strategies—or at least the ability of 
individuals to engage in such strategies if directed to do so.  
The OFC has extensive connections with the dlPFC as well as the amygdala and 
is considered important in stimulus-reinforcement association learning—altering 
behavior in response to feedback (Kringelbach & Rolls, 2004; Pears, Parkinson, 
Hopewell, Everitt, and Roberts, 2003; Stein et al., 2007). The lateral OFC in particular is 
thought to be involved in mediating responses during negative affective states (Milad & 
Rauch, 2007). The dorsal ACC is thought to be involved in cognitive processing as well 
and is important in the generation of error signals and allocation of attentional resources 
(Critchley, 2005; Phillips et al., 2003). Therefore, enhancement of PFC, OFC, and dorsal 
ACC activations by DCS may increase rational, cognitive processing and the ability to 
modulate responses to negative emotional stimuli. The negative correlation between OFC 
and amygdala activation within the DCS phobic group, provides further evidence that 
DCS may involve enhanced modulation by prefrontal regions. Enhanced PFC activation 
may serve as a common mechanism for recent findings showing DCS-augmented ERP to 
beneficially influence both anxiety and depressive symptoms (Wilhelm et al., 2008). 
In recent years, the insula has received increasing focus within the anxiety 
disorder literature (Paulus & Stein, 2006; Simmons, Matthews, Paulus, and Stein, 2008; 
Stein et al., 2007). The insula has been consistently reported to activate during phobic 
symptom provocation paradigms (Dilger et al., 2007; Schienle et al. 2007; Straube et al., 
2007) and this activity has been shown to normalize with successful treatment (Goosens 
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et al., 2007; Straube et al, 2006). The insula is understood to be involved in interoceptive 
function and the integration of internal body states with external events (Cechetto, 1994; 
Craig, 2002; Phillips et al., 2003). Paulus and Stein (2006) recently presented an insula 
hypothesis of anxiety disorders, implicating the insula as a primary locus of dysfunction. 
They postulate that individuals with anxiety disorders have altered interoception that 
includes an altered prediction signal regarding expected body state (i.e. in response to 
certain objects or situations). The neural system that underlies interoception converges in 
the anterior insula (Craig, 2002). Additionally, the insula lies between and has strong 
connections with areas of the PFC (including the ACC) and the amygdala (Craig, 2002). 
Therefore, it is optimally located to receive signals concerning saliency of environmental 
stimuli and how such stimuli may affect bodily states. Information is relayed from the 
insula to the ACC, which is involved in the generation of error signals and allocation of 
attentional resources. The dorsal aspects of the ACC are thought to particularly be 
involved in the integration of cognitive processes with autonomic arousal (Critchley, 
2005; Phillips et al., 2003).  
Increased activation in both the insula and dorsal ACC with DCS may reflect a 
more complete integration of information regarding various aspects of the fear 
experience. This could relate to a stronger cognitive representation of the fear itself (as 
discussed further in the next paragraph)—enabling the individual to integrate their bodily 
state predictions with the actual response experienced. Such an effect could presumably 
have a strong influence on the learning process during extinction, strengthening new 
associations between stimulus and response. Originally, it was hypothesized that insula, 
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along with amygdala, activation would decrease with the administration of DCS. This 
was based on knowledge that the insula and amygdala share extensive connections with 
one another, and the idea that both structures are involved in the initial response to 
emotionally-salient stimuli (Phillips et al, 2003). The current finding that, during initial 
symptom provocation, acute DCS significantly enhanced insula, but not amygdala, 
activation suggests that each of these regions play a distinct role in fear processing. 
It has been shown that DCS increases generalization of fear extinction (i.e. after 
fear extinction to one CS+, fear response to a second CS+ is also decreased; Ledgerwood, 
Richardson, & Cranney, 2005). Researchers have postulated that this effect may be due to 
a devaluing of the UCS itself. In other words, the DCS-treated mice become extinguished 
to not simply the CS+, but also to their cognitive representation of the UCS (Davis et al., 
2006; Ledgerwood et al., 2005). In fact, animal studies have shown the generalization 
effects observed for DCS are very similar to the effects observed after extinction sessions 
with the UCS (Ledgerwood et al., 2005). It is possible that this is the effect we are seeing 
in the current study and that the increased PFC, ACC, and insula activations represent 
higher level processing in which abstract cognitive representations of spiders (and the 
fear of spiders) is held in mind. This would be in contrast to the processing of only 
concrete aspects of the picture stimuli.  
In the human anxiety disorder literature, it has been postulated that there are two 
required elements of successful ERP therapy: 1) the fear structure must be activated and 
2) information incompatible with the fear prediction must be incorporated (Foa & Kozak, 
1989). The “fear structure” is thought to involve information related to the feared 
 103
situation, information about predicted and actual responses to such stimuli (i.e. verbal, 
physiological, and behavioral responses), and interpretations regarding the meaning of 
the stimulus-response elements (Foa & Kozak, 1989; Lang, 1977, 1979; Rodebaugh and 
Chambless, 2004;). Therefore, exposure therapy is thought to rely on activation of a 
cognitive representation of the core fear—not simply activation of sensory and attentional 
resources to the stimulus presented. For example, ERP for a spider phobic patient may 
involve exposure to words associated with spiders (i.e. “spider”, “creepy”, “bites”), 
pictures and videos of spiders, and live spiders. These individual exposure stimuli are all 
used to elicit the core fear of spiders and spider bites. During every exposure, the patient 
is encouraged to focus on thoughts related to that core fear and related stimulus-response 
predictions (i.e. “Spiders are gross and disgusting. They are dangerous and will bite me. 
The bite will be painful and it will kill me.”). The power of ERP most likely comes from 
habituation to that core fear and related catastrophic stimulus-response interpretations—
not simply to the individual, concrete stimuli.  
DCS appears to enhance activation of PFC, ACC, and insula regions, potentially 
allowing patients to focus more easily on the cognitive representations of the core fear—
including information about predicted and actual responses to such stimuli, and 
interpretations regarding the meaning of the stimulus-response elements. This hypothesis 
is consistent with the fMRI data, but should be considered preliminary because there 
were no behavioral measures in the current study to support or refute it. Such a difference 
in cognitive processing would not necessarily cause changes in initial anxiety level or 
alter memory for concrete aspects of the exposure (i.e. the spider pictures). Kamphuis and 
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Telch (2000) reported that greater focus on core threats (as well as less distraction) during 
exposure was associated with greater fear reduction. Additional studies have reported 
memory for anxious responses and abstract information during exposure relates to 
treatment outcome (Kamphuis and Telch, 2000; Kindt et al., 1999; Zoellner, Echiverri, 
and Craske, 2000).  Future studies investigating DCS-augmented ERP therapy should 
include measures related to higher-level, more abstract cognitive processing such as those 
used in the studies mentioned.  
Animal studies examining DCS effects on fear learning have primarily utilized 
either systemic administration or intracerebral infusion directly into the basolateral 
amygdala (Davis et al., 2006; Ledgerwood, Richardson, & Cranney, 2003, 2004; Walker 
et al., 2002). There is evidence that NMDA receptor activity within both the 
hippocampus and amygdala is influenced by DCS (Rouaud and Billard, 2003; Yaka et al., 
2007; Yang & Lu, 2005; Yamamoto et al., in press). Current theories of DCS revolve 
around enhancement of the consolidation of memory extinction—a process known to 
involve the hippocampus and amygdala (Corcoran et al., 2005; Davis et al., 2006; 
Hofmann et al., 2006b; Hofmann, 2007; Maren et al., 1997; Quirk & Mueller, 2008; 
Richardson et al., 2004). The only other neuroimaging study conducted to examine the 
effects of acute DCS administration, reported DCS to decrease overall amygdala 
activation (Britton et al., 2007). Although in the current study, amygdala and 
hippocampal activations met criteria for significance only in the placebo groups (and not 
the DCS groups), the effect of treatment was not statistically significant in these regions.  
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The contradictory findings between the current study and those of Britton et al. 
(2007) may be due to differences in the study population and/or the dosage of DCS. The 
Britton et al. study included only non-anxious healthy control subjects whereas the 
current study included an anxiety-disordered population. Current results suggest that 
DCS may modulate activity differently in phobic and non-phobic populations—
enhancing more dorsal PFC regions in phobic and more ventral regions in controls. The 
current study administered 100 mg DCS whereas Britton et al. used 500 mg. There is 
reason to believe, from both animal and human literature, that higher doses of DCS are 
less effective for enhancing fear extinction (Rothbaum, 2008). Therefore, different doses 
of DCS may have different effects on neural and cognitive processes.  
Differences in results between animal and human neuroimaging studies of acute 
DCS administration may be due to differences in non-primate and human brain anatomy 
and function. It is possible that DCS influences the neural network in humans differently 
than in animals—causing the PFC, rather than the hippocampus and amygdala, to assume 
the role of creating and consolidating new association memories. It is also possible that 
contradictory results are due to the fact that most animal studies examine the entire fear 
extinction process whereas the current study only examined the initial phase of fear 
extinction, symptom provocation.  It is possible that DCS is associated with modulation 
of hippocampal and amygdala activation in humans during later phases of the fear 
extinction process. 
In summary, the current findings suggest that DCS causes an increase in 
prefrontal (lateral PFC and OFC, dorsal ACC) and insula activation—possibly enhancing 
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the cognitive processing of feared stimuli (including interoceptive and attentional 
awareness), the modulation of responses to those stimuli (autonomic, cognitive, and/or 
behavioral), and the learning of stimulus-response associations.  
Study Limitations 
The current study did not include a CBT treatment arm, nor did it include 
complete in-session habituation to phobic stimuli. It is therefore possible that the neural 
effects reported for DCS in the current study are not the primary mechanisms through 
which DCS enhances fear extinction. DCS may exert a different influence during various 
phases of fear extinction (including acquisition, habituation, and maintenance). Future 
research could address this possibility by examining the effects of DCS during repeated 
sessions of symptom provocation, conducted pre- and post- ERP treatment. Additionally, 
the effects of DCS could be examined using an fMRI habituation paradigm involving 
more prolonged exposure to stimuli. This would allow examination of DCS effects 
during multiple phases of fear extinction.  
The current sample size (though comparable to those of other fMRI studies) was 
most likely not sufficient to provide complete characterization of behavioral and 
neuropsychological differences between groups. Therefore, results related to the effects 
of phobia diagnosis and DCS administration on cognitive functioning require replication 
for any specific conclusions to be made.  
Conclusions 
The current study represents the first investigation of acute DCS effects on neural 
processing during phobic symptom provocation. It is also the first study to examine acute 
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DCS effects on neuropsychological functioning. Results are important in providing 
direction for future research examining the use of acute DCS administration in enhancing 
fear extinction, exposure therapy, and cognitive functioning in general.  
 Results suggest that specific phobia may be associated with subtle differences in 
cognitive functioning. The current study also provides evidence that DCS may have 
subtle effects on emotional decision-making. Further research is needed to examine 
cognitive functioning in specific phobia and the potential neuropsychological effects of 
DCS. 
The primary finding of the current study was that DCS enhances PFC, cingulate, 
and insula activations during phobic symptom provocation. Enhancement of activation in 
these regions may relate to higher-level, cognitive processing and the integration of 
interoceptive information during emotional processing. Future animal and human 
research with DCS should further investigate how DCS may modulate activity in these 
regions, as well as how these activations relate to changes in emotion, cognition, and 
behavior.  
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Table 1.  
Abbreviations 
Region   Abbreviation 
Neuroanatomical 
 Region of interest ROI 
 Prefrontal cortex PFC 
  medial mPFC 
  dorsolateral dlPFC 
  ventrolateral vlPFC 
 Orbitofrontal cortex OFC 
 Anterior cingulate cortex ACC 
 Parahippocampal gyrus PHG 
 Bed nucleus of the stria terminalis BNST 
 Brodmann area BA 
Measures 
 Subjective Units of Distress SUDS 
 Behavioral Avoidance Test BAT 
 Spider Phobia Questionnaire SPQ 
 Magnetic resonance imaging MRI 
 Functional MRI fMRI 
 Blood oxygenation level dependent  BOLD 
 Positron emission tomography PET 
Other 
 D-cycloserine DCS 
 Exposure and Response Prevention ERP 
 Conditioned stimulus CS 














































































































































































































































































































































Table 9.  
Placebo phobic > placebo control (RFX, p<.001)        
       Side Region                                      # voxels   Max T      x y  z 
Spiders > Butterflies, RFX .001 
 left dlPFC (BA 9) 15 -4.54  -48 23 31 
 right frontal operculum 8 -4.21  48 -16 19 
 left frontal operculum 10 -4.41  -45 -13 16 
 right insula 9 -4.70  33 -16 13 
 left putamen 4 4.56  -24 -7 1 
 right parahippocampal gyrus 16 -4.80  24 -25 -20 
       right   bed nucleus of stria terminalis 4 4.42  9 -1 -2 
Spiders > low-level baseline        
 right frontal operculum 72 5.26  45 14 -2 
 right frontal operculum 14 4.70  45 -1 1 
right frontal operculum 30 4.31  36 20 1 
 left frontal operculum 3 4.21  -42 11 7 
 mid dorsal cingulate 15 4.24  0 5 40 
 left insula 15 4.72  -27 17 -5 
 left insula 58 4.39  -30 17 10 
 right insula 114 6.03  39 -10 -8 
 left medial caudate 13  4.48  -15 5 1 
 right medial caudate 3 4.07  12 11 10 
 left putamen 7  4.13  -24 -4 1 
       right   bed nucleus of stria terminalis 15 4.88  9 -1 -2 
Butterflies > low-level baseline       
 right frontal operculum 29 4.58  42 -4 4 
 left frontal operculum 11 4.24  -33 14 16 
 left posterior cingulate 33 4.64  -3 -31 34 
 left anterior cingulate 43 4.67  -6 29 10 
 right posterior cingulate 26 5.24  12 -16 37 
 left isthmus of cingulate gyrus 33 5.28  -9 -49 4 
 left insula 54 5.32  -36 -25 10 
 right insula 26 5.32  42 -13 7 
 right insula 7 3.98  39 -7 10 
 left insula  15 4.38  -39 -4 10 
 left medial caudate 7 4.35  -24 8 7 















Table 10.   
DCS phobic > Placebo phobic (RFX, p<.001)       
       Side    Region # voxels Max T x y z    
Spiders > Butterflies 
 left dlPFC (BA 9) 5  4.41 -36 29 31 
 left dlPFC (BA 46) 4 4.00 -48 23 32 
 left inferior frontal (BA 44) 41 4.47 -48 23 26 
 right inferior frontal (BA 45) 16 4.67 48 8 28 
 right inferior frontal (BA 45) 9 4.24 36 -13 46 
 right cingulate (BA 24) 6 3.98 12 14 34 
 right insula 4 3.86 33 -16 13 
 left insula 47 6.19 -39 -7 10 
 left insula 4 4.15 -39 -16 -5 
Spiders > low-level baseline    
 left inferior frontal (BA 45) 22 4.88 -48 23 22 
 right basal operculum 3 3.98 30 20 -8 
 right dlPFC (BA 9) 4 4.14 27 41 31 
 left presubiculum 23 -4.66 -18 -22 -14 
Butterflies > low-level baseline; RFX .001     
 left inferior frontal (BA 44) 96 -4.75 -33 1 31 
 left dlPFC (BA 9) 4 -3.94 -18 35 31 
 left anterior cingulate  48 -5.61 -3 -31 34 
 right isthmus of cingulate gyrus 3 -4.13 6 -46 10 
 right subiculum 19 -4.34 24 -37 -5 
 left parasubiculum 2 -4.00 -18 -13 -20 
 right claustrum 9 -4.21 30 -22 4 

























Table 11.  
Spiders > Butterflies: main effect for each group separately (RFX, p < .001) 
Side  Region                                # voxels     Max T           x            y z 
Placebo Phobic 
 right   vlPFC (BA 45)  91 8.22   45      32     10 
 right   dlPFC (BA9)  28 7.35   42      5  37 
 left      frontal operculum  4 -5.49  -48     -13    16 
 left      frontal operculum  7 5.23  -45     23  7 
 right    frontal operculum  15 5.47   45      2  1 
 right    insula  6 5.41   36      2  1 
 right    posterior insula  61 -9.59   33      -16     13 
 right    compact insular claustrum  5 5.71   30      11  1 
 left      limitans claustrum  17 6.88        -33     -13     -5 
 left      lateral amygdala   531 9.06         -24     -4       -14  
           (cluster also includes central and basomedial amygdala)          
 right    basomedial amygdala  45 5.97         18      -1 -11 
 right    central amygdala  4 4.72  24      -4 -11 
 right  bed nucleus of the stria terminalis 5 4.93  12 -1 -5 
 right    CA1 field of the hippocampus  35 6.37         27      -10  -14 
 left      CA3 field of hippocampus  10 5.56        -24    -19  -14 
 left      ventral putamen  8 5.33        -30    -22  -5 
Placebo Control 
 right  inferior frontal gyrus (BA 45) 7 5.59 45 -1 31 
 left  OFC   6 5.37 -30 32 -5 
 left superior frontopolar (BA 10) 6 -5.40 -18 59 1 
 left frontal operculum 5 5.33 -45 2 1 
 right insula 3 5.43 39 -7 1 
 right insula 11 5.12 36 2 1 
 right preamygdalar claustrum 16 5.32 27 -1 -11 
 left lateral amygdala 20 5.29 -27 -4 -20 
DCS Phobic        
 left inferior frontal (BA 45) 9 5.21 -45 20  22 
 right inferior frontal (BA 44) 5 4.89 60 11  16 
 right inferior frontal (BA 45) 35 5.79 54 5  25 
 right inferior frontal (BA 44) 12  5.17 45 8  28 
 left dlPFC (BA 9) 3 5.32 -33 35  34 
 right dlPFC (BA 9) 41 5.68 36 29  31 
 left dlPFC (BA 9) 760 8.00 -24 44  28 
 right dlPFC (BA 46) 5 5.28 39 41  19 
 right dlPFC (BA 46) 8 5.60 45 35  13 
 right dlPFC (BA 46) 19 5.47 42 41  14 
 right inferior OFC 9 5.21 45 17  -5 
 left lateral OFC 14 5.00 -33 35  -11 
 right frontal operculum 98 5.87 39 26  1 
 right frontal operculum 167 5.71 46 5  4 
 right frontal operculum 3 5.27 39 -1  10 
 right frontal operculum  313 8.22 36 17  13 
 right frontal operculum 3 4.72 48 14  -2 
 left frontal operculum 20 5.47 -45 2  1 
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Table 11.  
Spiders > Butterflies: main effect for each group separately (RFX, p < .001), Continued 
       Side    Region                                       # voxels Max T x            y          z 
DCS Phobic 
 right dorsal cingulate (BA 32) 6  5.16 6  17 31 
 left dorsal cingulate (BA 32) 213  6.78 -3 17 31 
 right dorsal cingulate (BA 24) 2922 8.79 6  2 46 
 left insula                                            299  8.03 -30 20 10 
 right insula                                        124 6.68 36 2 4 
 right caudate 637 9.67 15 -10 13 
 left dorsal claustrum 7 4.93 -33 -13 -2 
 right putamen 50 5.75 27 -19 1 
 right medial putamen 46  6.54 24 5 7 
 right parahippocampal gyrus 52 6.20 24 -43 -8 
DCS Controls        
 L/mid superior rostral gyrus (BA 10) 298  6.39 -6 5 6 4 
 left vlPFC (BA 45) 9 5.60 -48 26 7 
 left dlPFC (BA 9) 25 5.23 -42 5 43 
 left dmPFC (BA 9) 5 5.20 -6 50 34 
 left lateral OFC 21  5.12 -36 29 -11 
 left frontal operculum 30 5.64 -39 20 10 
 left posterior cingulate (BA 23) 7 4.80 -3 -22 34 
 left anterior cingulate (BA 32) 40 6.90 -15 44 10 
 left parahippocampal gyrus 17 5.23 -24 -34 -14 
 left CA1 field hippocampus 7 -4.85 -30 -40 -2 























Figure 1. Theoretical neural circuitry model of anxiety 
Figure 2. Average Iowa Gambling Test (IGT) block scores for all four groups. 
Figure 3. BOLD response for selected regions found to have greater activation for the 
spider than the butterfly condition in the placebo phobic group but not the placebo control 
group.  
Figure 4. BOLD response for selected regions found to be differentially activated for the 
placebo-treated and DCS-treated phobic groups when comparing the spider and butterfly 
conditions. 
Figure 5. Regional activations for the spiders > butterflies contrast in a) placebo-treated 
phobic group, b) DCS-treated phobic subjects, and c) treatment interaction. 
Figure 6. Regional activations for the spiders > butterflies contrast in a) placebo-treated 



















































Figure 2. Average Iowa Gambling Test (IGT) block scores for phobic and control groups. The phobic 
group as a whole performed worse than the control group in blocks 3 (t(46)=2.28, p=.027), 4 (t(46)=2.54, 
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Figure 3. BOLD response (represented by & signal change) for selected regions found to have greater 
activation for the spider than the butterfly condition in the placebo phobic group but not the placebo control 
group: a) right basomedial amygdala (t(11)=5.97, x,y,z=18,-1,-11), and b) left hippocampus (t(11)=5.56, 
x,y,z=-24,-19,-14). BOLD response for a region of the extended amygdala is also shown, which was 
significant for the condition (spider > butterfly) x diagnosis (phobic > control) interaction: c) BNST 



































                                                              












Figure 4. BOLD response (represented by & signal change) for selected regions found to be differentially 
activated for the placebo-treated and DCS-treated phobic groups when comparing the spider and butterfly 
conditions: a) right insula (t(21)=3.86, x,y,z=33,-16,13), and b) dorsal ACC (t(21)=3.98, x,y,z=12,14,34). 
BOLD response is also shown for a selected region of the amygdala, which met criteria for significance in 
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Figure 5. Regional activations for the spiders > butterflies contrast in: a) placebo-treated phobic group; 
bilateral lateral amygdala (sagittal and coronal images; t=9.06, x,y,z=-24,-4,-14), right dlPFC (axial image, 
BA 9, t(11)=7.35, x,y,z=42,5,37); b) DCS-treated phobic subjects; dorsal cingulate (all 3 images; BA 32, 
t(10)=6.78, x,y,z=-3,17,31), bilateral dlPFC (transverse/axial image; BA 9, t(10)=8.00, x,y,z=-24,44,28), 
bilateral insula (t(10)=8.03, x,y,z=-30,20,10), right putamen (t(10)=5.75, x,y,z=27,-19,1), right frontal 
operculum (t(10)=8.22; x,y,z=36,17,13), and right inferior frontal gyrus (coronal image; BA 45, t(10)=5.79, 
x,y,z=54,5,25); and c) treatment interaction (DCS > placebo); anterior cingulate (1st coronal image; BA 24, 
t(21)=3.98, x,y,z=12,14,34), left insula (2nd coronal image; t(21)=4.15, x,y,z=-39,-7,10), right primary 
motor area (2nd coronal image, BA 4, x,y,z=39,-7,52), left dlPFC (axial image; BA 46, t(21)=4.00, x,y,z=-

















   
























Figure 6. Regional activations for the spiders > butterflies contrast in: a) placebo-treated control group; left 
lateral amygdala (coronal image, t(11)=-36,29,-11; x,y,z=-27,-4,-20) and lateral frontal cortex (sagittal 
image; BA 4; t(11)= -5.05, x,y,z=-24,-16,52), b) DCS-treated control goup: left frontal operculum (sagittal 
image; t(11)=5.64, x,y,z=-39,20,10), and medial superior rostral gyrus (transverse/axial image; BA 10, 
t(11)=6.39, x,y,z=-6,56,4), and c) treatment (DCS > placebo) interaction; ventral ACC (sagittal and axial 
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Appendix A.  
Risks/benefit analysis and data and safety monitoring plan submitted to the KUMC 
Institutional Review Board. 
Risks and Benefits of the Proposed Study 
 This study is considered to involve moderate risk, as it involves 1) a study drug and 2) 
research associated procedures (MRI and the BAT assessment) with a low frequency of serious 
adverse events. As described above, DCS has been shown through 30 years of research and 
clinical treatment with tuberculosis, to be safe for human use (Heresco-Levy et al., 2002). The 
following side effects of daily, prolonged administration of DCS (for 1 week or more) have 
been reported: tremor, hallucinations, delusions, catatonic reactions, clinical depression, 
exaggerated reflexes, speech difficulties (dysarthria), and slight paralysis (Cascella et al., 1994; 
Mandell & Sande, 1990; Storey & McLean, 1957). Additionally, there is some indication that 
epilepsy patients may be at higher risk of developing side effects from repeated administration 
with DCS (Wlaz et al., 1994). No drug-related side effects have been reported in studies using 
acute administration with a single dose of 250 mg DCS. Exclusion criteria implemented in the 
proposed study (describe above) will serve to further reduce the risk of side effects. DCS 
administration will be monitored by nursing staff at the General Clinical Research Center 
(GCRC) of KUMC 2-3 hours after administration. The medical monitor (Sharon Cain, M.D.) 
and Sharon Cain, M.D. will be available for consultation should side effects or adverse events 
occur. If medically necessary, Dr. Hall or KUMC investigational pharmacy staff, under the 
direction of the medical monitor (Sharon Cain, M.D.) or Cary Savage, Ph.D. can break this 
blind and inform research personnel of the group assignment of a particular subject. 
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Participants will also be asked to contact Cary Savage, Ph.D. if they experience any side effects 
within one week following participation.  
The MR imaging procedure does not pose a significant risk to subjects meeting the entry 
criteria for this study. Some subjects may experience mild claustrophobia during MRI. Also, 
the MRI unit makes loud noises during the examination. To minimize any possible discomfort 
from these, participants will be given earplugs and ear phones. Although participants are 
usually left alone in the MRI suite during scanning, research personnel will stay if requested by 
the participant. To minimize the occurrence of claustrophobic symptoms, participants 
identified during initial assessment (using the ADIS) as having claustrophobia will be excluded 
from the study. Every effort will be made to reassure the patient and minimize any discomforts.  
Many of the assessments and tasks involved in this study will require participants to 
look at pictures of spiders, be in the same room as a live spider, and answer questions 
regarding their thoughts and feelings about spiders. This may cause the participants with 
spider phobia to experience discomfort. However, these tasks are not dangerous to the 
participant's physical or emotional health. Lisa Hale, Ph.D. and Sharon Cain, M.D. will 
be available for consultation during the administration of DCS and throughout the fMRI 
and testing procedures to be consulted in case of psychological or psychiatric 
complications. Through the behavioral avoidance task, subjects will be given the 
opportunity to touch and/or hold the Chilean rose hair tarantula used in the study. 
However, subjects will never be forced to touch or hold the spider. Chilean rose hair 
tarantulas, hereafter referred to as CHR tarantulas, were chosen for the current study 
based on their docile nature and intimidating appearance. Because of the location of its 
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fangs, a tarantula must raise itself on its hind legs to inflict a bite. However, tarantulas 
rarely inflict bites on humans (Diaz, 2004). It has been estimated that only 1 in 100,000 
CHR tarantulas will actually bite humans (Schultz, 2005). Bites from the tarantula, which 
are as painful as a bee sting, are relatively innocuous and result in a low-grade histamine 
reaction (Lewis et al, 2006). This may cause irritation, mild to severe itching, swelling 
and redness. There is a very small chance that, if a subject or research personnel 
experienced an allergic reaction to a tarantula bite, anaphylaxis could follow (Fell & 
Kukula, 2005). Additionally, the tarantula has very fine, fiberglasslike, sharp, barbed 
hairs on its abdomen. There are approximately 10,000 hairs per square millimeter of 
abdomen. The CHR tarantula has Type III hairs which can penetrate up to 2 mm, causing 
local inflammation. When a tarantula is handled, it releases these hairs which can cause 
skin, eye and respiratory tract irritation. The dermatologic effect is a local urticarial 
reaction. These hairs may also become imbedded in the handler’s eye. If imbedded in the 
conjunctiva, conjunctival infection results. The hairs can also become imbedded in the 
cornea and may penetrate the cornea to cause anterior chamber inflammation. Rarely, this 
inflammation lasts up to six years. Inhalation of these hairs may cause significant allergic 
rhinitis, but this is uncommon (Fell & Kukula, 2005). In a combined retrospective and 
nested prospective study of spider bites, a case series of nine tarantula bites in humans 
was described. In all of these nine instances, only mild effects occurred, including local 
pain (severe in four cases), puncture marks, and transient bleeding from the puncture site. 
Mild systemic toxicity occurred in one of the cases. There have been no reports of a 
human dying as a result of a tarantula bite or through contact with a tarantula (Isbister et 
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al., 2003 as reported in Diaz, 2004; Schultz, 2005). Further, our research team’s 
consultation with other laboratories in the US, Canada, and Europe that use live spider 
stimuli yielded no reported occurrences of bites nor other recommended precautions (Viz. 
Lars-Göran Öst, Ph.D. Department of Psychology, Stockholms Universitet, Sweden; 
Michelle Craske, PhD and Jayson Mystkowski, Ph.D., UCLA Anxiety Disorders 
Behavioral Research Program. Dr. Ost originated the protocols for spider phobia 
treatments commonly used today, and Drs. Craske & Mystkowski, have directed more 
than ten years of studies utilizing exposure tasks with tarantulas). 
Should a study subject come in contact with the tarantula, they will be asked to keep 
the tarantula far away from their eyes and face and will additionally be asked to 
subsequently wash their hands with soap and water. Research personnel who will be 
caring for and feeding the tarantula and may therefore come in contact with the CHR 
tarantula, will be required to sign a risk information form, recognizing that they are aware 
of the risks involved in handling the spider and the precautions that should be taken (see 
Appendix J). Should a tarantula bite occur, the puncture will be cleaned with soap and 
water and the subject will be offered a bandage. If it is suspected that a subject or 
research personnel are experiencing any symptom associated with a mild allergic reaction 
to a tarantula bite or the CHR abdominal hairs, the individual will be offered an oral dose 
of Benadryl and the study medical monitor will be consulted. If the medical monitor 
judges the reaction to require additional medical attention, the appropriate medical 
personnel will be consulted. An Ophthalmologist will be consulted when it is suspected 
that tarantula hairs have become imbedded in one’s eye. Dr. Nathan Culley provided a 
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basic husbandry SOP for spiders, which will be used to direct research personnel 
regarding the care of the tarantula (Appendix K).  
The risks associated with the behavioral and cognitive tests, magnetic resonance 
imaging (MRI), and the single 250 mg dose of DCS, are minimal and serious adverse 
events are not expected (as discussed previously). If an adverse event should occur (either 
serious or non-serious), the participant will, of course, have the opportunity to withdraw 
from the study. Additionally, the medical monitor (Sharon Cain, M.D.) and Lisa Hale, 
Ph.D. will be available for constulation should an adverse event occur. If any of these 
health practitioners believe it to be in the participant’s best interest to withdraw from the 
study, participation of that individual will be terminated.  
Results from the current study will provide valuable information as to the effects of 
DCS on brain reactivity and cognitive functioning in spider phobia and healthy controls. 
This will inform future clinical research about the mechanisms involved in DCS-
supplemented exposure therapy. and could lead to more effective treatments for phobia 
and other anxiety disorders. It is believed that the minimal risk involved in the proposed 
study is reasonable considering that it could lead to more effective treatments for phobia 
and other anxiety disorders. 
Data and Safety Monitoring: The intial assessment and all behavioral and cognitive 
assessments will be completed in a private room with only the examiner present. If there 
is reason for additional research staff to be present or to observe such assessments (e.g. 
for research personnel training), the participant will be asked for their verbal consent. The 
MRI control room and scanner is located in a private area. The door to the control room 
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will be locked during scanning to prevent individuals not involved in the study from 
entering. Only research personnel and MRI technicians will be allowed within the 
scanning room when the participant is being scanned. If the participant wishes for family 
members or friends to observe the MRI scan, these individuals will also be allowed in the 
control room.  
Sharon Cain, M.D. will serve as the medical monitor and Jeff Burns, M.D. will serve 
as the safety monitor for the proposed study. Throughout the study, research personnel 
will be monitoring for issues related to safety of participants and personnel as well as 
privacy of data. When issues arise related to medical safety, the medical monitor will be 
contacted for assistance. Should an adverse event occur, it will be documented by 
research personnel. After such an event, the situation will be reviewed by a safety 
monitor that is independent of the study (Jeff Burns, M.D.), who will make 
recommendations regarding any changes in the protocol, consent form, or other aspect of 
the study. While the safety monitor is reviewing the adverse event, no additional data will 
be collected. The following information will be monitored throughout the study: number 
of subjects screened and enrolled, drop-outs, primary and secondary efficacy endpoints, 
and serious and non-serious adverse events. This data, with the exception of serious 
adverse events, will be reported every 12 months, coinciding with HSC periodic review. 
Because no serious adverse events are anticipated in this study, any such events will be 
immediately reported to the KUMC Institutional Review Board and the GCRC and 
appropriate changes to the study or consent form will be completed. Serious adverse 
events will be reported to the KUMC Institutional Review Board and GCRC using the 
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Common Toxicity Criteria (CTC)-III scale for categorization and classification of 
adverse events. If the severity of an adverse event requires emergency medical attention, 
appropriate KUMC providers/staff will be contacted to provide medical attention. 
However, as the University of Kansas Medical Center does not provide free medical 
treatment or other forms of compensation to persons injured as a result of participating in 
research, the participant will be billed for such medical care. Non-serious anticipated 
events will not be reported to the IRB whereas non-serious, unanticipated events will be 
reported every 12 months, as described. 
Identification numbers will be assigned to each subject at the time of the initial 
assessment. DCS and placebo will be obtained from and prepared by the KUMC 
investigational pharmacy. Medications will be administered at the beginning of the 
appointment by the KUMC General Clinical Research Center (GCRC). Randomization of 
participants to receive either DCS or placebo will be conducted by Sandra Hall, Ph.D. 
(Research Assistant Professor, Department of Preventive Medicine and Public Health, 
KUMC), who will communicate the results of randomization (subject numbers and group 
assignment of each) to staff at the KUMC investigational pharmacy. This is to ensure that 
investigators, test administrators, and participants will be blind to group assignment. Dr. Hall 
will conduct separate, block randomizations for the phobic and non-phobic groups, so that half 
of each group will be randomized to receive DCS while the other half is randomized to receive 
placebo. Each subject will therefore have a 50% chance of receiving DCS. The list of subject 
ID numbers and corresponding randomization will be provided in a sealed envelope to the 
KUMC investigational pharmacy. Staff at the investigational pharmacy will find the 
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appropriate ID number for each subject as they come in and determine from the randomization 
list whether to give the subject drug or placebo. If medically necessary, Dr. Hall or KUMC 
investigational pharmacy staff, under the direction of Cary Savage, Ph.D. or Sharon Cain, 
M.D., can break this blind and inform research personnel of the group assignment of a 
particular subject. 
 All other data collected through the duration of the study will be kept in locked 
cabinets within HBIC. Data used for analysis will be de-identified and accessible by only 
research personnel. The staff of the GCRC will have access to information regarding 
demographic and medical information (as collected through the eligibility survey, 
Appendix A) and identification number each subject. After the data is initially entered by 
a member of the research team, an additional member will review the data and identify 
errors. A log will be kept of all data collection and analysis steps completed for each 
subject. For the MRI scans, a research log will be kept by the lab technicians regarding 
steps completed and any errors detected. MRI data will be saved on a CD kept by the lab 
technicians, as well as a CD kept by research personnel. Behavioral and cognitive data 
will be saved to a hard drive and backed up on a CD kept by research personnel. The CDs 












Appendix B.  
Tables displaying complete results for each statistical contrast conducted for the fMRI 
symptom provocation paradigm. 
 
Table 1.  
Placebo phobics; Spiders > Butterflies, RFX .001 
Side Region            # voxels Max T            x       y  z 
right  vlPFC (BA 45/46)  91 8.22 45     32    10 
right  dlPFC (BA 9)  28 7.35 42     5 37 
left       lateral frontal (BA 4)  3 -5.05 -24    -16   52 
right     lateral PFC (BA 6)   7 5.21 9       2 55 
right     lateral frontal (BA4)  4 -5.04 48      -16   31 
left       frontal operculum  4 -5.49 -48    -13   16 
left       frontal operculum                 7 5.23 -45    23  7 
right     frontal operculum  15 5.47 45     2  1 
right     insula  6 5.41 36     2  1 
right     posterior insula  61 -9.60 33     -16    13 
right     compact insular claustrum  5 5.71 30     11  1  
left      limitans claustrum  17 6.88 -33    -13    -5 
left       lateral amygdala   531 9.06 -24    -4      -14  
            (cluster also included basolateral, central, and basomedial amygdala)          
right     basomedial amygdala  45 5.97 18     -1  -11 
right     central amygdala  4 4.72 24     -4  -11 
right     ventral pallidum  5 4.93 12     -1  -5 
right     CA1 field of the hippocampus  35 6.37 27     -10  -14 
left       CA3 field of hippocampus  10 5.56 -24   -19  -14 
left       ventral putamen  8 5.33 -30   -22  -5 
left       cerebral peduncle  169 6.14 -12   -13  -14 
right     mammilary nucleus  75 6.68         6     -10  -11 
left       central tegmental tract  212 5.86 -3    -28  -5 
right     dorsal hypothalamus  10 5.83 6      -7  -2 
left       fusiform gyrus (BA 19)   4 4.70 -21   -64  -14 
right     fusiform gyrus (BA 19)   62          7.51 24     -58  -14 
left  inferior temporal (BA 37)  15 5. -45   -70  1 
left       anterior transverse temporal gyrus  77 -7.57 -51   -13  4 
right  planum temporale (BA 40)   9 5.00 60     -37  28 
right  medial temporal gyrus (BA 19)    451 10.40 48     -67  -2 
right  dorsal temporopolar (BA 28)   32 7.41 36      11  -20 
left  inferior temporal gyrus (BA 21)   6 5.36 -39     2  -35 
right  occipital (BA 19)    9 5.20 39     -73     1 
left  occipital (BA 19)   65 6.22 -42    -64    -14 
left  occpital gyrus (BA 19)   4 5.33 -30    -73    -17 
mid  lingual gyrus (BA 18)   69 -6.61  3      -70     4 
left  occipital gyrus (BA 18)   56 5.70  -24   -67   -17 
right     parietal operculum   8 -4.92  54    -13    13 
right     cerebellum   81 6.47  37    -55    -28 
left       cerebellum   22 6.03  -39   -61    -23 
left       cerebellum   173 6.71  -24   -31    -20 
Abbreviations: BA=Brodmann area; PFC=prefrontal cortex; dlPFC=dorsolateral PFC; vlPFC=ventrolateral 
PFC. 
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Appendix B. (cont.) 
 
Table 2.  
Placebo controls: Spiders > Butterflies, RFX .001        
Side        Region                                       # voxels  Max T  x  y z 
right  inferior frontal gyrus (BA 45) 7 5.59 45 -1 31 
right lateral frontal (BA 4) 28 6.24 18 -16 61 
left OFC (BA 47)  6 5.37 -30 32 -5 
left superior frontopolar gyrus (BA 10) 6 -5.40 -18 59 1 
left frontal operculum 5 5.33 -45 2 1 
right insula 3 5.43 39 -7 1 
right insula 11 5.12 36 2 1 
right preamygdalar claustrum 16 5.32 27 -1 -11 
left lateral amygdala 20 5.30 -27 -4 -20 
right fusiform gyrus (BA 37) 40 6.80 27 -43 -17 
left fusiform gyrus (BA 37) 14 6.30 -24 -43 -17 
left fusiform gyrus (BA 19) 63 6.08 -39 -67 -14 
right fusiform gyrus (BA 36) 18 7.34 36 -34 -20 
right cerebral peduncle 17 5.55 15 -16 -5 
left dorsal trigeminal-thalamic tract 4 4.69 -6 -28 -5 
left temporal gyrus (BA 37) 140 6.73 -51 -61 -7 
right superior temporal gyrus (BA 39)  10 -5.10 45 -67 31 
right medial temporal gyrus (BA 21) 43 7.23 45 -43 1 
right inferior temporal gyrus (BA 19) 1780 9.86 48 -64 -2 
left inferior temporal gyrus (BA 20) 4 4.97 -54 2 -20 
right inferior temporal gyrus (BA 37) 35 5.62 42 -40 -14 
right occipital gyrus (BA 19) 82 5.82 45 -70 7 
left occipital gyrus (BA 19) 44 6.57 -54 -64 -5 
left occpital gyrus (BA 37) 4 4.67 -45 -70 4 
left lingual gyrus (BA 31) 5 -5.28 -6 -70 10 
right cerebellum 5 4.73 39 -64 -23 
left cerebellum 451 9.02 -33 -37 -23 




















Appendix B. (cont.) 
 
Table 3.  
Placebo phobic > placebo control; Spiders > Butterflies, RFX .001        
Side Region                                             # voxels     Max T  x   y  z 
right lateral frontal (BA 3/4) 30 -5.02 48 -16 31 
right lateral parietal (BA 1/3) 58 -4.88 45 -19 49 
left lateral parietal (BA 1/3) 114 -4.91 -55 -16 46 
left dlPFC (BA 9) 15 -4.54 -48 23 31 
right frontal operculum 8 -4.21 48 -16 19 
left frontal operculum 10 -4.41 -45 -13 16 
right insula 9 -4.70 33 -16 13 
left putamen 4 4.56 -24 -7 1 
right parahippocampal gyrus 16 -4.80 24 -25 -20 
right bed nucleus of the stria terminalis 4 4.42 9 -1 -2 
right parietal operculum 3 -3.97 48 -22 19 
left inferior parietal lobe (BA 40) 63 -4.46 -36 -43 58 
left temporal cortex (BA 7) 3 -4.19 -51 -61 7 
mid precuneus (BA 7) 7 -4.49 3 -49 58 
right cerebellum 19 4.57 33 -58 -38 
right cerebellum 3 4.03 22 -25 -38 
mid cerebellum 19 4.11 3 -46 -38 






























Appendix B. (cont.) 
 
Table 4.  
Placebo phobic > placebo control; Spiders > low-level baseline, RFX .001       
Side Region                                             # voxels    Max T  x y  z 
right lateral PFC (BA 6) 7 -4.68 60 5 28 
right lateral PFC (BA 6) 23 5.14 39 -7 43 
mid cingulate (BA 24) 15 4.24 0 5 40 
right frontal operculum 72 5.26 45 14 -2 
right frontal operculum 14 4.70 45 -1 1 
right frontal operculum 30 4.31 36 20 1 
left frontal operculum 3 4.21 -42 11 7 
left insula 15 4.72 -27 17 -5 
left insula 58 4.39 -30 17 10 
right insula 114 6.03 39 -10 -8 
left medial caudate 13 (+6) 4.48 -15 5 1 
right medial caudate 3 4.07 12 11 10 
left putamen 7 (+5) 4.13 -24 -4 1 
mid pons 148 5.61 0 -19 -17 
right bed nucleus of the stria terminalis 15 4.88 9 -1 -2 
left cerebral peduncle 5 4.35 -18 -19 -5 
left cucullaris nucleus 144 4.68 -3 -16 13 
mid superior cerebellar peduncle 4 4.25 3 -31 -14 
left dorsal temporopolar (BA 38) 3 4.04 -39 11 -14 
right inferior parietal lobe (BA 40) 13 4.24 57 -40 28 
left cerebellum 26 4.60 -24 -37 -23 
right cerebellum 16 4.22 9 -43 -17 

























Appendix B. (cont.) 
 
Table 5.  
Placebo phobic > placebo control; Butterflies > low-level baseline, RFX .001       
Side Region                                             # voxels    Max T  x   y  z 
left lateral PFC (BA 6) 18 4.84 -15 -16 70 
mid superior PFC (BA 6) 25 4.56 3 -10 55 
right lateral parietal (BA 2) 21 4.92 54 -19 31 
left lateral parietal (BA 3) 10 4.61 -24 -31 67 
right lateral frontal (BA 4) 4 -4.65 54 -10 25 
left lateral frontal (BA 4) 17 4.78 -30 -22 64 
right lateral frontal (BA 4) 12  4.45 24 -19 55 
mid posterior cingulate (BA 31) 33 4.64 -3 -31 34 
left anterior cingulate (BA 24/32) 43 4.67 -6 29 10 
right posterior cingulate (BA 24) 26 5.24 12 -16 37 
left isthmus of cingulate gyrus 33 5.28 -9 -49 4 
right frontal operculum 29 4.58 42 -4 4 
left frontal operculum 11 4.24 -33 14 16 
left insula 54 5.32 -36 -25 10 
right insula 26 5.32 42 -13 7 
right insula 7 3.98 39 -7 10 
left insula  15 4.38 -39 -4 10 
left medial caudate 7 4.35 -24 8 7 
right putamen 17 4.75 15 14 1 
mid fornix 42 4.79 -3 -4 1 
right perirhinal cortex 40 4.81 27 -7 -23   
left inferior temporal (BA 21) 19 4.67 -42 8 -32 
right superior temporal (BA 22/42) 25 4.64 48 -6 7 
right superior temporal (BA 22) 4 4.45 51 5 -5 
right superior temporal (BA 42) 242 5.26 54 -28 13 
left parietal (BA 7/40) 5 4.29 -27 -40 52 
right inferior parietal lobe (BA 40) 66 4.50 53 -37 28 
right superior parietal lobe (BA 7) 19 5.24 24 -46 61 
left occipital (BA 19) 16 4.30 -33 -67 34 
left cerebellum 6 4.37 -21 -28 -41 
left cerebellum 17 4.14 -9 -61 -23 
right cerebellum 16 4.19 9 -61 -23 
right cerebellum 29 4.83 15 -58 -23 
left cerebellum 35 5.33 -6 -61 -8 













Appendix B. (cont.) 
 
Table 6.  
DCS-treated phobics: Spiders > Butterflies, RFX .001        
Side Region # voxels Max T x y z    
mid superior PFC (BA 6) 5 4.971816 -3 -7 64 
left lateral PFC (BA 6) 5 5.367335 -9 23 55 
left lateral PFC (BA 6) 78 7.883197 -15 -7 61 
left lateral PFC (BA 6) 3 5.149535 -18 -16 64 
right lateral PFC (BA 6) 3 4.943971 45 -7 37 
left lateral PFC (BA 4/6)                           278 8.029253 -48 -4 40 
right lateral frontal (BA 4) 531 10.307141 36 -7 49 
left inferior frontal (BA 45) 9 5.214232 -45 20 22 
right inferior frontal (BA 44) 5 4.892351 60 11 16 
right inferior frontal (BA 45) 35 5.786233 54 5 25 
right inferior frontal (BA 44) 12 5.168444 45 8 28 
left dlPFC (BA 9) 3 5.321159 -33 35 34 
right dlPFC (BA 9/46) 41 5.678327 36 29 31 
left dlPFC (BA 9/46) 760 7.998677 -24 44 28 
right dlPFC (BA 46) 5 5.282866 39 41 19 
right dlPFC (BA 46) 8 5.603292 45 35 13 
right dlPFC (BA 46) 19 5.468701 42 41 14 
right inferior OFC (BA 47) 9 5.206333 45 17 -5 
right inferior OFC (BA 47) 98 5.874109 39 26 1 
left lateral orbital gyrus 14 4.995579 -33 35 -11 
right dorsal cingulate (BA 32) 6 5.155251 6 17 31 
mid dorsal cingulate (BA 32) 213  6.776052 -3 17 31 
right ventral cingulate (BA 24) 2922 8.786025 6 2 46 
right frontal operculum 167 5.707574 46 5 4 
right frontal operculum 3 5.273075 39 -1 10 
right frontal operculum  313 8.216325 36 17 13 
right frontal operculum 3 4.718333 48 14 -2 
left frontal operculum 20 5.473941 -45 2 1 
left insula                                              299 8.026821 -30 20 10 
right insula                                                124  6.676866 36 2 4 
right caudate and internal capsule 637 9.666705 15 -10 13 
left dorsal claustrum 7 4.928164 -33 -13 -2 
right putamen 50 5.75498 27 -19 1 
right medial putamen 46 6.5412 24 5 7 
right parahippocampal gyrus 52 6.204882 24 -43 -8 
mid precuneus 4 -4.73595 3 -61 22 
right fusiform gyrus (BA 36) 1238 8.502882 39 -52 -20 
right fusiform gyrus (BA 36) 75 6.894574 33 -13 -26 
left fusiform gyrus (BA 36/37) 499 7.572194 -24 -40 -17 
left fusiform gyrus (BA 20) 3 4.924512 -27 -4 -32 
left inferior temporal gyrus (BA 37 )      1293 7.727646 -42 -58 -11 
left inferior temporal gyrus (BA 37) 15 5.092521 -39 -46 -17 
right inferior temporal (BA 19) 243 6.74443 39 -58 -2 
right superior temporal gyrus (BA 22) 4 5.03045 51 5 -2 
left angular gyrus (BA 19) 34 5.571859 -27 -61 43 
right angular gyrus (BA 40) 6 5.009749 33 -52 46 
right superior parietal lobe (BA 19)            191 6.539726 21 -67 43 
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Appendix B. (cont.) 
 
Table 6 (cont.).  
DCS-treated Phobics: Spiders > Butterflies, RFX .001        
Side              Region                                # voxels   Max T    x   y  z   
left superior parietal lobe (BA 7) 9 6.184313 -15 -55 55 
left medial geniculate nucleus 124 5.763817 -18 -28 -5 
left ventroanterior thalamus 47 5.80396 -9 -10 10 
left ventrolateral posterior thalamus 9 5.572302 -12 -22 4 
right right inferior pulvinar nucleus 4 4.820837 21 -31 10 
left inferior pulvinar nucleus 41 6.187953 -21 -31 10 
mid central tegmental tract 55 6.657354 -3 -28 -5 
right red nucleus, parvocellular part 139 10.242029 6 -22 -5 
right cerebral peduncle 3 5.275124 6 -16 -14 
right cerebral peduncle 28 5.808577 15 -22 -8 
right pons 13 5.157822 6 -22 -17 
left occipital gyrus (BA 18/31) 4 4.718277 -21 -70 22 
left lingual gyrus (BA 19) 25  6.883592 -21 -58 -5 
right occipital (BA 19) 42 5.310084 45 -73 10 
right occipital gyrus (BA 19/37) 210 7.604238 42 -64 -17 
left sagittal striatum 4 4.665262 -24 -76 7 
right occipital gyrus (BA 19) 525 8.428448 36 -70 -2 
right cerebellum 96 7.718362 33 -61 -26 
right cerebellum 19 5.507664 30 -40 -23 
right cerebellum 8 5.545151 33 -70 -32 
right cerebellum 117  5.17111 21 -70 -20 
right cerebellum                                         117 6.446866 9 -43 -17 
right cerebellum 23 5.901428 6 -61 -35 
mid cerebellum 27 5.135165 0 -52 -35 
left cerebellum 10 5.249269 -3 -43 -20 
left cerebellum 9 5.024959 -6 -70 -23 
left cerebellum 30 5.441673 -21 -67 -20 
left cerebellum 176  6.526022 -33 -55 -29 



















Appendix B. (cont.) 
 
Table 7.  
DCS-treated controls; Spiders > Butterflies, RFX .001        
Side                 Region # voxels   Max T x  y z 
L/mid superior rostral gyrus (BA 10) 298  6.39 -6 56 4 
left vlPFC (BA 45/46) 9 5.609 -48 26 7 
left lateral PFC (BA 6) 9 5.369 -9 53 13 
left lateral PFC (BA 6) 15 5.089 -9 5 67 
left dlPFC (BA 9) 25 5.293 -42 5 43 
left dlPFC (BA 9) 5 5.209 -6 50 34 
left lateral OFC 21  5.12 -36 29 -11 
mid posterior cingulate (BA 23) 7 4.80 -3 -22 34 
left anterior cingulate (BA 32) 40 6.90 -15 44 10 
left frontal operculum 30 5.64 -39 20 10 
left parahippocampal gyrus 17 5.23 -24 -34 -14 
left CA1 field of hippocampus 7 -4.85 -30 -40 -2 
right piriform cortex 6  5.33 27 11 -11 
left uncinate fasciculus 3 5.20 -30 5 -5 
right fusiform gyrus (BA 37) 59 6.69 45 -52 -20 
left fusiform gyrus (BA 37) 28 6.16 -39 -49 -14 
right inferior temporal (BA 19) 15 5.51 45 -67 -2 
left temporal gyrus (BA 37) 5  4.91 -51 -61 10 
right superior temporal gyrus (BA 37/21) 49 5.68 42 -58 4 
left superior temporal gyrus (BA 38) 7  5.52 -48 11 -20 
left temporal gyrus (BA 39) 3 4.85 -51 -70 13 
left occipital gyrus (BA 19) 7 5.54 -33 -73 10 
right cerebellum 9 -5.45 28 -37 -38 
mid cerebellum 8 -4.72 -2 -49 -10 























Appendix B. (cont.) 
 
Table 8.   
DCS-treated phobics > Placebo-treated phobics; Spiders > Butterflies; RFX .001       
Side Region # voxels Max T x y z    
left dlPFC (BA 9) 5  4.41 -36 29 31 
left dlPFC (BA 46) 4 4.00 -48 23 32 
left inferior frontal (BA 44) 41 4.47 -48 23 26 
right inferior frontal (BA 45) 16 4.66 48 8 28 
right inferior frontal (BA 45) 9 4.24 36 -13 46 
right lateral frontal (BA 4) 14 4.39 48 -13 31 
right lateral frontal (BA 4) 15 4.46 39 -7 52 
right lateral PFC (BA 6) 6 4.23 3 -1 58 
right cingulate (BA 24) 6 3.98 12 14 34 
right insula 4 3.86 33 -16 13 
left insula 47 6.19 -39 -7 10 
left insula 4 4.15 -39 -16 -5 
right zona incerta 23 4.13 15 -19 -2 
right fusiform gyrus (BA 36) 29 5.27 34 -13 -26 
right inferior temporal gyrus (BA 19) 22 4.27 45 -61 -2 
left superior temporal (BA 21) 12 4.19 -45 -43 10 
left temporal cortex (BA 37) 16 4.16 -42 -58 4 
left superior parietal lobe (BA 7) 25 4.64 -27 -58 52 
right lingual gyrus (BA 18) 28 4.32 15 -67 -11 
right lingual gyrus (BA 19) 173  5.22 15 -58 1 
left lingual gyrus (BA 19) 25 4.68 -21 -58 -5 
right occipital cortex (BA 37/19) 171 7.56 33 -70 1 
right cerebellum 4 3.84 9 -61 -23 
left cerebellum 9 4.03 -6 -67 -41 
mid cerebelum 96  4.84 0 -67 -20 






















Appendix B. (cont.) 
 
Table 9.  
DCS-treated phobics > placebo-treated phobics; Spiders > low-level baseline, RFX .001      
Side Region # voxels Max T x y z    
left inferior frontal (BA 45) 22 4.88 -48 23 22 
right basal operculum 3 3.98 30 20 -8 
right dlPFC (BA 9/46) 4 4.14 27 41 31 
left presubiculum 23 -4.66 -18 -22 -14 
right thalamic fasciculus, field H1 20 4.38 9 -22 -2 
right fusiform gyrus (BA 36) 5 4.30 31 -16 -26 
left superior temporal (BA 37) 4 4.04 -42 -58 7 
right inferior parietal lobe (BA 40) 35 -4.71 54 -37 25 
left occipital cortex (BA 19) 11 4.20 -24 -67 28 
left cerebellum 29 4.55 -6 -64 -32 





































Appendix B. (cont.) 
 
Table 10.  
DCS-treated phobics > placebo-treated phobics; Butterflies > low-level baseline, RFX .001      
Side Region # voxels Max T x y z    
right lateral PFC (BA 6) 24 -4.78 12 2 58 
left lateral PFC (BA 6) 4 -3.95 -42 17 47 
left inferior frontal (BA 44) 96 -4.75 -33 1 31 
left dlPFC (BA 9) 4 -3.94 -18 35 31 
left cingulate (BA 31) 48 -5.61 -3 -31 34 
right isthmus of cingulate gyrus 3 -4.13 6 -46 10 
right subiculum 19 -4.34 24 -37 -5 
left parasubiculum 2 -4.00 -18 -13 -20 
right claustrum 9 -4.21 30 -22 4 
mid precuneus 4 -4.05 0 -58 55 
left medial caudate 7 -4.64 -24 8 7 
left ventrolateral posterior thalamus 69 -4.57 -15 -22 19 
left cerebral peduncle 8 -4.44 -15 -19 -8 
left reticular thalamic nucleus 3 -4.34 -27 -34 4 
right superior temporal (BA 22) 5 -4.23 48 -49 16 
left lingual gyrus 126 -5.50 -21 -52 1 
left internal sagittal stratum 32 -4.62 -39 -46 1 
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Table 11.  
DCS-treated controls> placebo-treated controls, RFX .001 
Side  Region # voxels Max T x y z 
Spiders > Butterflies        
 left ventral ACC (BA 24) 6 3.92 -6 26 4 
 left medial caudate 3 4.61 -9 14 10 
 left parietal cortex (BA3) 11 -4.70 -30 -31 55 
 right fusiform gyrus (BA 37) 39 -4.91 42 -58 -14 
 left inferior temporal gyrus (BA 20) 4 4.17 -45 -7 -20 
 right cerebellum 31 4.43 45 -52 -41 
Spiders only        
 right lateral PFC (BA 6) 33 5.11 43 5 52 
 right lateral PFC (BA 6) 5 4.17 30 -7 43 
 left lateral PFC (BA 6) 25 4.40 -6 -10 58 
 right lateral PFC (BA 6) 10 4.13 9 8 68 
 left frontal operculum 3 3.92 -42 11 7 
 right lateral parietal (BA 2) 10 4.47 54 -19 31 
 left superior cerebellar peduncle 5 4.23 -3 -31 -14 
 left cerebellum 9 4.11 -45 -45 -38 
 right cerebellum 8 4.28 39 -49 -41 
Butterflies only       
 left insula 3 3.99 -33 13 10 
 left frontal operculum 4 4.58 -36 14 16 
left lateral caudate 6 4.12 -18 -1 22 
 left putamen 4 4.45 -24 2 16 
 right piriform cortex 10 4.48 27 2 -11 
 right subcallosul stratum 21 4.21 18 -1 25 
 right inferior parietal (BA 40) 29 4.91 54 -19 28 
 right superior parietal (BA 7) 18 4.65 25 -46 61 
 left precuneaus  26 4.31 -6 -34 49 
 left cerebellum 26 4.66 -6 -4 -38 
Abbreviations: BA = Brodmann area; PFC=prefrontal cortex; ACC=anterior cingulate cortex. 
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